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Abstract 
 
The blood clot is composed of a mesh of fibrin fibres with cellular elements 
embedded in this network. The structure of the fibrin clot can determine predisposition 
to atherothrombotic conditions, as compact clots composed of thin fibres and small 
pores are associated with premature and more severe cardiovascular disease. Both 
genetic and environmental effects can cause qualitative and quantitative changes in 
procoagulant and anti-fibrinolytic proteins, altering fibrin clot formation, structure and 
lysis. 
 
Three hypothesese were tested in this work: Firstly, the BβArg448Lys fibrinogen 
variant affects clot structural and functional properties in T2DM patients. Secondly, α2-
AP is the protein responsible for the differences in lysis of recombinant BβArg448Lys 
fibrinogen variants in the plasma environment. And lastly, I proposed the 
AαTrp334Cys/Asn335Tyr changes in the Birmingham II patient are responsible for her 
clinical presentation. Accordingly, the aims of this work were to identify any additional 
effect of BβArg448Lys on fibrin network in type 2 diabetes, study the mechanisms 
behind the effects of the BβArg448Lys mutation on fibrin clot structural and functional 
properties, and finally, investigate the effect of fibrinogen AαTrp334Cys/Asn335Tyr on 
clot structure and lysis and abnormal patient phenotype.  
 
Compact clots with resistance to fibrinolysis were detected in carriers of 
Bβ448Lys variant of fibrinogen with diabetes. A direct role of the polymorphism in the 
changes observed with plasma clots was identified, and this may add to an already 
increased level of vascular risk in women with diabetes. 
In a recombinant system, differences in lysis between BβArg448Lys variants 
were attributable to the interplay between porosity of the clot, the fibrin-α2-AP 
interaction and plasmin generation.  
Finally, we confirm the AαTrp334Cys/Asn335Tryr substitutions in the fibrinogen 
BII patient are responsible for a clinical presentation of bleeding and thrombosis, 
providing mechanistic explanations for this patient phenotype.  
 
In summary, I extensively investigated the interplay between the fibrinogen 
molecule, fibrin clot structure, fibrinolysis and the environment and made a number of 
novel observations. Data generated has shed light on the mechanisms of increased 
thrombosis risk in patients with compact clots made of thin fibres, through genetic or 
environmental influence, which in turn will help to develop effective treatment strategies 
to reduce ischemic events in high risk patients. 
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Chapter 1. Introduction 
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Clot formation is an essential physiological process to prevent blood loss upon 
vessel injury, however changes in various parameters involved in the clotting cascade 
can lead to pathological complications with serious clinical implications. Alterations in 
clot formation, morphology and lysis can increase risk of cardiovascular disease (CVD) 
and can result in irreversible end organ damage. Consequently it is important to 
understand the mechanisms behind the clotting process to elucidate the impact on 
atherothrombotic and CVD and to help develop preventative and therapeutic targets. 
1.1 An overview of blood clot formation 
Thrombus formation occurs via a series of interlinked events known as the 
coagulation cascade that involves interplay between cellular elements and plasma 
proteins. Exposure of tissue factor (TF) as a result of vessel injury leads to exposure of 
a prothrombotic core and activation of various clotting factors which liberate active 
thrombin. This thrombin activates platelets, cleaves fibrinogen to form fibrin and 
activates Factor 13 (FXIII). The resulting clot is made of a mesh-like network of fibrin 
fibres to which various clotting factors and cellular components bind and crosslink 
forming the mature clot which prevents continued bleeding.  
1.1.1 The role of coagulation factors 
Coagulation factors FXII, FXI, FIX, FVII, FVIII are essential components of the 
blood clotting process, being activated sequentially to activate FX and FV, resulting in 
the formation of thrombin, which in turn converts soluble fibrinogen into insoluble fibrin 
network, thereby forming the mature clot. Complex interactions and feedback 
mechanisms control the activity of these factors, so change or deficiency in any of 
these proteins has profound effects on clot formation, structure and lysis and 
consequently susceptibility to disease.  
1.1.2 The role of platelets 
Platelets, the major cellular element involved in the blood clotting process, 
become activated at sites of vessel injury where collagen is exposed and there are 
increased levels of clotting factors such as thrombin. Once activated, platelets can bind 
many coagulation factors (Von Willebrand factor (vWF), thrombin, FXI, fibrinogen and 
prothrombin) via a number of exposed receptors, leading to their adherence to the site 
of injury and aggregation1. Platelet activation, adherence and aggregation act to form a 
platelet plug using vWF and fibrinogen as a connecting agent. This platelet plug not 
only helps to stop the initial bleeding but helps wound repair by the secretion of growth 
factors by the activated cell2. 
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It is the interplay between all of these factors that determine how the clot behaves 
and thus risk of pathogenic consequences. Both quantitative and qualitative changes in 
the cellular and acellular components can be caused by genetic and environmental 
factors, which increase susceptibility to vascular disease.  
1.2 The coagulation cascade 
The fibrin network represents the backbone of the blood clot with cellular 
elements, including platelets and red and white blood cells, embedded in this network. 
Thrombus formation represents the last step in the atherothrombotic process and 
occurs via a series of interlinked events that progress through steps known as the 
coagulation cascade. Traditionally, this has been divided into two independent 
cascades that converge to a common pathway; the intrinsic, composed of FXII, XI, IX 
and VII and the extrinsic composed of TF which activates FVIII converging to activate 
FX, FV, thrombin and fibrinogen. However, this is more of an in-vitro model and does 
not necessarily represent in-vivo coagulation, particularly as thrombus formation also 
relies on the interplay between these factors and platelets1. Therefore, in vivo clot 
formation is a more complex process that involves cellular elements and plasma 
proteins. Exposure of TF as a result of vessel injury (secondary to atherosclerotic 
plaque rupture) leads to exposure of a prothrombotic core and activation of FVII/TF 
complexes and consequent FIX, FX and FV activation. The latter two factors liberate 
active thrombin from its precursor, prothrombin. This activates platelets adhered to the 
site of injury via interaction with vWF and collagen3. This interaction works to fully 
activate the platelets leading to their degranulation and consequent FV release which is 
later activated by FXa and thrombin. FVIII also plays a role in thrombus formation by 
interacting with FIXa as a result of thrombin activation, increasing coagulation. This 
complex feedback mechanism generates enough thrombin to cleave fibrinogen to form 
fibrin and to activate FXIII, enhancing fibrin crosslinking and thus clot stability. The 
coagulation cascade is summarised in Figure 1-1. 
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Figure 1-1. Schematic representation of the coagulation cascade resulting in 
fibrin clot formation 
Vessel injury results in activation of coagulation factors, cleavage of prothrombin to 
thrombin, platelet activation and resultant  conversion of fibrinogen to fibrin, FXIIIa 
crosslinking and clot stabilisation. 
 
Most of the proteins involved in the clotting process belong to the serine 
endopeptidase family which are characterised by their ability to cleave a specific 
peptide bond in their substrate and contain a serine residue in their active site. The 
substrates of these enzymes are usually endopeptidase precursors, resulting in 
amplification of the pathway via consecutive enzyme activation4. The resulting clot is 
made of a mesh-like network of fibrin fibres to which various clotting factors bind and 
crosslink forming the mature clot which prevents continued bleeding. Whilst platelets 
have a crucial role in clot formation, my thesis concentrates on the acellular arm of 
coagulation, in particular the fibrinogen molecule, which will be the focus of my work. 
1.3 Serine proteases 
Serine proteases are a family of enzymes characterised by their ability to cut 
certain peptide bonds in proteins due to their unique active site featuring a preserved 
serine residue. They are abundant in the digestive system and complement cascade, 
as well as being involved heavily in blood clotting. Digestive enzymes such as trypsin, 
chymotrypsin and elastase, secreted by the pancreas, are all serine proteases, sharing 
the same position of serine in their active site. Despite this similarity they have 
specificities for varying substrates and different peptide bonds. In plasma, several of 
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the clotting factors are serine proteases, including FX, FXI and FXII as well as thrombin 
and plasmin. 
These proteins circulate in the plasma in an inactive proenzyme state from which 
they must be activated by specific proteolysis to their active catalytic state. They are 
multidomain proteins, consisting of a serine protease domain and a series of other 
domains such as kringles, fibronectin- and epidermal growth factor-like domains. Two 
anti-parallel β barrels are surrounded by four helical segments to make up the 
enzymatically active serine protease domain, the active cleft of which is formed by a 
‘catalytic triad’ of histadine, asparagine and serine residues. The other domains 
facilitate the efficient activity of the enzyme by aiding the binding of the enzyme and 
target5. The structure of these proteins is illustrated in Figure 1-2. 
 
 
Figure 1-2. Schematic representation of the primary structure of a human serine 
protease (plasminogen) 
The signal peptide, the N terminal peptide, the plasmin cleavage site (Lys77-Lys78), 
kringles 1-5, the protease domain, the catalytic triad (His603, Asp 646 and Ser741) and 
the activation site (Arg561-Val562) are shown. 
1.4 Serine protease inhibitors 
Serine protease inhibitors (serpins) regulate many physiological processes such 
as coagulation, fibrinolysis, inflammation, angiogensis and apoptosis by irreversibly 
inhibiting serine proteases in these systems6. Three β-sheets (A-C), nine α-helices (hA-
hI) and a relatively mobile reactive centre loop (RCL) make up the standard serpin 
structure, with the scissile bond of the serine protease recognition site lying in the RCL 
at the surface of the molecule. Serpins are capable of adopting several different 
conformations as a result of their mobile RCL; the native form, the latent reactivatable 
form (with the RCL inserted into the Aβ sheet, with the scissile bond shielded), the 
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substrate form (with cleaved RCL), the protease-complex form and an inactive 
polymerised form (RCL inserted into the Aβ-sheet of another serpin molecule)7. 
The inhibition by serpins is said to be ‘suicide inhibition’ due to the fact they are 
consumed and inactivated during the inhibition reaction. This is a multi-step process, 
the first of which is fast and reversible, while the remaining steps proceed slowly and 
are irreversible. First a non-covalent 1:1 Michaelis-like complex is formed with the 
serine protease, followed by the cleavage of the reactive peptide scissile bond in the 
RCL due to the insertion of the RCL into the β-sheet A. This results in the movement of 
the RCL 71 Å to the opposite side of the serpin, thus transferring the bound protease 
with it. Consequent attachment of the serpin to the catalytic triad serine residue of the 
serine protease via a covalent bond then completely inactivates the protease5, 6. The 
protease can now no longer be released from the serpin, where it is proteolytically 
destroyed6. 
In plasma, the action of these serpins, which make up nearly 20% of the proteins 
in blood, is hugely important. The large scale rapid amplification of a relatively small 
initiation reaction in the clotting cascade is essential to the blood clotting process. 
However it is equally important for there to be a mechanism by which this amplification 
can be controlled and stopped when the need for it is over. 
1.5 Fibrinogen 
1.5.1 Structure of fibrinogen 
The primary structure of fibrinogen, a 340,000 Dalton multi-domain protein, has 
been fully sequenced. It is formed by three pairs of polypeptide chains, Aα, Bβ and γ, 
made of 610, 461 and 411 amino acid residues respectively, noted as (Aα, Bβ, γ)2. The 
protein is said to consist of 3 nodular regions; two lateral domains (D domains) which 
are 67200 Da each, composed of globular carboxyl termini of Bβ and γ chains, and one 
dimeric central domain (E domain) to which the carboxyl termini of the Aα chains are 
folded. The domains are linked by arms or ‘coiled coils’ formed from one each of the 3 
Aα, Bβ and γ chains supercoiled as α helices. Cyanogen bromide cleavage has 
revealed 5 ‘disulfide knots’ (or fibrinogen-cyanogen-bromide fragments) containing all 
29 disulfide bridges present in the protein. In this way, it has been shown disulfide 
bonds hold the coiled coils’ supercoiled α helix structure in place as well as forming 
disulfide rings as the attachment to the central and lateral domains8. At the amino 
terminal, 11 disulfide bridges directly link the pair of γ chains that make up the so called 
‘backbone’ of the protein, to which the Aα and Bβ chains are covalently linked to form 
the central domain9.  
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Of the 29 disulfide bonds, 17 are interchain while the remaining 12 are intrachain 
connections, 6 in each half-molecule. These form loops in the carboxyl terminal of each 
of the chains (AαCys442-Cys472; BβCys201-286, 211-440 and 394-407 and γCys153-
182 and 326-339)10. These structures are depicted in Figure 1-3. The amino-terminals 
of the Aα and Bβ chains are thickened due to the presence of fibrinopeptides A and B 
respectively which are cleaved by plasmin to form fibrin, noted (αβγ)2.  
 
 
Figure 1-3. Schematic representation of the structure of fibrinogen  
The locations of the interchain rings (Aα28, α36-β65 and γ8-γ9) and bonds and 
intrachain disulfide loops (AαCys442-Cys472; BβCys201-286, 211-440 and 394-407 
and γCys153-182 and 326-339) in relation to the coiled-coil region and the N-linked 
oligosaccharides are shown. Adapted from Zhang & Redman (1996)10. 
 
The amino acid residue sequence of the coiled coils is such that the inside is 
hydrophobic and the outside polar, along which there are 3 clusters of half cysteine 
residues8. Four carbohydrate side chains (2500 Da each), made up of sialic acid, 
galactose, mannose and N-acetylglucosamine, exist which are linked at the N-terminal 
to asparagine residues on the lateral domains of the β chains and near the central 
domain area of the γ chains11.  
Acuna et al. (1987)12 showed the protein to be essentially rigid in the 10-1000 ns 
time range, they estimated it to be a 47 x 10.5 nm elongated cylinder, carrying 4 g of 
water per 1 g protein. This confirms the intrinsic rigidity and stable conformation of the 
molecule in solution, with no free movement of the bulky segments. This fits in nicely 
with the requirement of rigidity to facilitate the non-covalent interactions formed in the 
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half-staggered structure of protofibrils and to form a bridge in platelet aggregation to 
crosslink individual activated platelets. 
The γ chain is subject to alternative splicing at its C-terminus, producing either γA 
or γ’ (gamma prime). The majority of γ’ circulates in a heterodimer with the more 
common γA as γA/γ’. The difference occurs due to polyadenylation at various sites on 
the messenger RNA transcript. The 411 amino acid γA chain is composed of 10 exons 
and 9 introns due to polyadenlyation occurring downstream of exon 10. However when 
polyadenlyation occurs at an alternative site, in intron 9, intron 9 is not spliced out and 
γ’ is secreted with an extra 20 amino acid extension coded by intron 9 instead of amino 
acids γA408-411 from exon 1013.  
1.5.2 Assembly and secretion of fibrinogen 
Fibrinogen is assembled in a stepwise process from the formation of Aα-γ and 
Bβ-γ complexes from single chains, to the addition of a third chain to form half-
molecules (Aα.Bβ.γ) which then dimerise at the amino-terminal (Figure 1-4). These 
connections rely entirely on disulfide bonds: Symmetrical interchain disulfide bonds 
form at the amino terminal between the two half-molecules at adjacent CysAα28, 
Cysγ8 and Cysγ9 residues as well as CysBβ65 and CysAα36 residues becoming 
disulfide linked. Interchain disulfide rings on the carboxyl terminal of the coiled coil 
region, though not playing a crucial part in chain assembly, are required for proper 
protein folding. In addition, Bβ and γ intrachain loops affect the addition of the third 
chain to Aα-γ and Bβ-γ complexes in cooperation with the amino acid sequence of the 
α helix and the flanking interchain disulfide rings, by allowing proper alignment of the 
additional chain10. This process takes place independently of hepatocyte specific 
machinery via information inherent in the protein chains themselves. The protein is 
secreted by a general secretory mechanism from hepatic parenchymal cells14 after 
which it has a half life of approximately 4 days in vivo, circulating at 2-4 mg/ml (6-12 
µM) in plasma3. 
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Figure 1-4. Schematic representation of the assembly of the 3 fibrinogen chains 
into a single fibrinogen molecule (Aα.Bβ.γ)2  
Either βγ or αγ polymers are formed, then the α or the β chain is attached to form the 
half molecule. These are then joined to form the fibrinogen molecule. 
1.5.3 Conversion of fibrinogen to fibrin 
The conversion of fibrinogen to fibrin is catalysed by thrombin, a two chain 
disulfide linked 39k DA enzyme homologous with trypsin and chymotrypsin. Thrombin 
is a very specific enzyme, hydrolysing only Arg-Glu bonds at the N-termini of the Aα 
and Bβ chains of fibrinogen, leaving the rest of the molecule intact15.  
1.5.3.1 Fibrinopeptide A release 
Thrombin  binds to the E domain of fibrinogen, hydrolysing bonds to first release 
the 16 residue fibrinopeptide A (FpA) from the Aα chain, exposing the so called ‘a-site’ 
of the N terminus. This newly exposed site is able to interact with an ‘A-pocket’ already 
exposed in the D domain of the γ chain, allowing the E domain a-site of one molecule 
to covalently interact with the D domain A-pocket of another, resulting in elongation of 
the fibrin chain, leading to the formation of half staggered, double stranded protofibrils.  
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1.5.3.2 Fibrinopeptide B release 
Secondary hydrolysis of Arg-Glu bonds in the Bβ chain N-terminal results in the 
release of the 14 residue fibrinopeptide B (FpB) and exposure of an E domain ‘b-site’. 
In this case, the b-site interacts with a site in the D domain of another fibrinogen 
molecule’s Bβ chain known as the ‘B-pocket’. This in turn allows lateral growth of the 
polymer, thickening the fibrin fibre16. The initial linear growth of the polymer, before FpB 
release is represented as a ‘lag’ phase during clot formation in which there is no 
turbidity increase. The role of Fibrinopeptide A and B release in protofibril formation 
and fibrin polymerisation is depicted in Figure 1-5. Lateral association and interaction of 
two protofibrils to form a fibrin fibre is depicted in Figure 1-6. 
Using a fibrinogen variant which causes significantly reduced and delayed FpA 
release, the role of FpB and the impact of delayed FpA release in clot formation and 
structure has been further investigated. Clots made from this variant fibrinogen have 
similar clottability and fibre thickness/branch points compared with those of wildtype 
(WT) fibrinogen, but form more slowly. This implies the ionic environment, rather than 
the order of peptide release, determines fibre size and that although FpA release 
supports polymerisation of fibrin more strongly, FpB release is still sufficient to support 
normal polymerisation and clot formation, but at a slower rate17. 
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Figure 1-5. The role of fibrinopeptide A and B release on formation of the 
intermediary protofibril and fibrin fibre 
FpA release allows the formation of the early protobfibril. Following FpB release allows 
lateral growth of these fibrils into fibrin fibres. 
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Figure 1-6. Lateral association of protofibrils to form fibrin fibres 
The a-sites of the E domain of one molecule interact with the A-pockets of the D 
domain of another while the E domain b-sites and the D domain B- pockets of opposite 
molecules interact. 
1.5.3.3 Lateral aggregation and the αC domains 
The C terminal parts of the Aα chains form two compact structures (αC domains) 
which strongly interact intramolecularly with each another and the central E domain. 
They are relatively mobile structures compared to the bulk of the molecule due to their 
connection to the molecule terminus through extended flexible polypeptide junctions. A 
conformational change occurs when fibrinogen is converted to fibrin; the αC domains 
dissociate from each other and the central E domain and are thus free to interact 
intermolecularly with other fibrin molecules. Their role in fibrin polymerisation is 
promotion of the ordered assembly of the complex fibrin, helping orientate the fibres 
with their binding partners. It also appears the interactions αC domains form are critical 
in lateral aggregation; clots formed from αC domain truncated fibrinogen (Aα251) are 
made up of densely packed thinner fibres, with more branch points and reduced 
permeability than WT fibrinogen. Truncation of the αC domains also leads to clots that 
are much less stiff, showing αC domains to be important in determining the viscoelastic 
and mechanical properties of fibrin and promoting clot stability. They also show less 
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resistance to lysis than clots made from WT fibrinogen implicating the αC domains in 
fibrinolysis susceptibility18, 19.   
1.5.4 Fibrinogen α chain 
The mature 66 kDA fibrinogen α-chain is made up of 610 amino acids with a 16 
residue signal peptide at the 5’ end, so called fibrinopeptide A. An additional 15 amino 
acids at the carboxyl terminal of the polypeptide chain is predicted by the 
complementary deoxyribonucleic acid (cDNA) sequence which is not observed by 
protein sequencing of plasma fibrinogen, presumed to be due to removal during 
assembly, secretion or circulation by limited proteolysis20. 
1.5.5 Fibrinogen β chain 
The entire 461 amino acid sequence of the human β chain of fibrinogen has been 
described. It is 52 kDA and has one carbohydrate chain. The percentage of cDNA in 
the liver represented by the β fibrinogen chain (2.6%) is significantly greater than found 
for the α or γ chains (1.3 and 1.7% respectively). This may be due to increased levels 
of β chain messenger RNA (mRNA) in liver or higher cloning efficiency of the β chain 
from existing mRNA. Of the 10 kilobases of DNA coding the β chain, only 20% of the 
DNA constitutes coding sequence, with eight exons and 7 introns, thought to separate 
the gene into regions in relation to the proteins structural domains. Exon 1 (aa 1-9) 
contains the signal peptide and part of FpB, the second (9-72) contains the thrombin 
cleavage and fibrin polymerisation sites while the third and fourth (73-133 and 134-204) 
contain the interdomainal connecting superhelical structures21.  
1.5.6 Fibrinogen γ chain 
The 46.5 kDA γ chain of fibrinogen consists of 411 amino acids with one carbohydrate 
side chain linked at Asn52. The carboxyl-terminal plays important roles in fibrin 
polymerisation and FXIII catalysed covalent cross-linking of various molecules22.  
The main functional activities of each of the fibrinogen chains are summarised in Table 
1-1. 
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Table 1-1. The main functional activities of the three fibrinogen chains 
Chain Main functional activities 
Alpha 
 Thrombin binding and fpA release; initiation of fibrin assembly15, 17 
 Alignment for end-to-middle staggered fibril formation10 
 Promotion of  lateral fibril associations (αC domain)18, 19 
 tPA and plasminogen binding (αC-domain - Aα148-160); 
enhanced plasminogen activation5, 8, 23, 24 
 Platelet interactions (Aα95-98 & 572-575)8, 25 
 FXIII crosslinking3, 26, 27 
o α-α crosslinking 
o γ-α crosslinking 
o α2-AP crosslinking (αC-connector - Lys303)  
o PAI-2 crosslinking 
o Fibronectin crosslinking  
 α2-AP (αC-domain) and fibronectin binding28 
Beta 
 Thrombin binding and FpB release; lateral growth of the fibre15-17 
 Alignment for end-to-middle staggered fibril formation10 
 Alignment for FXIII crosslinking – increasing clot strength3, 27 
 Platelet interactions (fibrin Bβ15-42)8, 25 
Gamma 
 Fibrin polymerisation and crosslinking10 
 Alignment of crosslinking regions in fibrin10 
 Binding and regulation of FXIII (Lys406)3, 8, 26, 29 
o FXIIIB binding 
o γ-γ crosslinking  
o γ-α crosslinking 
 tPA binding and enhanced plasminogen activation (γ312-324)24 
 Platelet interactions (γ400-411)8 
 
1.5.7 Mechanical properties of fibrin 
The mechanical properties of a clot are very important in determining its ability to 
stop bleeding and to withstand the pressure of blood flow. Clots are capable of being 
deformed to a great extent and still show complete recovery, clearly demonstrating that 
fibrin is an elastic protein30. Viscoelastic properties can determine the fate of the clot; to 
what extent blood flow will cause it to deform, reversibly or irreversibly, and whether it 
will rupture or embolise. This implicates these properties as important in clinical 
15 
 
outcome as tight, rigid clots are likely to be more friable and have a greater tendency to 
embolise31. It is accepted that it is the properties of the individual fibres making up the 
clot that dictate the mechanical properties of the structure. Three domains of the fibrin 
monomer have been proposed as areas of interest: the coiled coil connectors, the 
folded globular nodules and the αC regions. 
Weisel and colleagues32 showed an initial linear increase in the force required to 
stretch a clot accompanied by fibre alignment, bundling and a decrease in clot volume. 
They proposed the expulsion of water from the clot following exposure of hydrophobic 
residues as a result of unfolding of the coiled-coil connectors. Work by others has 
demonstrated four abrupt changes in the fibrin molecule when external force is applied 
to a clot. They propose the first change to be the breakage of an unknown interaction 
close to the A-a bond, the next two events comprising unfolding of the D region. They 
suggest rupture of the A-a bond secondary to weakening by prior unfolding of the 
molecule accounts for the 4th event33. Further studies have shown individual fibre 
extensibility to vary with the length of the αC region, showing a concomitant rise in 
extensibility with αC connector length implicating this region in playing a key role in 
fibre extensibility34. It is likely that a mixture of all of these areas contribute to the 
mechanical and viscoelastic properties of the clot. Clots with a looser architecture and 
fewer branch points will have more room for deformation or compaction as their fibres 
will be more extensible thanks to fewer ‘junctions’ along their length. Changes in any of 
the contributing areas, especially the flexible αC region of fibrin could greatly affect the 
clot’s mechanical strength. 
Many variables can alter the mechanical properties of a forming clot. Clot 
stiffness has been shown to be greater in the presence of transglutaminase FXIIIa, 
which can also crosslink proteins into the clot affecting its mechanical structure and 
resistance to lysis. Fibrinogen gene mutations such as Fibrinogen Dusart (Aα554) can 
affect viscoelastic properties by interfering with lateral aggregation of fibin monomers, 
leading to stiff clots made of thin fibres and many branch points35. 
1.6 FXIII 
FXIII is able to form covalent γ-γ and γ-α crosslinks which reinforce inter-fibre 
contacts, increasing fibre elasticity and resistance of the clot to lysis through various 
mechanisms discussed below3. 
1.6.1 Structure 
Plasma FXIII is a tetrameric protein of 320 kDa made up of 2 A- and 2 B-subunits 
with each monomeric chain of 75 kDa and 88 kDa respectively. The globular A-
subunits contain the active site of the protransglutimase while the inert B subunits 
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function as carriers in plasma. These subunits are bound by noncovalent bonds, 
though unbound B subunits are also found in plasma, and play a key role in preventing 
spontaneous activation of A-subunits and thus preserving molecule half life. In contrast, 
cellular FXIII is present only as A-subunit dimers36. 
1.6.2 Synthesis and secretion 
FXIII B-subunits are synthesised in hepatocytes and secreted through the 
classical secretory pathway. The major source of FXIII A-subunits is cells from the 
bone marrow, with relatively insignificant contributions made by hepatocytes.  Unlike 
the B-subunit, A-subunits are released as a result of cell destruction. The two subunits 
then combine upon contact in the plasma circulation27 and circulate at 21.6 µg/ml (67.5 
nM). Practically all FXIII in circulation is bound to fibrinogen (Kd ~10-8 M) as fibrinogen 
is at a 20-100 fold excess, displaying an even higher affinity for fibrin. Platelets are also 
carriers of FXIII A-subunits in plasma; it is only upon activation and degranulation of 
these platelets that these A-subunits become free in the plasma, where they are able to 
associate with B-subunits already in circulation. This degranulation of platelets thus 
results in a FXIII ‘blast’27. 
1.6.3 Activation 
Plasma FXIII is activated by thrombin via cleavage of the Arg37-Gly38 peptide 
bond of the FXIII A-subunit. This separates a 37 residue activation peptide (4 kDa) 
from the FXIIIA N-terminal37 which remains in place occluding the FXIIIA active site, 
weakening the bond between the A- and B-subunits. Binding of 2 Ca2+ ions to the FXIII 
A-subunits leads to dissociation of the B-subunits from the partially activated A-
subunits and exposure of the active site cysteine of the catalytic core of FXIIIA, 
releasing fully active FXIIIA (Figure 1-7). This activation is accelerated in the presence 
of increased Ca2+ and fibrin(ogen), an effect requiring the FXIII B-subunits for 
orientation of FXIIIA in the fibrin-FXIII matrix, this acceleration can be as much as 100-
fold in the presence of polymerised fibrin. This is because thrombin cleaved FXIII 
becomes attached to fibrin polymers, on the surface of which the dissociation of the 
subunits takes place, after which the B-subunits detach from the fibrin surface. The 
cleavage and release of only one of the FXIIIA activation peptides is sufficient to 
expose the active thiol group of both cleaved and uncleaved A-subunits. In contrast 
cellular FXIII is activated via a slow non-proteolytic mechanism initiated by influx of 
Ca2+ into the cell27. 
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Figure 1-7. Activation of plasma FXIII by thrombin 
Thrombin cleaves the Arg37-Gly38 peptide bond of the FXIII A-subunit separating an 
activation peptide. Binding of 2 Ca2+ ions to the FXIII A-subunits leads to dissociation of 
the B-subunits from the partially activated A-subunits and exposure of the active site 
cysteine of the catalytic core of FXIIIA, releasing fully active FXIIIA.  
1.6.4 Crosslinking action 
Once converted to an active transglutaminase, FXIIIa is able to stabilise fibrin 
clots by catalysing formation of E-(γ-glutamyl)lysine isopeptide bonds. Intermolecular γ-
γ, γ-α and α-α bonds are formed between fibrin chains. Carboxyl terminal D domains of 
γ chains are cross-linked rapidly, forming γ-γ dimers resulting from bridges between 
Lys406 of one chain and Glu398/399 of another γ chain aligned anti-parallel8. The 
relatively slower process of α-α crosslinking results in oligomers and large α-polymers, 
forming bridges between glutamine residues at Aα328 and 366 and lysine residues at 
Aα508, 556 and 56226. FXIIIa’s enzyme activity relies on the transfer of an acyl group 
from the transglutaminase to an acyl-acceptor ε-amino group from a lysine residue on a 
molecule of fibrinogen, which then becomes linked to a γ-glutamyl residue on another 
fibrinogen molecule, releasing ammonia27. This crosslinking leads to the formation of 
thick fibres with increased elasticity and rigidity that are more resistant to lysis in the 
plasma environment. It is thought to be the interchain crosslinks themselves conferring 
resistance to lysis, as well as inhibiting the binding of plasminogen and increasing 
inhibitor crosslinking.  
1.6.5 Control of crosslinking 
Since FXIII crosslinking confers resistance to fibrinolysis, it follows that 
uncontrolled crosslinking of fibrin fibres and of plasma proteins into a clot may result in 
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a fibrinolysis-resistant thrombus, which may have adverse effects in individuals with 
vascular disease. Inhibition of FXIII crosslinking activity within a thrombus has been 
demonstrated, though the mechanisms of inactivation are unclear. As no protein 
inhibitor has been identified for FXIIIa, it is likely inactivation is by way of proteolytic 
cleavage38. 
1.6.6 Other substrates of FXIII 
FXIII is also capable of crosslinking other factors into the clot, such as α2-AP, 
vWF, thrombospondin and fibronectin (Table 1-2) which can further protect the clot 
from proteolysis while enhancing mechanical strength, elasticity and viscosity8, 36.  
Table 1-2. Substrates of FXIII in the circulation 
Protein Substrate 
Coagulation factors 
Fibrin(ogen) α chain8 
Fibrin(ogen) γ chain26 
Fibrinolytic proteins 
α2-AP28 
Plasminogen5 
TAFI39 
PAI-240 
Adhesive/ matrix proteins 
Thrombospondin41 
Vitronectin42 
Fibronectin43-46 
Osteopontin47 
vWF48, 49 
Cytoskeletal proteins 
Actin50 
Myosin50 
Others α2-Macroglobin44 
 
1.6.6.1 Anti-fibrinolytic proteins 
α2AP, the primary substrate for FXIII besides fibrin, is crosslinked to fibrin α- 
monomers and polymers (discussed in more detail in Section 1.9.4) and protects the 
fibrin network from lysis by inhibiting activity of plasmin. PAI-2, an inhibitor of uPA, can 
be crosslinked to fibrin(ogen) by FXIIIa where activity is retained and inhibition of 
fibrinolysis by uPA is achieved.  This crosslinking may also serve to compartmentalise 
the PAI-2 in the clot40. TAFI can be both polymerised and crosslinked to fibrin by 
FXIIIa, it is thought that crosslinking of TAFI may help activation of the enzyme, 
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stabilise its activity and prevent proteolytic degradation that would otherwise happen in 
the milieu39. When activated to TAFIa, by thrombin and thrombomodulin, it works to 
remove C-terminal lysine residues that become exposed on fibrin upon plasmin 
degradation. This reduces the number of sites for tPA and plasminogen binding thus 
reducing plasminogen activation and suppressing fibrinolysis. High molecular weight 
multimers of plasminogen and fibronectin-plasminogen heteropolymers can also be 
formed by the crosslinking action of FXIIIa43.  
1.6.6.2 Adhesive proteins 
Fibronectin, a glycoprotein present in connective tissue and basement 
membrane, is a substrate of FXIIIa, which is crosslinked to fibrin and collagen44, 45. 
Fibronectin on the surface of, and within, fibroblasts can also be crosslinked into 
assembling extracellular matrices by FXIIIa46. vWF in its monomeric form only can be 
crosslinked by FXIIIa to form polymers, whilst both monomeric and polymeric vWF can 
be crosslinked to the fibrin α-chain and collagen. Incorporation of amines into vWF is 
also catalysed by FXIIIa48, 49. Vitronectin and osteopontin are both substrates for FXIIIa, 
promoting cell attachment and spreading, and mediating osteoclast attachment to bone 
respectively 42, 47. Thrombospondin, secreted during platelet activation, can act as a 
FXIIIa substrate wherein FXIII polymerises thrombospondin to homopolymers and 
heteropolymers with fibrin41. 
1.6.6.3 Cytoskeletal proteins 
Both platelet and skeletal muscle actin and myosin are substrates for FXIIIa, 
which catalyses the incorporation of amines into myosin to form myosin polymers50. 
1.6.7 Clinical relevance 
1.6.7.1  Wound Healing 
FXIII plays a major role in wound healing, since deficiency of the clotting factor 
leads to delayed wound healing, incomplete re-epithelisation, persisting necrotised 
fissure and abnormal scarring51, with substitution of the FXIII restoring wound healing 
to control. FXIIIs effect on promotion of wound healing is multifactorial, affecting 
fibroblasts, macrophages, the extracellular matrix and angiogenesis. Migration and 
adherence of fibroblasts to the site of injury is enhanced by FXIIIa crosslinking of fibrin 
α chains52 and the incorporation of extracellular matrix protein (e.g. fibronectin) into the 
clot by FXIIIa53. Similarly, FXIIIa enhances macrophage and monocyte migration to the 
site of injury and inhibits their apoptosis, providing an anchoring mechanism for the 
cells at the injury site54. Cellular FXIII also contributes to tissue repair by enhancing 
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receptor mediated phagocytoisis of monocytes and removal of cell debris and apoptotic 
cells55. 
1.6.7.2 Angiogenesis 
FXIIIa has a pro-angiogenic effect, a product of the enhanced endothelial cell 
migration and proliferation, as well as decreased apoptosis in its presence, allowing 
new capillaries to form at the site of injury to reperfuse the tissue. This effect seems to 
work through down regulation of TSP-1 (Thrombospondin-1), a glycoprotein involved in 
the inhibition of angiogenesis by inhibiting endothelial cell migration and proliferation 
and promoting apoptosis56. 
1.6.7.3 Pregnancy 
FXIII is essential for maintaining pregnancy, with studies showing FXIIIa deficient 
patients to suffer pregnancy loss in the first trimester57 and replacement therapy of 
FXIIIa allowing these patients to come to full term58.  Fibrin(ogen) and fibronectin have 
been identified as important substrates of FXIII in this situation as they are prevalent in 
the Nitabuch’s fibrinoid membrane, the layer of tissue the placenta dethatches itself 
from at birth59. It is thought FXIIIa crosslinks fibrin(ogen) and fibronectin, thus 
stabilising the membrane and conferring resistance to lysis. The pro-angiogenic effect 
of FXIII also plays a crucial role in normal placenta development. 
1.6.7.4 Cardiac complications 
Studies on FXIIIa deficient mice have shown FXIIIa to have a protective effect 
against cardiac rupture60. Deficient mice die within 5 days of left coronary artery ligation 
induced myocardial infarction (MI) due to left ventricle wall rupture compared to WT 
mice or FXIIIa deficient mice supplemented with FXIIIa, in which there are no deaths. 
The inflammatory response at the site of injury is reduced in FXIIIa deficient mice and 
this is due to impaired migration of monocytes to the lesion, a process requiring active 
FXIII61. The actions of FXIIIa are summarised in Figure 1-8. 
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Figure 1-8. Mechanisms of action of activated FXIII 
FXIIIa crosslinks various proteins to fibrin and forms interchain links between fibrin 
fibres thus producing clots resistant to lysis and causing changes in adhesion, 
migration, proliferation and apoptosis of fibroblasts, monocytes and macrophages. It 
also plays a role in angiogenesis and wound healing. 
1.7 Platelets 
In a healthy individual, platelets circulate in their inactive form at 150,000- 
450,000 per μL of blood, showing no binding to clotting proteins in the blood and a 
lifespan of 5-9 days. However at sites of vessel injury where collagen, vWF and TF are 
exposed and where there are increased levels of clotting factors, such as thrombin, 
platelets become activated. They can also become activated by high shear stress in 
conditions such as arterial stenosis25. Once activated, platelets can bind many 
coagulation factors via a number of exposed receptors; GpIb-IX-V is able to bind 
vWF/VII complexes, thrombin and FXI while GpIIb-IIIa binds fibrinogen and 
prothrombin, in this way coagulation factors promote platelet stimulation and 
aggregation1. Platelet activation, adherence and aggregation act to form a platelet plug 
using vWF and fibrinogen as a connecting agent. This platelet plug not only helps to 
stop the initial bleeding but helps wound repair by the secretion of growth factors 
(platelet derived growth factors (PDGF) and transforming growth factor beta (TGFβ)) by 
the activated cells. These stimulate invasion of fibroblasts to the site of injury and 
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deposition of extracellular matrix. Upon clot lysis, platelets are cleared by 
phagocytosis2. 
GpIIb-IIIa is a calcium-dependent heterodimer of the integrin family of adhesion 
receptors which can bind fibronectin, vWF, vitronectin as well as fibrinogen when 
exposed on the surface of activated platelets. The receptor undergoes a 
conformational change following platelet activation involving receptor binding by 
thrombin or ADP triggering initiation of the phosphoionositide signal transduction 
pathway leading to exposure of multiple binding sites on the extracellular domains of 
the receptor8.  The dissociation constant of the binding of fibrinogen to GpIIb-IIIa on 
stimulated platelets is around 100 nM, approximately 100-fold lower than the circulating 
fibrinogen concentration suggesting immediate fibrinogen binding upon platelet 
activation in plasma. It is thus evident that tight regulation of GpIIb-IIIa-fibrinogen 
binding is essential to prevent spontaneous and deleterious platelet aggregation. Three 
areas of the fibrinogen molecule have been suggested to bind to the GpIIb-IIIa 
receptor; the carboxyl-termini of the γ-chains, two regions of the α chain that contain an 
RGD motif (Arg-Gly-Asp-X) and sequences located between residue 15-42 of the β-
chain. It is thus clear that platelets play a major role in blood clot formation, cessation 
of bleeding and wound repair, with low levels of platelets or their activation causing 
excessive bleeding, while over-activation and excessive platelet count leading to a 
thrombotic environment. 
1.8 Fibrinolysis 
It is essential that once the blood clot is no longer needed, it is removed safely 
from the circulation as clots that remain can embolise, causing stroke and other organ 
ischaemia. This is achieved by fibrinolysis, progressive cleavage of fibrin polymers that 
can be cleared safely. Fibrinolysis is initiated by the release of tissue plasminogen 
activator (tPA) from endothelial cells upon the conversion of fibrinogen to fibrin and the 
consequent generation of plasmin from plasminogen. Plasmin causes fibrin 
degradation via cleavage at multiple sites in the fibrin molecule resulting in the 
formation of fibrin degradation products. This process is mainly inhibited by α2-AP and 
PAI-1, which bind free plasmin and inhibit plasminogen activation respectively23. The 
mechanisms of fibrinolysis are summarised in Figure 1-9. 
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Figure 1-9. The fibrinolytic system 
The fibrin clot is dissolved by plasmin which is converted from plasminogen by tPA and 
uPA. Various feedback mechanisms exist to control this process, including inhibitory 
proteins such as α2-AP which directly inhibits plasmin action on fibrin. 
1.8.1 Plasminogen 
1.8.1.1 Structure 
Plasminogen is a 90 kDA single chain glycoprotein made up of 791 amino acid 
residues and belongs to the serine peptidase family of proteins. During secretion a 19-
residue signal peptide is cleaved from a pre-cursive 810 amino acid protein to release 
mature Glu-plasminogen, the pro-enzyme of plasmin. Plasminogen has a multidomain 
structure composed of an N-terminal peptide (NTP), 5 kringles (triple loop structures 
stabilised by disulfide bridges) and 3 serine protease domains composing the catalytic 
triad His603, Asp646, Ser741. In circulation, plasminogen binds histidine-rich 
glycoprotein which serves as a high-affinity receptor to immobilise plasminogen to cell 
surfaces at sites of tissue injury5. Plasminogen circulates in two N-terminal variant 
forms, Glu- and Lys-plasminogen. Lys-plasminogen is formed by the release of a 76 
residue preactivation peptide from Glu-plasminogen by plasmin cleavage of the Lys76-
Lys77 bond of Glu-plasminogen. Lys-plasminogen is more readily activated by 
plasminogen activators and has a higher binding affinity to fibrin62. The increased fibrin 
binding affinity of Lys-plasminogen can be explained by the conformational change that 
Glu-plasminogen undergoes when it is proteolytically modified to Lys-plasminogen. 
While Glu-plasminogen has a compact spiral conformation, Lys-plasminogen and 
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plasmin exhibit an open, elongated structure5. This suggests the cleavage of the NH-
terminal peptide of Glu-plasminogen elicits a conformational change that exposes the 
high affinity fibrin binding site present in Lys-plasminogen62. 
1.8.1.2 Synthesis and Secretion 
Human plasminogen is synthesised in the liver and circulates in plasma at a 
relatively high concentration of around 2 µM. 
1.8.1.3 Activation 
Cleavage of the Arg561-Val562 peptide bond of plasminogen by tPA (and uPA), 
and the release of a 77 residue activation-NTP lead to plasminogen conversion to 
active plasmin. Consequent autocatalytic cleavage within the plasmin molecule of the 
78-79 residue peptide bond results in a two-chain disulfide linked molecule. A heavy 
chain (from residue 79-561, 483aa) contains all kringles (K1-5), while a light chain 
(from residue 562-791) contains the catalytic triad. Each kringle except K3 contain 
lysine binding sites (LBS), which mediate binding to fibrin(ogen) and α2-AP5, 63. 
1.8.1.4 Action 
Plasminogen binds intact fibrin throughout the clot upon clot formation and it is 
this plasminogen that is responsible for initiation of lysis. Plasmin cleaves polypeptide 
chains at lysine residues so new carboxyterminal lysine residues are revealed in the 
clot, producing further binding sites for plasminogen on fibrin. Fibrinolysis is greatly 
accelerated by both the consequent increase in local plasminogen concentration and 
increased plasminogen reactivity due to plasminogen binding to these sites. This 
increased reactivity is due to altered conformation leading to increased sensitivity to 
activation64. Two binding sites with different affinities for fibrin exist in plasminogen, 
both located on fibrin fragments D and E. The low affinity site is capable of activating 5 
times more plasminogen upon fibrin binding than the high affinity8.  
Plasmin specifically hydrolyses arginyl and lysyl bonds in the coiled-coils of fibrin. 
Initial cleavage breaks the Lys583-Met584 then the Lys206-Met207 and Lys230-
Ala231 bonds of the Aα chain, releasing a 4 kDA C terminal fragment and fragment X 
(260 kDA). Cleavage of fragment X across all three chains releases singular fragments 
Y (160 kDA) and D (100 kDa) and the consequent cleavage of this fragment Y releases 
a second D fragment and one fragment E (60 kDA). This allows the transformation of 
insoluble fibrin polymers into soluble fragments and ultimate dissolution of the clot5, 
summarised in Figure 1-10. 
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This progressive fragmentation leads to increased fibre diameter, bending of the 
fibres and splaying of the ends of the fibre before release of each fragment. It is now 
known this occurs by transverse cutting across the fibre rather than the previous theory 
of progressive cleavage uniformly around the fibre23. 
Plasmin has a broad specificity in-vivo, acting as a proteolytic factor not only in 
fibrinolysis but also extracellular matrix degradation, angiogenesis, wound healing and 
pathogen cell invasion. It can also inactivate and degrade other coagulation factors 
such as FVa, vWF and thrombospondin5. 
 
 
Figure 1-10. Dissolution of the fibrin clot by plasmin 
Plasmin cleaves the fibrin fibre to produce soluble fibrin fragments; firstly D-D:E 
complexes, then smaller D-D, E, Y and D fragments. 
1.8.1.5 Plasminogen activators 
Plasminogen is converted into its active form, plasmin, by tPA in plasma, while 
uPA works pericellularly to produce plasmin for intercellular processes. As mentioned 
above, they release active plasmin by cleaving at Arg561-Val562 of plasminogen to 
remove a 77 residue activation-NTP. 
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1.8.1.5.1 tPA 
tPA is a serine protease synthesised mainly in endothelial cells which circulates 
in plasma at 5-10 µg/ml (71-142 nM) as a single chain glycoprotein of 527 amino acid 
residues (70 kDa). This proenzyme form is converted to a two-chain completely active 
form by plasmin itself as well as FXa by cleavage of the Arg275-Ile276 bond and 
formation of an interchain disulfide bridge at Cys264-Cys395. The multidomain 
structure comprises one fibronectin type, one endothelial growth factor (EGF)-like and 
two kringle domains in one chain and the serine protease domain in the other. 
Binding of tPA to fibrin enhances the activation of plasminogen by tPA and 
consequently exposes C-terminal lysine and arginine residues by proteolysis by 
plasmin, these are capable of binding the LBS in K2 of tPA, increasing its local 
concentration and accelerating lysis5. Fibrin thus works to co-localise tPA and 
plasminogen on the its surface, working as both a template and a substrate for the 
two24. 
1.8.1.5.2 uPA 
uPA is a serine protease synthesised in the lung, kidney and endothelial cells 
which circulates in plasma at 5-10 µg/ml (91-182 nM) as a single chain glycoprotein of 
411 amino acids (55 kDA). Similarly to tPA, it is converted to its active two-chain form 
after cleavage of the Lys158-Ile159 bond by plasmin and FXIIa and formation of a 
interchain disulfide bridge. Its multidomain structure consists of one EGF-like and one 
kringle domain in one chain and a serine protease domain in the other chain5. 
1.9 Inhibition of fibrinolysis 
Though the lysis of clots is essential to prevent embolism and organ ischaemia 
and to facilitate wound healing, it is important that the clot remains at the site of injury 
long enough to prevent continued bleeding. There is thus tight control over promotion 
and inhibition of lysis in the circulation. A number of different proteins (e.g. α2-AP, 
(PAI)-1 and 2 and TAFI) inhibit lysis of the fibrin clot, contributing to the intricate 
balance of the coagulation system5. 
1.9.1 PAI-1 
Human PAI-1 is a serpin secreted from endothelial, smooth muscle, liver and fat 
cells which circulates at ~2-20 µg/L (40-400 nM) in plasma. It is a 50 kDa, 379 amino 
acid, single chain glycoprotein. Both uPA and tPA are inhibited by PAI-1, thereby 
reducing plasmin generation from plasminogen and modifying fibrinolysis rates. PAI-1 
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also inhibits thrombin, plasmin, trypsin and active protein C but at a much slower rate 
than it does tPA and uPA5. 
1.9.2 PAI-2 
PAI-2, also a serpin, is only detectable in plasma during early pregnancy or in 
pathological conditions when it circulates at around 5 µg/ml (83 nM). It is secreted from 
epithelial cells, monocytes, macrophages and keratinocytes as a mature single chain 
60 kDA, 415 amino acid glycoprotein. FXIIIa can catalyse the formation of isopeptide 
bonds between Gln83, 84 and 86 of PAI-2 and lysine residues in the fibrinogen Aα-
chain where it is an inhibitor of tPA and uPA, playing a role in maintenance of the 
placenta and embryonic development5. 
1.9.3 TAFI 
TAFI is a 401 amino acid, 60 kDA glycoprotein which circulates in plasma at ~75 
nM. Once activated by thrombin, TAFI inhibits fibrinolysis by its carboxypeptidase B 
activity; removing C-terminal lysine residues from degrading fibrin thus reducing the 
available tPA and plasminogen binding sites. FXIIIa is able to crosslink TAFI to fibrin 
which facilitates its activation, stabilises its enzymatic activity and stops degradation of 
the active enzyme as the carboxypeptidase activity is unstable when in serum (t1/2 ~ 10 
min)64, 65. 
1.9.4 Antiplasmin 
1.9.4.1 Structure 
α2-AP, a 67 kDA single chain glycoprotein of the serpin family, is the main 
inhibitor of plasmin in human blood.  In plasma, Met-α2-AP, a 464 residue protein with 
a methionine residue at the N-terminus is cleaved to produce a 452 residue protein 
with an asparagine N-terminus, named Asn-α2-AP. The 97 kDA proteinase responsible 
for this cleavage is antiplasmin-cleaving enzyme (APCE) which cleaves the Pro12-
Asn13 bond of Met-α2-AP66. Met- and Asn-α2-AP circulate at a ratio of 30:70 
respectively in the plasma67. 
1.9.4.2 Synthesis and secretion 
α2-AP is synthesised in the liver and circulates in plasma at concentrations 
around 1 µM. 
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1.9.4.3 Action 
α2AP is able to directly inhibit free plasmin in the circulation as well as fibrin 
bound plasmin, regulating fibrinolysis, however α2AP incorporation into the clot by first 
noncovalent binding and then covalent FXIII-mediated crosslinking results in increased 
clot resistance to lysis. 
1.9.4.4 Binding 
Tsurupa et al. (2010)28 showed α2-AP to bind non-covalently only to polymeric 
fibrin D regions and αC domains, or fibrin adsorbed to a membrane, displaying no 
binding to fibrinogen in solution or monomeric fibrin. This suggests that α2-AP binding 
sites that are cryptic in fibrinogen become exposed upon fibrin polymerisation (or 
surface adsorption). The dissociation constant (Kd) of the noncovalent α2-AP-
polymeric fibrin interaction is 45-68 nM, far below the physiological α2-AP 
concentration, demonstrating the high affinity of the two molecules in vivo, suggesting 
binding of α2-AP can regulate fibrinolysis. Using surface plasmon resonance (SPR), 
this binding occurs Lys-independently to the D region (D1 and D-D fragments) and the 
αC domain (Aα221-610 fragment), which are cryptic in fibrinogen and become exposed 
in fibrin. This noncovalent binding may serve to orientate the α2-AP molecule on 
fibrinogen, enhance crosslinking and inhibit plasmin in the early stages of fibrinolysis, 
before covalent crosslinking by FXIII takes place. The affinity of α2-AP binding to D-D 
fragments is greatly increased in the presence of plasminogen, while the affinity to 
other binding fragments is unaffected by its presence. This may be due to 
plasminogen-fibrin binding induced conformational changes in the fibrin D-region 
exposing α2-AP binding sites or the ability of α2-AP to bind to plasminogen, thus 
facilitating simultaneous binding of α2-AP to fibrin and fibrin-bound plasminogen28. 
1.9.4.5 Crosslinking 
The binding sites of the serpin to fibrin (in the αC domain and D regions) are 
separate to the FXIIIa crosslinking site which lies in the αC connector. FXIIIa crosslinks 
the 42 amino acid N-terminal of α2-AP to fibrin forming covalent bonds between Gln2 
(of Asn-α2-AP) or Gln14 (of Met-α2-AP) and Lys303 in the αC connector of the Aα-
chain of fibrinogen28. Crosslinking of α2-AP into the fibrin clot causes inactivation of 
plasmin and thus inhibition of fibrinolysis due to formation of an inactive 1:1 
stoichiometric complex with plasmin67. Asn-α2-ap is crosslinked to fibrin ~13 times 
faster than Met-α2-AP and consequently Asn-α2-AP exhibits greater inhibition of 
plasmin induced fibrinolysis66. This is thought to be due to the extra N-terminal 12 
residue peptide of Met-α2-AP limiting accessibility of FXIIIa to the Gln14 crosslinking 
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site68.  Though α2AP does not show significant binding to fibrinogen in solution, it has 
been shown that the two can be crosslinked by FXIII, but due to the lack of preceding 
binding, this process is much less efficient than the crosslinking to fibrin28. The binding 
and crosslinking sites of α2-AP to fibrin are depicted in Figure 1-11. 
 
 
Figure 1-11. Sites of non-covalent binding and covalent crosslinking by FXIIIa of 
α2-AP to fibrin 
α2-AP binds non-covalently and Lys-independently to fibrin D regions (D1 and D-D 
fragments) and αC domains (Aα221-610 fragment). FXIIIa crosslinks the N-terminal of 
α2-AP to fibrin between Gln2 (of Asn- α2-AP) or Gln14 (of Met- α2-AP) and Lys303 in 
the αC connector of the Aα-chain of fibrinogen. 
1.9.4.6 Inhibition of lysis 
Clot lysis is slowed in direct proportion to the circulating level of α2-AP and 
homozygous deficiency of the α2-AP gene is associated with a bleeding tendency, 
emphasising its physiological relevance in haemostasis66. The inhibition of plasmin by 
α2-AP mimics that of all serpins, with the C-terminal domain of α2-AP and kringle 
structures of plasmin interacting so that the Arg364 of α2-AP and the active serine in 
plasmin covalently bond resulting in the cleavage of the reactive site peptide bond in 
α2-AP (Arg376-Met377) and formation of an inactive α2-AP-plasmin complex67, 69. The 
C-terminal extension of α2-AP from Asn410 to Lys464 consists of 55 amino acids, 5 of 
which are conserved lysine residues (418, 427, 434, 441, 448 and 464). These are 
instrumental in the interaction of α2-AP and plasmin kringle domains (K1 and K4) 
enhancing the α2-AP-plasmin interaction 30-60 fold70. Lys464 and Lys448 of α2-AP 
have been identified as the most important in initiating binding and increasing the rate 
of interaction with plasmin kringle domains, although all lysine residues contribute to 
this process. This has been shown by the progressive loss of plasmin association, 
binding and inhibition by α2-AP with consecutive mutation of the conserved lysine 
residues, and the same level of binding and inhibition as C-terminally truncated α2-AP 
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when all lysine residues are mutated. Though these lysine residues are clearly of great 
importance, even C-terminally truncated α2-AP can associate with and bind to plasmin. 
Exosites in the α2-AP core, away from the reactive scissile bond, and the active site of 
plasmin interact, contributing to target protein recognition and specificity71. 
Alongside the fibrin-binding and the active site of α2-AP, it also has a site 
capable of binding plasminogen, thereby preventing its binding to fibrin, providing 
another mechanism by which α2-AP affects clot lysis67. It is interesting to note that tPA 
and plasminogen bind to the fibrin D and αC regions without disturbing α2-AP binding, 
possibly due to their different nature of Lys-dependent binding. The ability of fibrin to 
simultaneously accommodate all 3 proteins in the same vicinity allows the fine control 
of fibrinolysis through intricate and closely controlled crosstalk between the proteases 
and serpin28.  
1.10  Factors influencing fibrin structure 
Fibrin clot structure can be influenced by both quantitative and qualitative 
changes in fibrinogen and these can be due to both genetic and environmental 
influences. These changes have marked effects on clot permeability and elasticity, lysis 
rates and platelet binding and thus risk of clotting complications, it is therefore 
important to understand factors that affect clot structure.  
1.10.1 Quantitative changes in clotting factors 
Circulating levels of plasma fibrinogen are influenced by genetic and 
environmental factors with evidence suggesting up to 50% of variability is determined 
by genes. High concentrations of fibrinogen are associated with dense and tight clots3; 
they can also affect blood viscosity and platelet aggregability. 
1.10.1.1 Genetic Interactions 
Twin studies have revealed that levels of coagulation factors are influenced by an 
individual’s genetic background; one study showed that genes account for 51% of the 
variance in plasma levels of fibrinogen72. Several single nucleotide polymorphisms 
(SNPs) in the genes encoding all 3 fibrinogen chains are associated with variation in 
plasma fibrinogen levels. One example of which is the Gly445Ala SNP in the promoter 
region of the fibrinogen β gene which causes increased fibrinogen levels; this genetic 
variant has distinct nuclear protein binding properties affecting the expression of the β 
chain and therefore synthesis of intact fibrinogen. This may be due to the presence of 
(IL)-6 responsive sequences in the promotor regions of this gene resulting in 
genetically determined sensitivity of fibrinogen expression as (IL)-6 is the main 
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mediator of acute phase fibrinogen synthesis73. These changes in fibrinogen 
concentration affect clot structure as discussed above. 
1.10.1.2 Environmental interactions 
Hypertension, diabetes, hyperlipidemia, obesity, sedentary life style, alcohol 
consumption and smoking all lead to increased levels of many clotting factors such as 
TF, fibrinogen, tPA, PAI-1 and FXIII leading to a more thrombotic environment1.This 
can be due to endothelial dysfunction, increased inflammatory markers and/or 
hyperglycaemia itself. 
1.10.2 Qualitative changes in clotting factors 
Not only can levels of proteins in the circulation change, but the form in which 
they circulate can be modified by various mechanisms, discussed below. 
1.10.2.1 Genetic interactions 
Genetic variations in clotting factors can induce qualitative changes in the protein, 
without affecting plasma levels, consequently altering clot structure. For example, the 
substitution of a threonine for an alanine at position 312 in the coding region of the 
fibrinogen α-chain, results in increased stiffness of clots and decreased fibrin density74. 
FXIII crosslinking and lateral aggregation are affected due to the polymorphism’s 
position in the αC domain resulting in the formation of thick fibrin fibres while levels of 
plasma fibrinogen are not affected75. A substitution of valine with leucine at position 34 
in FXIII can also affect clot structure. Possession of the FXIIIVal34Leu mutation has 
been shown to increase FXIII activation by thrombin, causing earlier cross-linking, and 
reduction in lateral aggregation and thus clots with thin fibres36.  
1.10.2.2 Environmental interactions 
Environmental changes affecting the blood such as increased glucose or 
oxidative stress can cause changes in fibrinogen after it is secreted.  
1.10.2.2.1 Posttranslational modifications of fibrinogen 
After translation of each fibrinogen chain in the hepatocytes, the molecule can be 
modified by various post-translational modifications (PTMs). These can change the 
functional properties of the protein by covalent addition of functional groups to amino 
acid side chains. 
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1.10.2.2.1.1 Glycation  
One of the most common PTMs of fibrinogen is the non-enzymatic glycation by 
reducing sugars such as glucose, forming fructosamines and advanced glycation 
endproducts (AGEs). The initial reaction is between an amino group in the protein and 
the aldehyde group of glucose forming amadori products of the N-substituted (1-deoxy-
ketos-2-yl)amine arrangement, AGEs are only formed after consequent oxidation and 
dehydration76. Glycation adducts can also be formed by the proteins reaction with α-
oxoaldehydes such as glycoxal and methyloxal. Glycation by α-oxoaldehydes takes 
place on arginine residues whilst that by glucose is directed on lysine residues77, 78.  
Clots made from glycated fibrinogen result in a tight and rigid network, resistant 
to lysis, this may be because certain areas of the fibrinogen molecule corresponding to 
plasmic cleavage sites and crosslinking sites are preferentially glycated, thus impairing 
crosslinking and plasmic digestion. It has also been shown that glycoaldehyde, 
generated during inflammation and hyperglycaemia can react with arginine and lysine 
residues to impair protein function delaying plasma coagulation and fibrin 
polymerisation, with clots made of thinner fibres79.  
Other circulating factors are also susceptible to glycation; recently, plasminogen 
has been shown to be more extensively glycated in diabetes.  This causes impaired 
fibrinolysis through decreased plasmin generation and impaired functional protein 
activity as a result of decreased plasmin generation and reduced enzyme catalytic 
activity upon conversion from plasminogen in diabetes. These changes are reversible 
with moderate improvement of glycemic control, directly implicating circulating glucose 
levels in this PTM in diabetes80. 
1.10.2.2.1.2 Oxidation 
Reactive oxygen species (ROS) and AGEs, levels of which are increased in 
oxidative stress, inflammation and diabetes can lead to oxidation of circulating 
proteins81. Oxidation of fibrinogen, usually on lysine residues, results in the protein 
being more readily transformed to fibrin, enhanced platelet aggregation and decreased 
plasminogen activation by tPA thus creating a prothrombotic environment. The oxidised 
form of fibrinogen also modifies blood viscosity and reduces erythrocyte deformability. 
Acetylation of fibrinogen can inhibit this oxidation and thus prevent the reduction in 
catalytic efficiency induced82, 83. 
1.10.2.2.1.3 Acetylation 
It has been shown that aspirin is capable of acetylating lysine residues on the α-
chain of fibrinogen. Work in our laboratory has shown that fibrinogen can be acetylated 
by aspirin, resulting in clots composed of thick fibres and large pores with reduced 
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rigidity which are less resistant to lysis. This may be because the acetylation leads to 
changes in charge distribution and fibrin conformation84.  A recent study has shown 
that Lys539, 429, 224 and 208 are some of the acetylation sites on fibrinogen, 
interestingly these are all residues involved in FXIIIa crosslinking thus implicating 
acetylation of these residues in FXIII crosslinking and final fibrin structure85. 
1.10.2.2.1.4 Phosphorylation 
Fibrinogen circulates in its phosphorylated form in plasma, modified in the Aα-
chain at Ser3 and Ser345. It is of particular interest that the phosphorylated Ser3 lies 
within fpA and it has been shown the degree of modification of this residue, increased 
in acute phase reaction conditions, modulates fpA release by enhancing thrombin 
binding. A concomitant increase in resistance to plasmin-induced fibrinolysis is also 
evident with the degree of protein phosphorylation86. 
1.10.2.2.1.5 Homocysteinylation 
Sulfhydryl groups can be introduced into fibrinogen on lysine residues by 
homocysteine thiolactone, a metabolite of homocysteine, this leads to fibrin that is not 
able to support plasminogen activation by tPA and thus clots that are resistant to lysis. 
Since fibrinolytic proteins bind at lysine residues as well as them being the sites of 
plasmin cleavage it is not surprising modification of these residues would have this 
effect87. 
1.10.2.2.1.6 Nitration 
Fibrinogen can be nitrated in vivo on tyrosine residues 292 and 422 of the β 
chain leading to accelerated clot formation, altered clot morphology, increased FXIII 
crosslinking, fibrin stiffness, increased permeability and resistance to lysis88. 
1.10.3 Other factors affecting clot structure  
Several other factors influence the formation, structure and lysis of a fibrin clot, 
including pH, ionic strength, and concentrations of calcium, dextran or anticoagulants. 
Clots made of thicker fibrin fibres are seen in the presence of high plasma calcium 
levels when compared with those formed in the absence of calcium due to its 
requirement for the assembly of procoagulant complexes and thrombin generation. 
Antithrombin prolongs time to clot formation by effectively lowering plasma thrombin 
concentration, resulting in thicker fibred clots. In contrast, plasma proteins such as 
albumin and haemoglobin shorten the onset of fibrin clot formation3. Dietary factors 
such as increased fibre levels result in clots which are more permeable and less rigid 
due to decreased cholesterol and lipoprotein levels and decreased rate of fibrinogen 
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conversion89, while increased incorporation of inflammatory molecules, due to high 
plasma protein levels, such as C3 results in clots with thin fibres and impaired lysis90.  
1.10.4 Effect of fibrin structure on fibrinolysis potential 
Dense clots made of thin fibres are more resistant to lysis in the plasma 
environment than those made of loosely woven thick fibrin fibres23. However at the 
level of individual fibrin fibres, thick fibres are more resistant to lysis. This phenomenon 
is explained by the difference in distribution and movement of fibrinolytic components 
through the fibrin network showing fibrin network architecture to govern clot lysis rather 
than fibre diameter. Loosely woven clots made of thick fibres have a decreased fibrin 
density and number of fibres for the same amount of total protein. This allows 
fibrinolysis components such as tPA to bind more broadly across the clot and move 
quicker through the fibrin network. It has also been suggested plasminogen binding 
and activation may be inhibited in clots made of fine fibres23, 84. This indicates not only 
rate of plasmin generation but its movement through the clot is rate limiting for 
fibrinolytic activity and that it is not fibrin fibre diameter, but fibrin network structure, that 
governs the distribution of fibrinolytic proteins23. Both quantitative and qualitative 
changes in clotting factors can determine fibrin clot structure and susceptibility to 
fibrinolysis as discussed above. 
1.11 Cardiovascular disease 
Cardiovascular disease is an important cause of morbidity worldwide and results 
in approximately one third of global mortality, with around 200,000 deaths per year in 
the UK alone (www.heartstats.org). The formation of an obstructive thrombus in a 
blood vessel is the last step in the atherothrombotic process, leading to organ 
ischaemia, which if prolonged results in irreversible tissue damage manifesting 
clinically as MI or stroke. Atherosclerosis often progresses from endothelial dysfunction 
leading to permeation of the vascular wall with lipid particles and inflammatory 
molecules allowing the formation of foam cells, which are cholesterol laden 
macrophages that form fatty streaks, a pathology that can be found at a very early age. 
The inflammation caused by this reaction leads to increased levels of cytokines and 
chemo-attractant proteins, exacerbating the situation. Mature atherosclerotic plaques 
are formed from chronic inflammation products and fibrous tissue deposition into the 
fatty streaks. When mature and unstable plaques rupture, exposing a prothrombotic 
core, the lumen of the vessel can become occluded due to thrombus formation 
secondary to platelet and coagulation factor activation84. 
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1.11.1 Clot structure and susceptibility to cardiovascular disease 
The structure of the clot governs susceptibility to atherothrombotic complications. 
Ex vivo fibrin networks with thin fibres, small pores and dense structure are associated 
with premature and more severe atherothrombotic disease91, 92.  
1.11.1.1 Effect of quantitative changes in clotting factors on CVD risk 
Increases in many clotting factors have been associated with various CVD; 
plasma concentrations of fibrinogen, vWF, PAI-1 and lipoprotein were found in 
coronary artery disease (CAD) patients, with fibrin stiffness and fibrin architecture being 
predictive of CAD92. As discussed above, high concentrations of fibrinogen are 
associated with dense, tight clots made of thin fibrin fibres; this confers increased risk 
of cardiac disease. The Northwick Park Heart study showed an 84% increase in MI 
development with an increase of one SD in fibrinogen levels (equivalent to 0.6 g/L). On 
top of the risk imparted by the development of clots with a tight network structure, the 
accumulation of fibrinogen directly integrated into arteriosclerotic lesions is proportional 
to plasma fibrinogen concentration. The problem is exacerbated by the fact 
atherosclerosis can provoke acute phase fibrinogen synthesis before clinical incidents 
are detected through activation of the coagulation cascade and resultant increased 
local production of fibrinogen degradation products such as fragment D. These 
degradation products can facilitate the release of IL-6 from macrophages, increasing 
not only the hepatic synthesis of fibrinogen, but other acute phase proteins93. The 
presence of fragment D in arterial lesions further exacerbates CVD risk through 
stimulation of smooth muscle cell proliferation and its chemotactic influences on 
monocytes94. 
1.11.1.1.1 Genetic interactions 
The role of genetic variation in the fibrinogen gene in predisposition to CVD has 
not been elucidated despite some of the polymorphisms effect on protein levels 
appearing to predispose to cardiovascular events92. 
1.11.1.1.2 Environmental interactions 
Regular exercise and a diet high in vegetables, fish and dairy and low in red 
meats correlate with low plasma fibrinogen levels and reduction in CAD risk. 
Conversely smoking leads to increased fibrinogen levels and concomitant risk in CAD 
risk secondary to the inflammatory reaction in the lungs in response to smoke 
inhalation. 
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1.11.1.2 Effect of qualitative changes in clotting factors on CVD risk 
1.11.1.2.1 Genetic interactions 
Vascular risk is influenced by genetic factors, with twin studies revealing 
increased concordance of death from coronary heart disease (CHD) in monozygotic 
twins. Other studies show altered fibrin clot structure in relatives of patients with CAD, 
implicating genetic factors affecting fibrin in determining predisposition to CVD. For 
example, the fibrinogen AαThr312Ala polymorphism discussed above is associated 
with increased post-stroke mortality95, venous thrombosis, pulmonary embolism and 
chronic thromboembolic pulmonary hypertension. This may be due to the increased 
stiffness of the clots formed from this variant and consequent risk of fragmentation and 
embolisation96. Though in vitro work has shown the FXIIIVal34Leu polymorphism 
causes clots to form with thin fibres, a typically prothrombotic phenotype, possession of 
the FXIII34Leu allele is associated with decreased risk of atherothrombotic disease. A 
clear gene-environment interaction can be seen in that with increased insulin 
resistance, the protective effect of the polymorphism is lost. 
1.11.1.2.2 Environmental interactions 
Environmental risk factors such as diabetes, hyperlipidaemia and life style factors 
such as smoking also influence atherothrombotic risk. PTMs change the functional 
properties of the protein as discussed above, altering clot structure, in this way they too 
can modify CVD risk. Hyperglycemia as a result of diabetes causes increased glycation 
of fibrinogen, consequently resulting in the formation of a compact clot with reduced 
susceptibility to lysis97, potentiating the development of atherosclerosis and related 
complications. AGE residues can be used as risk markers and factors of disease 
development, with increased plasma concentrations found at sites of vascular 
complications in vitro, and increased levels of the residues implicated in vascular 
complication in diabetes, uraemia and aging in vivo. Levels of the adducts of fibrinogen 
homocysteinylation are associated with risk of stroke and coronary heart disease87 and 
increased levels of nitrated fibrinogen are associated with CAD and atherosclerotic 
lesions88, 98. 
1.11.2 Effect of fibrinolysis potential on CVD risk 
The increased risk of disease associated with dense clots made of thin fibres is 
partially due to more difficult lysis of clots composed of such structure23, secondary to 
slower rate of tPA induced plasmin generation in the presence of thin compared with 
thick fibres and increased risk of embolisation. Fibrin stiffness and fibrin architecture 
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are also predictive of CAD, partly due to their effect on fibrinolysis92. A significant 
predictive value of inactive tPA/PAI complexes, indicating elevated PAI activity and 
impaired fibrinolysis, has been shown for MI, ischemic heart disease (IHD) and stroke. 
tPA levels have also been identified as a risk factor due to the protein’s mitogenic effect 
on smooth muscle cells and its ability to liberate active plasmin from plasminogen 
which is able to activate proteases which can weaken atherosclerotic plaques and 
cause them to rupture94.  
1.12 Fibrinogen variants  
Fibrinogen variants provide a useful tool to investigate the effect of small changes 
in the fibrinogen gene on clot structure and susceptibility to disease. They allow us to 
see how a change in a specific part of the protein can affect its function, shedding light 
on the native function of that area. The more common changes are termed 
‘polymorphisms’ while those that are extremely rare are called ‘dysfibrinogenemias’. 
Some of these variants are discussed below. 
1.12.1 Fibrinogen polymorphisms 
Several SNPs (single nucleotide polymorphisms) in the genes encoding all 3 
fibrinogen chains are associated with variation in plasma fibrinogen levels. The 
Gly445Ala SNP in the promoter region of the fibrinogen β gene causes increased 
fibrinogen levels and distinct nuclear protein binding properties affecting the expression 
of the β chain and therefore synthesis of intact fibrinogen73. These changes in 
fibrinogen concentration affect clot structure as discussed above. 
The AαThr312Ala mutation in the coding region of the fibrinogen α-chain, results 
in increased stiffness of clots and decreased fibrin density74. FXIII crosslinking and 
lateral aggregation are affected due to the polymorphism’s position in the αC domain 
resulting in the formation of thick fibrin fibres while levels of plasma fibrinogen are not 
affected75.  This polymorphism is associated with increased post-stroke mortality95, 
venous thrombosis, pulmonary embolism and chronic thromboembolic pulmonary 
hypertension96. The linkage disequilibrium of this polymorphism with the fibrinogen 
BβGly455Ala SNP, itself a predictor of venous thrombotic embolism (VTE), confounds 
the deleterious properties of this mutation. A common mutation in the Bβ chain of 
fibrinogen (BβArg448Lys) results in compact clots, composed of thin fibres, small 
pores, increased stiffness and resistance to lysis, a pathology leading to predisposition 
to CAD, triple vessel pathology, venous thromboembolic disease, hypofibrinolysis and 
embolisation99, 100. 
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1.12.1.1 Fibrinogen BβArg448Lys 
The main focus of this study, a mutation lying in the coding region of the carboxyl 
terminal of the fibrinogen β-chain, is associated with increased risk of CAD, triple 
vessel pathology, venous thromboembolic disease, hypofibrinolysis and embolisation99, 
100. The mutation is in strong linkage disequilibrium (LD) with two other mutations, the 
Gly445Ala and the Cys148Thr in the 5’ flanking region and the promoter region of the 
Bβ-chain fibrinogen gene. Several mutations in the fibrinogen β-chain (e.g. Gly445Ala) 
are linked to plasma fibrinogen levels and this has been attributed to both sensitivity of 
this mutation to IL-6, the main acute phase protein that induces fibrinogen production, 
and the fact that the β-chain is rate limiting for the synthesis of the fibrinogen 
molecule73. This LD may affect transcription rate of the β-chain polypeptide by 
interaction with an IL-6 responsive element close to the mutation site which controls 
binding of nuclear proteins, consequently contributing to higher plasma fibrinogen 
levels in the Bβ448Lys variant101. Added to this, a functional role of the mutation has 
been suggested by its link with increased risk of stroke in females independent of 
plasma fibrinogen levels101.  
The BβArg448Lys mutation results from a mutation at position 1236 of the gene 
causing a guanine base to be replaced with an adenine, and consequently an arginine 
residue to be replaced with a lysine at position 448. It occurs at a frequency of ~25% in 
the white population, causing significant changes in clot formation, structure and lysis 
when studied in the plasma environment102. When compared with Bβ448Arg, clots 
formed from Bβ448Lys variant have a more compact structure composed of thin fibres 
and small pores with increased stiffness; a pathology leading to predisposition to 
cardiovascular and atherothrombotic disease. This altered clot structure also 
predisposes to disease via interactions with endothelial cells and fibroblasts, impairing 
their reorganisation into microtubules, affecting angiogenesis and promoting 
atherosclerosis102. 
Fibrinolysis rates are significantly slower in the Bβ448Lys variant when compared 
to Bβ448Arg in the plasma environment. However, in a purified system, no difference 
between lysis rates of clots of the two variants is seen, explained by the increased 
number of fibres in Bβ448Lys variant being compensated for by quicker lysis of thin 
fibres. In the presence of plasma proteins, the incorporation and crosslinking of 
different proteins into the clot may vary between the variants, hence affecting 
fibrinolysis rates102. 
Clot stiffness in the Bβ448Lys variant is greater than that of the Bβ448Arg 
variant, an effect that is even more pronounced in the presence of FXIII, with Bβ448Lys 
final stiffness reaching more than 3-fold that of Bβ448Lys and continuing to increase 
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after 3 hr. Continual structural rearrangement of the fibrin fibres with Bβ448Lys has 
been proposed as a mechanism for this phenomenon. 
The clots formed from Bβ448Lys variant being composed of thinner fibres 
suggests the mutation has an effect on lateral aggregation. Molecular modelling 
suggests loss of 3 hydrogen bonds in an area of the β-chain thought to be involved in 
lateral aggregation and stabilisation of the coiled-coil caused by the mutation could be 
responsible by affecting an area of the αC domain and causing conformational 
changes in the Bβ chain. It seems the B448ArgNH1-B315GluOE2 hydrogen bond 
cannot form between B448LysNZ-B315GluOE2 which could destabilise the Bβ398-
Aα157 interaction in the coiled coil. Residues Bβ397Glu and Aα398Asp appear more 
mobile in Bβ448Lys, these residues are involved in B-B interactions during fibrin 
polymerisation and may thus affect the fibrin network structure102. While both arginine 
and lysine residues are polar and as such sit on the outside of proteins, lysine residues 
are only capable of forming one hydrogen bond due to their single amino group, 
whereas arginine residues are capable of making multiple hydrogen bonds. 
 
 
Figure 1-12. Molecular modelling showing the effect of BBArg448Lys variant on 
position of the fibrinogen BB448 residue 
(A) BB448Arg and (B) BB448Lys are shown. Potential loss of a hydrogen bond 
between BB448 and BB315 could destabilise the Bβ398-Aα157 interaction in the coiled 
coil. Figure adapted from Ajjan et al. (2008)102. 
 
The mechanisms behind the observed changes in fibrin structure, clot rigidity and 
fibrinolysis rate of Bβ448Arg and Bβ448Lys variants need further exploration, though 
many hypotheses for the influence of the mutation have been suggested. The proximity 
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of the BβArg448Lys to 3 important sites in the β-chain that influence clot structure, 
formation and lysis (a β-chain polymerisation site, an interaction site for the C-terminal 
of the α-chain and a calcium binding site on the β-chain) may implicate these areas in 
the observed changes. The effects of the Bβ448 arginine to lysine substitution are 
summarised in Figure 1-13. 
 
 
Figure 1-13. Changes seen due to the BβArg448Lys polymorphism  
Bβ448Lys causes hyperfibrinogenaemia and formation of compact clots with thin fibres 
and small pores that are more resistant to lysis in the plasma environment. It 
predisposes to increased risk of CAD, VTE and embolisation. 
1.12.2 Dysfibrinogenemias 
Dysfibrinogenemia, a disease in which an abnormality in the fibrinogen molecule 
is inherited, results in defective fibrin clot formation, manifesting in potentially life-
threatening symptoms103. These conditions provide a useful tool to investigate the 
effect of small changes in the fibrinogen gene on clot structure and susceptibility to 
disease. Nonsense/missense mutations, insertions/deletions and chain truncations in 
the fibrinogen genes have all been identified as responsible for various fibrinogenemias 
resulting in modifications of fibrinopeptide release, fibrin polymerisation, fibrin 
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crosslinking and/or fibrinolysis. The position in which the mutation lies governs whether 
the dysfibrinogenemia will present as a bleeding or prothrombotic disease. Missense 
mutations often lead to the development of hypofibrinogenemia (low plasma fibrinogen 
concentrations) due to their effect on intracellular transport mechanisms and 
consequent accumulation in the endoplasmic reticulum (as in the γGly284Arg 
polymorphism) where the variant molecules are not expressed in plasma. Truncations 
can result in hypofibrinogenemia due to a complete lack of expression of the mutant 
molecules in plasma as the truncated polypeptide cannot be assembled with the other 
fibrinogen chains (as in the β-chain Gly-40 truncation)104.  
The severity of the condition can depend on whether the variant is homo- or 
heterozygous. Very few homozygote dysfibrinogenemias have been identified, but 
these result in a homodimeric fibrinogen molecule with two mutant chains. The by far 
more common heterozygous forms can result in one of two homodimers (either two 
normal or two abnormal chains) or a heterodimer with one normal chain and one 
abnormal chain. Heterozygotes that have 50% normal fibrinogen molecules are usually 
asymptomatic as this amount of normal fibrinogen molecules is able to maintain normal 
blood coagulation. Symptoms appear when the dysfibrinogen interferes with functional 
components of the fibrinogen molecule35. 
One of the most prevalent dysfibrinogenemias results from a single amino acid 
substitution in the fibrinogen Aα chain, causing an arginine at position 16 to be 
replaced by a cysteine or histidine. Prolonged clotting time, impaired polymerisation 
and hemorrhagic complications result from decreased fibrinopeptide A release by 
thrombin as in Ledyard105, Milano IV106 and Bern III107 dysfibrinogenemia.  
Another phenotypically important mutation is fibrinogen Dusart, which is 
associated with thrombophilia and results from heterozygosity for a single base change 
(cytosine to guanine) in the Aα-chain gene, causing amino acid 554 of the chain to be 
changed from arginine to cysteine. The functional defect of recurrent thrombosis is 
associated with reduced plasminogen binding, impaired plasminogen activation by tPA 
and abnormal fibrin polymerisation, causing thinner fibres due to defective lateral 
association of fibres and disulfide-linked fibrinogen-albumin complexes35. In this study 
we look at a newly identified dysfibrinogenemia, the Fibrinogen Aα Birmingham II 
mutant, discussed further in section 1.12.2.1. 
1.12.2.1 Fibrinogen Aα Birmingham II mutant 
While BβArg448Lys mutation is relatively common, a rare novel fibrinogen variant 
has been detected in a 34 year old woman, which is associated with 
hypodysfibrinogenemia108. Clinically, the individual presented with a bleeding tendency 
associated with venous thrombotic events. A familial history of hypofibrinogenemia with 
42 
 
a bleeding tendency was recorded but there were no cases of thrombosis. This is the 
only case that has been identified, showing compound heterozygosity for Trp334Cys 
and Asn335Tyr mutations in the α-chain of fibrinogen. Two mutations in the 
polypeptide have been identified at positions 1001 and 1002 causing a guanine and an 
adenine respectively to be both replaced by thymine. SIFT analysis suggests these 
changes could affect protein function and polyphen analysis predicts them as 
damaging. However, no studies have been conducted to analyse whether these amino-
acid changes cause alterations in clot structure/lysis that explain the clinical phenotype. 
The aspargine to tyrosine substitution results in the replacement of a polar residue that 
is comfortable at the surface of proteins and is often involved in active and binding sites 
with an easily phosphorylated, hydrophobic residue that likes to be hidden in the centre 
of the protein structure. Tryptophan, a hydrophobic residue is also replaced with a 
cysteine; a residue that is often found in enzyme active sites and capable of forming 
disulfide and covalent bonds. The amino acid residues affected by the candidate 
mutations are both highly conserved residues in the αC domain of fibrinogen, which 
have a role in crosslinking during fibrin polymerisation. Changes in binding of 
fibrinolytic modulators, altered clot structure and increased resistance to lysis have 
been linked to other mutations in this region. 
1.13 Diabetes 
Diabetes is a complex multifactorial condition in which both genetic and 
environmental factors play a role. It is associated with qualitative and quantitative 
changes in procoagulant and anti-fibrinolytic proteins leading to fibrin clots with tight 
network structure and resistance to lysis, consequently predisposing to a thrombotic 
environment102, 109, 110 (Figure 1-14). 
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Figure 1-14. Mechanisms by which diabetes and insulin resistance effect the 
coagulation system and cardiovascular disease 
Increased levels of procoagulant and antifibrinolytic proteins in diabetes lead to 
compact clots made of thin fibres that are more resistant to lysis. This results in an 
increased thrombosis potential and increased risk of CVD, atherothrombosis and IHD. 
1.13.1 Diabetes and the prothrombotic environment 
Diabetes causes increased levels and activity of procoagulant and antifibrinolytic 
proteins (e.g. platelets, tissue factor, thrombin, PAI-1 and fibrinogen), qualitative 
changes in clotting factors and increased levels of inflammatory proteins. This 
predisposes to a thrombotic environment and premature atherosclerosis109, 110.  
1.13.2 Mechanisms of compact clots and hypofibrinolysis in diabetes  
Clots made from plasma purified fibrinogen of type two diabetes mellitus (T2DM) 
patients are characterised by thinner fibres, increased branching, tight network 
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structure and resistance to lysis111. Plasma clots also show reduced permeability 
compared to controls, indicating a more compact structure91. This is due to qualitative 
and quantitative changes in clotting factors in the blood in this condition. 
1.13.2.1 Quantitative changes in coagulation factors 
1.13.2.1.1  Fibrinogen 
Hyperfibrinogenaemia is evident in both T1DM and T2DM with Framingham 
data109 showing a concomitant rise in fibrinogen concentration throughout a range of 
blood sugar levels. However others have shown insulin sensitivity to be the only 
variable able to predict fibrinogen values, confirming a negative correlation between the 
two. Other mechanisms explaining hyperfibrinogenaemia in DM have been proposed to 
be due to increased circulating free fatty acids and enhanced inflammation. Free fatty 
acid release is increased in both T1DM and T2DM which can lead to stimulation of 
hepatic fibrinogen synthesis whilst cytokines such as TNF-α and IL-6, released during 
increased inflammatory events in these conditions, can also cause hepatic fibrinogen 
synthesis promotion112. It is most likely interplay of all of these conditions occurring in 
diabetes that lead to the increase in circulating fibrinogen concentration rather than one 
alone.  
1.13.2.1.2  Tissue Factor 
Tissue factor expression is up-regulated in T2DM due to increased exposure of 
VSMC (vascular smooth muscle cells), which constitutively express TF, secondary to 
plaque rupture and enhanced stimulation by the inflammatory response. It appears 
baseline circulating levels of TF are also increased by the high levels of both glucose 
and insulin that appear in T2DM and the increased levels of AGEs of ROSs activating 
nuclear factor kappa-light-chain-enhancer of activated B cells (NFkB), further 
enhancing TF production. Studies have shown that inducing hyperglycaemia in healthy 
subjects leads to increased TF levels, while improving glycaemic control in T2DM 
reduces levels, implicating TF as a factor in the thrombotic condition in T2DM113, 114.  
1.13.2.1.3  FVII 
FVII levels are increased in T2DM which is associated with the increased 
circulating triglycerides due to poor glycaemic control in the condition, with reduction in 
triglyceride levels causing a concomitant reduction in FVII levels, suggesting better 
glycaemic control may lead to reduced FVII levels. It has also been shown that 
hyperglycaemia can increase FVII levels independent of triglycerides115. 
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1.13.2.1.4  Thrombin 
Hyperglycaemia causes increased thrombin production causing thrombin levels 
to be increased in T1 and T2DM through low grade activation of the coagulation 
cascade, enhancement of thrombin generation persists even when glycaemia is 
normalised116. 
1.13.2.1.5  Fibrinolytic proteins 
Diabetes and specifically hyperglycaemia also affects fibrinolysis potential by 
influencing PAI-1 and tPA levels. PAI-1 levels are increased while tPA levels decrease 
in hyperglycaemia, leading to a prothrombotic and anti-fibrinolytic environment.  
FXIII crosslinking of α2-AP to fibrin is enhanced in T2DM117 which also works to 
increase the resistance of the clot to lysis, the mechanism by which this occurs is not 
clear but structural alteration of the fibrin molecule in diabetes may lead directly to 
enhanced crosslinking, or indirectly promote activation of FXIII by thrombin. The 
increased resistance to lysis of diabetic clots is also related to reduced plasminogen 
and tPA binding and consequent impaired plasmin generation117. 
1.13.2.1.6  Inflammatory proteins 
C3 levels are increased in the associated low grade inflammation present in 
diabetes and are predictive of thrombotic events. Though complement proteins are 
traditionally regarded as inflammatory proteins, it appears they also interact with the 
coagulation system with work showing clot lysis time to concomitantly rise with plasma 
C3 levels, independent of fibrinogen and PAI-1 levels. Recent work has shown C3 to 
prolong lysis of clots made from diabetic fibrinogen compared with control and that this 
may be due to enhanced C3 incorporation into the clots of T1DM patients. They 
suggest C3 may interfere with tPA and plasminogen binding, increase mechanical 
resistance of the clot, or, as a competitive substrate of plasmin, affect plasmin binding 
to fibrin and thus compromise fibrinolysis. They showed clots formed of thinner fibres 
with C3 incorporation, suggesting it may affect lateral aggregation90. 
1.13.2.2 Qualitative changes in clotting factors 
Post-translational modifications in fibrinogen caused by changes in the blood 
environment in diabetes can also affect clot structure and fibrinolysis.  
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1.13.2.2.1  Glycation 
Glycation of fibrinogen secondary to hyperglycaemia has been demonstrated and 
fibrinogen glycation correlates well with capillary glucose in T2DM78, 110. Clots made 
from glycated fibrinogen result in a tight and rigid network, resistant to lysis, as 
discussed in section 1.10.2.2.1.1. It has also been shown that glycoaldehyde, 
generated during inflammation and hyperglycaemia can react with arginine and lysine 
residues to impair protein function delaying plasma coagulation and fibrin 
polymerisation, with clots made of thinner fibres79.  
1.13.2.2.2  Oxidation 
ROS and AGEs, levels of which are increased in oxidative stress, inflammation 
and diabetes can lead to oxidation of circulating proteins. Impaired fibrin polymerisation 
and thrombin induced clot formation to complete loss of clottability can result from 
oxidation of fibrinogen81. 
1.13.2.2.3  Acetylation 
Aspirin is regularly prescribed in diabetes due to its cardioprotective role through 
its action on platelet cyclo-oxygenase-1 (COX-1). Here it inhibits COX-1s activity, so 
decreasing levels of thromboxane-A2 and reducing platelet aggregation potential. 
Acetylation of lysine residues on the α-chain of fibrinogen can occur in the presence of 
aspirin resulting in clots composed of thick fibres and large pores with reduced rigidity 
which are less resistant to lysis. In patients with diabetes, the clinical efficacy of aspirin 
appears to be reduced, which is often termed clinical aspirin resistance. Compromised 
platelet inhibition by aspirin, secondary to reduced platelet protein acetylation, has 
been suggested as one mechanism, although this remains controversial118. A 
competition between acetylation and glycation of fibrinogen has also been suggested 
as another mechanism, but studies have mainly been conducted in vitro and definitive 
conclusions are still awaited85. 
1.13.3 Diabetes as an independent risk factor for disease 
Diabetes is a major health problem and cardiovascular complications remain the 
main cause of mortality in this population. The condition currently affects 347 million 
people worldwide and is projected to be the 7th leading cause of death by 2030 
(www.who.int). The rapidly increasing global prevalence of diabetes is a significant 
cause for concern as the risk of mortality in diabetes subjects due to atherothrombotic 
complications is equal to that of nondiabetic individuals with a history of ischemic heart 
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disease109, 110, 119. Not only are individuals with diabetes at higher risk of cardiovascular 
disease, their prognosis following vascular ischaemia is significantly worse than 
individuals with normal glucose metabolism. The reasons for this are probably 
multifactorial, including more extensive vascular pathology, increased thrombosis 
potential and high prevalence of heart failure, which is partly related to 
atherothrombotic complications. 
Diabetes predisposes to development of atherogenic risk factors, such as 
obesity, increased fibrinogen concentration, hypertriglyceridemia and raised blood 
pressure. However these factors have been shown to be of no greater significance in 
predicting atherogenic risk in diabetics than nondiabetics109. It follows that diabetes 
adds extra, independent, risk factors for cardiovascular risk above those ‘traditional’ 
risk factors such as obesity and fibrinogen concentration110. An independent effect of 
glucose intolerance on cardiovascular risk, after all standard risk factors, and 
fibrinogen, have been adjusted for has been identified109. And even in the pre-diabetes 
stage, when normoglycaemia remains but a state of insulin resistance is present, an 
increased risk of atherothrombotic events is evident 120.  
Hyperglycaemia itself can also cause atherosclerosis by enhancing the non-
reactive enzymatic glycation of other plasma proteins and lipids as a result of oxidative 
stress leading to increased levels of circulating AGEs. These AGEs can trigger 
inflammatory processes, blood-vessel wall perturbation and oxidised low density 
lipoprotein (LDL) formation, all of which can initiate atherosclerotic processes110. 
1.13.4 Glycaemic control 
Improving glycaemic control and insulin sensitivity go some way to reduce the 
hypercoaguable and atherthrombotic environment in diabetes and the use of drugs 
such as metformin and statins also show improvement in risk of cardiovascular events 
in these patients. 
1.13.5 Diabetes and BβArg448Lys 
Taken together, both diabetes and BβArg448Lys variants of fibrinogen modulate 
cardiovascular risk and induce thrombotic changes in fibrin networks. Despite the 
relatively high prevalence of both conditions and their role in atherothrombotic 
conditions, whether BβArg448Lys directly affects clot structure and lysis in a complex 
condition such as T2DM is unclear.  
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1.14 Aims of the work 
From the evidence presented above, it is clear that fibrinogen is essential in the blood 
clotting process, which in itself is crucial for preventing excessive bleeding upon injury. 
Disturbances at any point in the clotting system can lead to chronic symptoms and 
death. While a number of studies have investigated various fibrinogen mutations, the 
common BβArg448Lys mutation remains only partially characterised and the role of 
this polymorphism in high risk vascular conditions, such as diabetes, remains unknown. 
Equally, the novel AαTrp334Cys/Asn335Tyr mutation, which is associated with a 
peculiar clinical presentation, is yet to be fully investigated. Understanding the 
functional role of common and rare mutations in fibrinogen will unravel new 
mechanisms that will enhance our knowledge and will help in the long-term to identify 
novel therapeutic targets. Firstly, I hypothesise that the BβArg448Lys fibrinogen variant 
will affect clot structural and functional properties in T2DM patients. Secondly, I 
suggest α2-AP is the protein responsible for the differences in lysis of recombinant 
BβArg448Lys fibrinogen variants in the plasma environment. Lastly, I propose the 
AαTrp334Cys/Asn335Tyr changes in the Birmingham II patient are responsible for her 
clinical presentation. Therefore my work is aiming to: 
1) Identify any additional effect of BβArg448Lys on fibrin network in a high risk 
vascular condition with complex pathogenesis, such as T2DM.  
a. Analyse the effect of BβArg448Lys on ex vivo clot structure/fibrinolysis 
in subjects with T2DM.  
b. Analyse of the role of the polymorphism on previous and existing 
vascular pathology in this population.   
2) Study the effects of the common BβArg448Lys mutation on fibrin clot structural 
and functional properties. 
a. Analyse the effects of BβArg448Lys mutation on early protofibril 
formation, FXIII activation and cross-linking. 
b. Elucidate potential differences in binding and crosslinking of fibrinolytic 
proteins to Bβ448Arg and Bβ448Lys variants of fibrinogen.  
3) Investigate the role of the rare variant of fibrinogen AαTrp334Cys/Asn335Tyr on 
clot structure and lysis. 
a. Analyse the effects of this variant of fibrinogen on clot structure and lysis 
in plasma, purified and recombinant systems. 
b. Establish whether clinical presentation of the patient is due to 
abnormality in the fibrinogen molecule resulting in altered clot structure 
and/or lysis. 
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Materials 
General Materials 
Material Source 
Chinese Hamster Ovary cells (CHO cells) Susan Lord 
DMEM/ F12 1:1 liquid Invitrogen  
BD NuSerum supplement VWR 
Bovine calf serum ThermoScientific 
Penicillin-Streptomycin Sigma 
Trypsin/ EDTA Sigma 
DMSO ThermoScientific 
Cytodex microcarrier beads Sigma 
NaCl Sigma 
KCl Sigma 
Na2HPO4.2H2O Sigma 
KH2PO4 Sigma 
Boehringer Mannheim’s ITS Roche 
Aprotinin solution Sigma 
PMSF Sigma 
Ammonium sulphate ThermoScientific 
ε-amine n-caproic acid Sigma 
Benzamidine Sigma 
Pepstatin Sigma 
Leupeptin Sigma 
MES-buffer Sigma 
Tris Sigma 
EDTA Sigma 
Soybean trypsin inhibitor Sigma 
CaCl2 Sigma 
IF-1 monoclonal antibody to fibrinogen Kamiya Biomedical 
Sodium acetate Sigma 
SDS-Page sample buffer/ reducing agent Invitrogen 
MES SDS running buffer Invitrogen 
Perfect protein marker Novagen 
GelCode blue stain reagent ThermoScientific 
Thrombin Millipore 
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Sodium acetate trihydrate Sigma 
Sodium 5,5 diethylbarbituate Sigma 
HCl Sigma 
NaH2PO4.2H2O Sigma 
Calbiochem fibrinogen Millipore 
Tween20 Sigma 
OPD tablets DAKO 
H2O2 Sigma 
H2SO4 Sigma 
Tissue plasminogen activator Technoclone 
Factor 13 ZLB Behring 
Plasminogen ERL 
Antiplasmin Millipore 
Glycine Sigma 
Methanol Sigma 
Skimmed milk Marvel Foods 
Supersignal west pico luminal ThermoScientific 
Supersignal west pico stable ThermoScientific 
488 Alexa labelled fibrinogen Invitrogen 
Cadolydic acid Sigma 
Gluteraldehyde Sigma 
Acetone Sigma 
NiCl2 Sigma 
Acetate sample buffer Expedeon Ltd 
DTT Sigma 
HEPES running buffer Expedeon Ltd 
Alexa fluor 594 fibrinogen Invitrogen 
BSA Sigma 
Biotin ThermoScientific 
Streptavidin alkaline phosphotase Sigma 
P-nitrophenol phosphate Sigma 
Diethonalamine Sigma 
MgCl2 Sigma 
NaOH Sigma 
S2251 substrate Sigma 
Dpn I restriction enzyme Agilent 
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XL-1-Blue supercompetent cells Agilent 
SOC broth Sigma 
Metaphor agarose powder Lonza 
Acetic acid Sigma 
Ethidium bromide Sigma 
DNA loading buffer Bioline 
High molecular weight bioladder Bioline 
DH5α cells Invitrogen 
Geneticin 418 Invitrogen 
L-histidinol Sigma 
Antibodies 
Antibody Source 
Rabbit anti-fibrinogen  Agilent Technologies 
Goat polyclonal anti fibrinogen HRP Abcam 
Goat anti-human α2-AP HRP ERL 
Rabbit anti-albumin HRP Abcam 
Streptactin HRP Bio-Rad 
Equipment 
Equipment Source 
5702R centrifuge Eppendorf 
Nunclon petri dish ThermoScientific 
Falcon tube VWR 
Cryovial VWR 
850 cm3 polystyrene roller bottles Corning 
Roller bottle incubator VWR 
Filter paper GE Healthcare 
0.2 µm bottle top membrane filter ThermoScientific 
Stratus thermostatic water bath Northern Media 
Sorvall RC-5B refrigerated super speed centrifuge ThermoScientfic 
Automated chromatography system Biocad Sprint 
100,000 MWCO vivapsin concentrator tubes Generon 
Dialysis tubing Sigma 
ND-1000 spectrophotometer Nanodrop 
NuPAGE Novex Bis-Tris gel Invitrogen 
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Novex mini-cell tank Invitrogen 
KC10 Amelung coagulometer Amelung 
Clauss reference plasma Biomereux 
Nunc-immuno microwell maxisorp plate Sigma 
MRX microplate reader Dynex Technologies 
Clear polystyrene flat bottom plate Grenier Bio-One 
ELx-808 IU ultramicroplate reader Labtech International 
Immobilon-P transfer polyvinylidene difluoride membrane NENTM Life Sciences 
Western blot mesh Bio-Rad 
Whatman filter paper SLS 
Mini-PROTEAN 3 cell Bio-Rad 
Kodak image station 2000R Eastman Kodak 
Ibidi confocal slide Applied Biophysics 
LSM 510META microscope Zeiss 
E300 critical point dryer Quorum Technologies 
208HR high resolution sputter coater Cressington 
Quanta 200F FEGESEM electron microscope FEI 
Ultimate 3000 nano LC system Dionex 
PepMap C18 analytical column Dionex 
Time of flight mass spectrometer Synapt HDMS 
Alexa Fluor 488 labelling kit Invitrogen 
DB-5A dri-block heating block Techne 
QuickChange site directed mutagenesis kit Statagene 
PTC-200 Peltier Thermal Cycler MJ Research 
QIAprep spin miniprep kit Qiagen 
MIKRO 2000 centrifuge Hettich 
MultiImageTM light cabinet Alpha Innotech 
Plasmid MaxiPrep kit Qiagen 
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Methods 
2.1 Fibrinogen production and purification 
2.1.1 CHO cell culture 
2.1.1.1 Thawing of cells 
A 1 ml vial of the desired Chinese Hamster Ovary (CHO) cells were removed 
from liquid nitrogen storage and rapidly thawed at 37 C. When thawed, these cells 
were re-suspended in 9 ml growth media (GM – DMEM/ F12 1:1 liquid (Invitrogen, 
Carlshead, CA, USA), 5% BD NuSerum supplement (VWR, Arlington Heights, IL, 
USA), 5% bovine calf serum (ThermoScientific Waltham, MA, USA), 0.01% Penicillin-
Streptomycin (Sigma, St Louis, MO, USA) and centrifuged at 1000 rpm for 10 min in a 
5702R centrifuge (Eppendorf, Hamburg, Germany) to wash the cells of DMSO and 
produce a cell pellet. The media was removed from the pellet by aspiration and the 
pellet re-suspended in 20 ml GM. The cells were then transferred in 2 ml aliquots to 
100 mm Nunclon petri dishes (ThermoScientific) containing 8 ml GM. 
2.1.1.2 Growth to confluence 
Cell media was changed every 2-3 days and cells split when they reached 
confluence. To do this, all media was removed from the petri dish and 2 ml 
trypsin/EDTA (Sigma) added. The dish was incubated at 37 C for 2 min and a 
microscope used to check if the cells had become loose from the dish. When cells 
were no longer adhered to the dish, 8 ml GM was added and the cells split between 5 
fresh petri dishes containing 8 ml GM each. 
2.1.1.3 Freezing down cells 
The media was removed from the cells by aspiration, 2 ml trypsin/EDTA added 
and incubated until the cells became loose of the plate. 8 ml GM was added to the 
plate and the cells suspended by pipetting up and down before transferring to a 15 ml 
falcon (VWR). The cells were then spun down into a pellet by centrifugation in a 5702R 
centrifuge at 1000 rpm for 10 min. The supernatant was discarded and the cells re-
suspended in 2 ml of a 90%GM, 10%DMSO (ThermoScientific) solution. 1 ml of cells 
was transferred to each of two cryovials (VWR), which were labelled with the cell line 
and date of freezing. The cyrovials were then transferred to a pot containing 
isopropanol which was stored at -80°C for 10-24 hr before being moved to liquid 
nitrogen storage. 
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2.1.1.4 Transfer to Roller Bottles 
After reaching confluence, cells were split with trypsin/EDTA and transferred to 
850 cm3 polystyrene roller bottles (Corning, Tewksbury, MA, USA) containing 200 ml 
GM. One confluent 100 mm plate of cells was used per roller bottle; the media were 
removed from the plates by aspiration and 2 ml trypsin/EDTA added to each plate. For 
10 roller bottles, the cells were loosened and pooled in 50 ml GM. 5 ml of these pooled 
cells were added to each roller bottle containing 200 ml GM. The bottles were rotorted 
horizontally several times to distribute the cells evenly on the surface then placed in the 
roller bottle incubator (VWR; Figure 2-1) and grown until the cells were confluent (5-7 
days).   
 
 
Figure 2-1. Roller bottles in roller bottle incubator 
Cells were grown in roller bottles in a 37 °C roller bottle incubator. Cytodex microcarrier 
beads were added to increase cell surface area. 
2.1.1.4.1 Addition of cytodex microcarrier beads 
Once the cells were confluent, to increase the surface for adherent cell growth, 
cytodex microcarrier beads (Sigma) were added to each confluent roller bottle. For 
each bottle, 1 g of beads was needed. For 10 roller bottles; 10 g beads was suspended 
in 350 ml Phosphate-buffered saline (PBS; 137 mM NaCl, 2.7 mM KCl, 10 mM 
Na2HPO4.2H2O, 2 mM KH2PO4, pH 7.4) in a 500 ml bottle and autoclaved on a fixed 
media cycle. After cooling, the PBS was removed by aspiration with care taken not to 
disturb the beads. The PBS was replaced with GM and the bottle shaken and left till the 
beads settled to the bottom of the bottle. This GM was removed by aspiration in the 
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same way and the washing with GM repeated to remove all traces of PBS. 500 ml GM 
was then added to the beads and 100 ml of GM from each roller bottle removed and 
replaced with 100 ml of fresh GM. The beads were swilled to distribute them within the 
500 ml of GM and 50 ml of the bead mix added to each roller bottle. Each roller bottle 
was then rotorted horizontally to coat the side with beads before being placed back in 
the incubator without media change until cells covered the whole surface of the beads 
(5-6 days). 
2.1.1.4.2 Change to serum free media 
At this point the GM in each bottle was exchanged for serum free media (SFM; 
DMEM/ F12 1:1 liquid, 0.01% Penicillin-Streptomycin). All the media in the roller bottles 
were discarded and 50 ml SFM added to each roller bottle and the bottles rotorted 
several times to rinse. The rinse media were replaced with 100 ml SFM and cells 
washed overnight in the roller bottle incubator. Next day all SFM were removed and 
replaced with 200 ml fresh SFM. 
2.1.1.5 Harvesting media 
5 days after transfer to SFM, 100 ml media were harvested. These 100 ml were 
replaced with 100 ml fresh ITS media (DMEM/F12 1:1 liquid, 0.01 mg/ml Boehringer 
Mannheim’s ITS (Roche, Basel, Switzerland), 4 µg/mL aprotinin solution (Sigma), 
0.01% Penicillin-Streptomycin)). ITS added essential nutrients to the DMEM/F12 
solution, facilitating the growth of the CHO cells in a serum free environment whilst the 
aprotinin in the media protected the secreted fibrinogen from proteolysis.  
The roller bottles were removed from the incubator and placed in the sterile hood; 
100 ml media from each bottle was removed and poured into a plastic funnel lined with 
filter paper (GE Healthcare, Little Chalfont, United Kingdom) into a 1 L bottle to remove 
all detached beads and cells. 100 ml fresh ITS media was added to each roller bottle 
which were then put back into the roller bottle incubator. The collected filtered media 
were transferred into bottles labelled with the date and number of harvest. From each 
batch of harvest a 1 ml aliquot was removed and stored at -20 °C to be used to 
determine fibrinogen content of the harvested media by enzyme-linked immunosorbent 
assay (ELISA) as in section 2.3. Periodically the fibrinogen content was determined by 
ELISA. When fibrinogen concentration began to decrease significantly, harvesting was 
stopped and the bottles thrown away. Media were generally harvested over 6-8 weeks, 
every 2-3 days. 150 µl of 100 mM PMSF (Sigma) was added per 100 ml of harvested 
media to prevent proteolytic degradation during storage. The harvested media were 
then stored at -40 °C until protein purification. 
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2.1.2 Ammonium sulphate precipitation of fibrinogen 
2.1.2.1 Preparation of ammonium sulphate 
A saturated solution of ammonium sulphate was prepared by addition of 1520 g 
ammonium sulphate (ThermoScientific) to 2 litres of dH2O in a 5 litre beaker. The mix 
was placed on a hot plate and a stirrer added. The mix was heated while stirring until 
all ammonium sulphate dissolved. The hot solution was then filtered through a 0.2 µm 
bottle-top membrane filter (ThermoScientific) into 2 litre bottles. The bottles were stored 
at 4 C overnight or until crystals formed.  
2.1.2.2 Fibrinogen precipitation 
Media were thawed in a 37 °C Stratus thermostatic water bath (Northern Media, 
Hessle, United Kingdom); fibrinogen from 4 litres of medium was precipitated per day. 
In the cold room, thawed media were pooled and 2 litres poured into each of two 5 litre 
beakers that already contained 5 mM ε-amine n-caproic acid (Sigma), 5 mM 
benzamidine (Sigma), 1 µM pepstatin (Sigma), 1 µM leupeptin (Sigma), 100 µM PMSF 
and 0.7 M MES-buffer (Sigma). 
Leupeptin, a synthetic inhibitor of serine and cysteine proteases, inhibits plasmin, 
trypsin, papain, and cathepsin B. Pepstatin A is a potent inhibitor of acid proteases 
including pepsin, rennin and cathepsin D, and PMSF protects the fibrinogen in solution 
against a broad range of proteases. The pH of the solution was brought to 5.6 by the 
addition of 0.7 M MES buffer to increase the precipitation yields as this is the isoelectric 
point of fibrinogen. This is the pH at which a protein has no net electrical charge 
meaning it will precipitate out of solution. 
The fibrinogen in media was then precipitated with cold saturated ammonium 
sulphate solution. The amount of ammonium sulphate solution required was given by 
the volume of media multiplied by 0.67 (e.g. 1340 ml for 2 L media). A stirrer was 
added to the beakers and the media gently stirred (50 rpm). A funnel lined with filter 
paper was held above each beaker and the ammonium sulphate solution allowed to 
drop slowly through the filter into the media. When all ammonium sulphate had filtered 
through, the beakers were wrapped with saran wrap and left overnight at 4 C without 
stirring. 
2.1.2.3 Centrifugation 
The next day the Sorvall GS3 rotor was cooled to 4 ˚C in a Sorvall RC-5B 
refrigerated super speed centrifuge (ThermoScientific) during which time the 
precipitated media/ammonium sulphate mixture was distributed between in 6 of 400 ml 
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Sorvall centrifuge cups which were balanced equally in pairs. These were placed in the 
cool GS3 rotor, the exactly weighted tubes opposite each other in the rotor to ensure 
perfect balance, and the lid of the rotor secured. Media was then centrifuged for 30 min 
at 9000 rpm, 4 ˚C with the brakes off.  
During this time, a pellet buffer was prepared containing; 200 mM Tris, 0.3 M 
NaCl, 1 mM EDTA, 5 µM leupeptin, 5 µM pepstatin, 100 µM PMSF, 10 U/ml soybean 
trypsin inhibitor (Sigma), 5 mM ε-amine n-caproic acid and 5 mM benzamidine which 
was kept on ice until use. 
When the centrifugation was complete and a weakly attached yellow pellet had 
formed on the inner wall of the centrifuge cups, they were removed and taken back to 
the cold room with care so as not to disturb the pellet. The media were discarded and 
any excess removed from the tube with a pastette. The precipitated fibrinogen in each 
bottle was dissolved with 1.2 ml pellet buffer. The solution was pipetted up and down 
and along the walls of the bottle to give the fibrinogen time to dissolve. The dissolved 
pellet was pooled into a SS34 rotor tube and kept on ice until all precipitate had been 
collected, after which it was kept on ice for 30 min. During this incubation, the SS34 
rotor was cooled in the Sorvall centrifuge. The tube was balanced against a balance 
tube and centrifuged at 19,000 rpm for 30 min at 4 °C with the brakes on. The 
supernatant was transferred to a clean 15 ml falcon tube and put at 4 °C if loaded onto 
the column within the next 2 days or frozen at -80 °C.  
2.1.3 Protein purification 
2.1.3.1 Preparation of samples for fibrinogen purification 
2.1.3.1.1 Plasma 
To prepare the citrated plasma pools for purification on the IF-1 column, 1.2 ml 
plasma was added to a final volume of 5 ml of 100 U/ml heparin and 0.02 M CaCl2 in 
equilibration buffer (0.02 M Tris, 0.3 M NaCl, 1 mM CaCl2, pH 7.4).  
2.1.3.1.2 Recombinant 
If frozen, the supernatant from the Sorvall steps was thawed in a 37 ˚C water 
bath and kept on ice until use. 1 M CaCl2 was added to the sample to a final 
concentration of 10 mM, which was then mixed and left on ice for at least 30 min. 
2.1.3.2 IF-1 monoclonal antibody and BioCad 
Purification of fibrinogen was performed by affinity chromatography using calcium 
dependent IF-1 monoclonal antibody (Kamiya Biomedical, Seattle, WA, USA) and an 
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automated chromatography system (Biocad sprint, Applied Biosystems, Warrington, 
UK).  After loading the sample, the column underwent washing using 6 column 
volumes 0.02 M Tris,1 M NaCl, 1 mM CaCl2, pH 7.4 and 0.05 M sodium acetate, 0.3 M 
NaCl, 1 mM CaCl2, pH 6. Elution of fibrinogen was achieved by adding 7 column 
volumes 0.02 M Tris, 0.3 M NaCl, 5 mM EDTA, pH 7.4. The chromatograph produced 
was used to estimate a peak of the fibrinogen eluted. Those tubes of elutant within this 
peak were tested by spectophotometry as in section 2.1.3.5. All those fragments with a 
protein concentration >0.05 mg/ml, assessed by a ND-1000 spectrophotomer 
(Nanodrop, Wilmington, DE, USA), extinction coefficient 15.1, were pooled and stored 
at -80 ˚C. 
2.1.3.3 Concentration 
To concentrate the pooled fibrinogen eluted from the BioCad, 100,000 MWCO 
Vivaspin20 concentrator tubes (Generon, Maidenhead, Berkshire, UK) were spun at 
2000 g (3000 rpm) until the volume in the filter was 1 ml. The fibrinogen was 
transferred to a microcentrifuge tube in 200 µl steps making sure to wash the filter 
surface thoroughly with the solution to dislodge all fibrinogen caught in the membrane. 
2.1.3.4 Dialysis 
Dialysis tubing (Sigma) was prepared by boiling the tubing in 1 M EDTA. The 
tubing was rinsed with ddH2O and each of the fibrinogen samples dialysed against 50 
mM Tris, 100 mM NaCl pH 7.4 at 4 C for 2 consecutive hr and overnight with stirring 
(50 rpm).  
2.1.3.5 Concentration of fibrinogen determination 
Protein concentration was determined using a ND-1000 spectrophotomer 
(Nanodrop, Wilmington, DE, USA), extinction coefficient, 15.1. 
2.1.3.6 SDS Page 
A sodium dodecyl sulphate (SDS) polyacrylamide gel (Invitrogen) was run to 
determine the quality and purity of the dialysed fibrinogen. 15 µg samples of fibrinogen 
were prepared in 10 µl sample buffer and 4 µl reducing agent (Invitrogen) and made up 
to 26 µl with ddH2O and reduced at 70 C for 10 min. The samples were run on a 4-
12% NuPAGE Novex Bis-Tris gel (Invitrogen) at 200 V for 35 min using MES SDS 
running buffer in a Novex mini-cell tank (Invitrogen). 5 µl of Perfect Protein marker 
(Novagen, Madison, WI, USA) was added to one well as a molecular weight marker.  
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β 
α 
ᵞ 
2.1.3.7 GelCode staining 
After electrophoresis, the gel was rinsed with dH2O for 15 min, replacing with 
fresh water every 5 min. The gel was then stained with GelCode Blue Stain Reagent 
(ThermoScientific) solution for 1 hr with shaking. The gel was subsequently de-stained 
4 times for 15 min on each occasion with dH2O. The gel was visualised using Chemi-
imager software (Alpha Innotech, San Leandro, CA, USA) using a trans-white light. 
Three bands were expected (for the α, β and γ chains of fibrinogen), and correct sizes 
verified using an appropriate ladder (66, 56 and 48 kDa respectively) as shown in 
Figure 2-2.  
 
 
Figure 2-2. SDS-PAGE gel showing purified fibrinogen 
Each band is well defined and separated at the expected molecular weights. There is 
no smearing or any unexpected bands. 
 
Once the integrity and purity of the protein had been confirmed, the samples 
were pooled together, swirled to mix and concentration determined by 
spectophotometry. The stock was then diluted to the desired concentration by addition 
of permeation buffer (PB; 0.1 M NaCl, 0.05 M Tris, pH 7.4) and aliquoted into 
eppendorf tubes. The purified fibrinogen was stored at -80 °C. 
2.1.3.8 Clottability assay 
The protein concentration of sample of fibrinogen was assessed by 
spectophotometry as in section 2.1.3.5.10 µl of an activation mix (AM) was added to 90 
µl of each sample to final concentrations of 5 U/ml thrombin (Millipore, Billerica, 
Massachusetts, USA), 5 mM CaCl2. The samples were allowed to clot for 1 hr at 37 C 
after which they were centrifuged at 13,000 rpm for 10 min. The protein concentration 
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in the supernatant was then measured by spectophotometry and used to make an 
estimate of the percentage of protein that did not clot. 
2.2 Clauss Method for plasma fibrinogen level determination 
Plasma was diluted 1:10 in veronal buffer pH 7.35 (0.026 M sodium acetate 
trihydrate, 0.026 M sodium 5,5 diethylbarbiturate, 0.11 M NaCl, 0.016 M HCl in H2O) 
and incubated at 37 °C with 5 U/ml thrombin in a KC10 Amelung Coagulometer 
(Amelung, UK) with stirring. The time taken for the clot to form was compared to a 
calibration curve of reference plasma (Biomereux, Hampshire, UK) with a known level 
of fibrinogen and the fibrinogen concentration deduced.  
2.3 Fibrinogen ELISA 
A Nunc-Immuno MicroWell 96 well MaxiSorp flat bottom plate (Sigma) was 
coated with DAKO anti-fibrinogen antibody A0080 (Agilent Technologies, Santa Clara, 
CA, USA). 100 µl of 1.15 µg/ml of antibody in buffer A (0.0025 M NaH2PO4.2H2O, 
0.0075 M Na2HPO4.2H2O, 0.145 M NaCl) was added to each well, the plate covered 
with film and left at 4 °C overnight. A standard curve of known concentrations (0.5 
µg/ml, 0.25, 0.125, 0.0625, 0.03125, 0.015625) of calbiochem fibrinogen (Millipore) 
was made in buffer B (0.0025 M NaH2PO4.2H2O, 0.0075 M Na2HPO4.2H2O, 0.5 M 
NaCl, 2% Tween20). The collected samples of recombinant protein from the roller 
bottles were thawed and prepared neat, 1:10 and 1:20 in buffer B. The plate was 
washed by emptying the wells into the sink, reverse pipetting 200 µl buffer B into each 
well then pouring off into sink again, 3 times. The fibrinogen samples were loaded onto 
the plate; 100 µl of each sample per well, each in duplicate. Two ‘blank’ buffer B wells 
were also added to the standard curve. The plate was incubated for 2 hr with shaking 
at 300 rpm at room temperature, after which it was washed 3 times with buffer B. The 
second antibody was then loaded; 100 µl of 0.625 µg/ml goat polyclonal antibody anti 
fibrinogen HRP (Abcam, Cambridge, England) in buffer B to each well. The plate was 
incubated for 1 hr at room temperature with shaking at 300 rpm before washing 3 times 
with buffer B. 4 DAKO OPD Tablets (2 mg) were dissolved in 12 ml water to a 
concentration of 0.66 mg/ml with 5 µl H2O2. 100µl of this solution was loaded into each 
well. 100 µl 2 M H2SO4 was added to each well to stop the reaction when most wells 
had reached ~0.5 OD at 490 nm. The plate was read at 490 nm on a MRX Microplate 
Reader (Dynex Technologies, Ashford, Middlesex, UK). 
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2.4 Analysis of clot formation and lysis 
2.4.1 Turbidity 
The turbidity method provides a dynamic measurement of clot formation. As the 
clot starts to form, optical density increases; this is measured with a plate reader which 
estimates the amount of light absorbed by the clot when light of a set wavelength is 
directed through it (Figure 2-3A). 
2.4.2 Turbidity and lysis 
The lysis method provides a dynamic measurement of clot formation and lysis. 
As the clot lyses, optical density, and absorbance, decrease until they reach a baseline 
when the clot is fully dissolved (Figure 2-3B). 
2.4.3 Turbidimetric parameters 
Several clot formation and lysis parameters can then be calculated from this trace 
(Figure 2-3): 
Lag phase represents the initial stage of clot formation, when fibrinogen is 
converted to fibrin monomers which start to form protofibrils. During this phase, optical 
density remains at baseline. The end of lag phase is taken at the time point when there 
is an exponential increase in optical density above baseline. Short lag times have been 
associated with thrombogenic clots ex-vivo, although not all studies agree92, 119, 121. 
Maximum absorbance represents the stage at which the clot is fully formed; 
optical density increases from baseline as lateral aggregation of the protofibrils formed 
in lag phase occurs. MA was recorded as the highest reading of optical density from 
the turbidity trace. This measurement reflects both the thickness of the fibre fibres 
(purified system and in plasma) and can also measure compactness of plasma clots23. 
Clinically, a higher MA of clots prepared from plasma samples indicates a more 
thrombogenic clot23, 119, 121. 
Clot formation time represents the time between the end of the lag phase and 
the point at which MA is reached. This indicates the rate at which the fibrin fibres form, 
with long CFT indicating the formation of clots with higher final turbidity or ineffective 
fibrinolysis. A recent study has shown that longer CFT is associated with worse clinical 
outcome122.  
Lysis time represents the time from MA to the time at which 50% of the clot has 
lysed (i.e. 50% MA on the descending limb of the turbidity curve). This is an indicator of 
how susceptible the clot is to fibrinolysis, with longer LT associated with increased risk 
of CVD122, 123. 
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Lysis area is a complex measure of clot formation, clot maximum absorbance 
and lysis times. Hence, larger lysis area is associated with more thrombotic clots. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2-3. Illustration of the turbidimetric and lysis parameters generated 
(A) Turbidity only (B) Turbidity and lysis. Lag phase (LP), clot formation time (CFT), 
maximum absorbance (MA), lysis time (LT) and lysis area (shaded area) are shown. 
2.4.4 Clots made from plasma samples 
Clot turbidity and lysis measurements were conducted as previously described122.  
A total of 25 µl of each plasma sample was mixed with 75 µl lysis mix [LM; 100 mM 
NaCl, 50 mM Tris, 83 ng/ml tissue plasminogen activator (tPA) (Tecnoclone, Vienna, 
Austria), pH 7.4], at ambient temperature in a 96 well clear polystyrene flat bottom 
microplate (Grenier Bio-one, Gloucester, UK). Polymerisation was initiated by addition 
of 50 µl of AM [50 mM Tris, 100 mM NaCl, 0.09 U/ml thrombin, 22.5 mM CaCl2, pH 7.4] 
and increase in turbidity at 340 nm continuously monitored every 12 sec on a ELx-808 
IU ultramicroplate reader (BIO-TEK Instruments INC, Winooski, VT, USA) over a period 
of 60 min then every 2 min for 9 hr. Four replicates were performed for each variant. 
A. 
B. 
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Turbiditimetric assays of individual plasma clots were conducted by another member of 
the team. 
2.4.5 Clots made from plasma purified or recombinant protein 
Clot turbidity and lysis measurements were conducted as described before102. A 
total of 50 µl of purified/recombinant fibrinogen, at 0.5 mg/ml, was mixed with 50 µl LM 
[1.1 µg/ml FXIII, 18.75 µg/ml plasminogen (ERL, South Bend, IN, USA), in the 
presence and absence of 10 µg/ml calbiochem antiplasmin (Millipore) in 100 mM NaCl, 
50 mM Tris, pH 7.4] in a Greiner 96 well clear polystyrene flat bottom microplate in 
duplicate. Polymerisation and lysis were initiated by the addition of 50 µl AM [1.5 U/ml 
thrombin, 0.23 µg/ml tPA and 7.5 mM CaCl2 in 100 mM NaCl, 50 mM Tris, pH 7.4], at 
ambient temperature. Four replicates were performed for each variant. Increase in 
turbidity at 340 nm was continuously monitored every 12 sec on ELx-808 IU 
ultramicroplate reader over a period of 120 min. 
2.5 Western Blotting 
A NuPAGE Novex Bis-Tris gel (Invitrogen) was run as described in section 
2.1.3.6 and the gel incubated in transfer buffer (0.025 M Tris, 0.2 M glycine, 20% 
methanol, pH 8.4) with shaking for 10 min. Immobilon-P transfer Polyvinylidene 
Difluoride membrane (NENTM Life Science Products, Boston, MA, USA), pore size 0.45 
µM was cut in the top left-hand corner to orientate on the gel and soaked in methanol 
(15 sec), ddH2O water (2 min) and transfer buffer (2 min). A blot mesh (Bio-Rad, 
Hercules, CA, USA) was opened and onto the black mesh was placed a sponge, an 
8x8 cm piece of whatman filter paper (SLS, Nottingham, UK), the gel, the membrane, 
another filter paper, and then another sponge (all pre-soaked in transfer buffer). A 
syringe was used to wet each surface with transfer buffer and bubbles rolled out 
between each surface with a roller. A ‘blank’ mesh was made if only running one blot 
by inserting 2 filter papers instead of the gel and membrane. The meshes were then 
closed and secured before loading onto a rig in a Mini-PROTEAN 3 Cell (Bio-Rad) 
contained in a plastic tub. An ice brick was added to the tank which was then topped up 
to the rim with transfer buffer. The transfer was run for 1 hr at 100 V while stirring. 
Once run the rig was dismantled and the membrane washed in Tris-buffered saline 
(TBS; 40 mM Tris, 140 mM NaCl, pH 7.4)/ 0.05% Tween20 for 10 min at room 
temperature with shaking. The membrane was then incubated in blocking solution (5% 
skimmed milk in TBS/ 0.05% Tween20) overnight at 4 C and at room temperature for 
1 hr. It was washed 4 x 10 min with TBS/ 0.05% Tween20 at room temperature then 
incubated in blocking buffer with the antibodies in Table 2-1 for 1 hr at room 
temperature depending on which protein was to be visualised: 
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Table 2-1. Combinations of antibodies used for western blot analysis 
Protein 1 2 
α2-AP 
Goat anti-Human α2-AP HRP 
(ERL) (1:1000) 
N/A 
Fibrinogen 
Rabbit polyclonal anti-
Fibrinogen (DAKO) (1:1000) 
Goat anti-rabbit HRP 
(DAKO) (1:1000) 
Albumin 
Rabbit anti-Albumin HRP 
(Abcam) (1:1000) 
N/A 
Molecular Weight Marker 
Streptactin HRP (BioRad) 
(1:5000) 
N/A 
 
If two antibodies were used, the blot was washed 4 times with TBS/ 0.05% 
Tween20 between the 1 and 2 antibody. The blot was washed in the same way after 
antibody application and before development. The blot was developed with a 1:1 mix of 
Supersignal West Pico Luminol (Thermo scientific) and Supersignal West Pico Stable 
(Thermo scientific) for 5 min after which it was transferred to acetate and 
chemiluminescence captured using a Kodak Image Station 2000R (Eastman Kodak 
Company, New Haven, CT, USA). 
2.6 Laser scanning confocal microscopy  
Confocal microscopy was used to visualise hydrated clots. This technique is 
advantageous because the samples do not need special preparation such as fixing and 
dehydration, therefore the clots are imaged in a physiological and fully hydrated status. 
2.6.1 Preparing a clot for LSCM 
For plasma clots, 7.5 µl plasma and 1.5 µl 488 Alexa labelled fibrinogen (0.5 
mg/ml) (Invitrogen) were mixed with 21 µl PB. 28.5 µl purified/recombinant fibrinogen 
(0.5 mg/ml) and 1.5 µl 488 Alexa labelled fibrinogen (0.5 mg/ml) were mixed together. 
An AM of 0.035 M CaCl2 and 0.35 U/ml thrombin was prepared in PB. 5 µl AM was 
then added to 30 µl of plasma/fibrinogen mix, mixed thoroughly and 30 µl added to a 
well of an Ibidi confocal slide (Applied Biophysics, New York, USA). A cover was 
placed on to the slide which was stored in a humid dark box until imaging. 
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2.6.2 Imaging fluorescent samples 
The slide was visualised with LSM510 software on the LSM 510META 
microscope from Zeiss (Oberkochen, Germany), using the 488 Argon laser, green 
reflector and 40x 1.3 oil ph3 objective lens. The slide was loaded onto the specimen 
stage. Scan mode was then selected (LSM) and single track ‘CY2 alexa 488’ chosen. 
Detector gain was set to 999, offset to -0.217 and pinhole to 94. To view the same 
section of each clot the focus wheel was used to find the top of the clot using the ‘fast 
xy’ scanning mode and then the view moved 1.5 fine focus turns into the clot. For static 
images a 10242 image size was used and the resolution set to 8. For static Z stacks the 
resolution was reduced to 4. 3 Z-stacks of each clot were taken, with range 10, 20 and 
50 µM and intervals 1, 2 and 5 µM respectively. 
2.6.3 LSCM clot lysis 
Time series function was used with 400 scans with 1 sec between scans. The 
gain, offset and pinhole were set as above, with resolution at 8 pixels and picture size 
at 5122. 20 µl LM (100 µg/ml plasminogen, 10 µgml tPA in PB) was added to the Ibidi 
well and the slide tapped gently for 30 sec to encourage the LM into the clot channel. 
The slide was then left for 30 sec in a vertical position before loading onto the stage 
and clot visualisation. The lysis front was identified using fast xy scanning mode and a 
time series taken at 4 min after addition of LM so that the lysis front just approached 
the edge of the first frame of the time series. A ‘Lysis 2’ time series was also taken 30 
sec after the lysis front passed the frame of the first lysis. Images were viewed, edited 
and analysed using LSM image browser (Zeiss). 
2.6.4 Clot density by LSCM 
A macro was developed to assess clot density in collaboration with Gareth 
Howell of the Bioimaging Flow Facility at the University of Leeds. This macro works by 
processing the confocal clot image in Image J (National Institute of Mental Health, 
Bethesda, Maryland, U.S) in such a way that a single fibre becomes a single black line 
against a white background, as in Figure 2-4A-B. The macro then places a 20x20 grid 
(Figure 2-4C) on top of this image from which it can calculate how many times the 
fibres cross the gridlines. This gives an accurate estimate of how many fibres bundles 
are present in the image, and thus clot density. Development of a similar macro to 
measure density of fibres from EM images was attempted. However Image J could not 
process the image in the same way to produce the clot ‘skeleton’ as there is not a 
strong enough contrast between fibrin and background in these images, rather a 
transition through shades of grey. 
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Figure 2-4. Macro processing of LSCM clot images 
(A) LSCM image of confocal clot (B) Macro processed image (C) 20x20 image grid. 
Each time a line on B crosses a line on C a fibre is counted. 
2.7 Scanning Electron Microscopy 
2.7.1 Preparing a clot for electron microscopy 
To prepare a clot for electron microscopy (EM), the lid of a 0.5 ml eppendorf tube 
was cut off and holes pierced in the lid with a needle and labelled with pencil. The 
bottom of the lid was wrapped with parafilm to cover the holes.  
2.7.1.1 Clot preparation 
For purified fibrinogen 45 μl of fibrinogen (0.5 mg/ml) was mixed with 5 μl of AM 
(0.025 M CaCl2, 5 U/ml thrombin in PB). For a plasma clot, plasma was diluted 1:2 with 
PB and 5 µl AM (0.05 M CaCl2, 11 U/ml thrombin in PB) added. The mixture was 
pipetted up and down with a 200 µl tip with the end chopped off to evenly distribute 
A B 
C 
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AM. The clots were then left to form in the lids for 2 hr in a humidity chamber before 
washing.  
2.7.1.2 Fixing and dehydration 
The parafilm was removed from the bottom of the lid and the clots placed in a 
beaker of sodium cacodylate buffer (0.078 M Cacodylic acid (Sigma), pH 7.4) for 10 
min, the buffer was replaced with fresh buffer and left for another 10 min. The clot was 
fixed by transferring the lid to 2% Glutaraldehyde (Sigma) in sodium cacodylate buffer 
for 30 min then washed 2 x 10 min in sodium cacodylate buffer. The buffers were 
stirred gently with a flea while washing and fixing. The clots were then dehydrated by 
sequentially transferring them from 30% to 50% to 70% to 80% to 90% to 95% acetone 
for 10 min each. They were then transferred to fresh 100% acetone 3 times for 10 min 
before being transferred to fresh 100% acetone ready for critical point drying.  
2.7.1.3 Critical point drying  
Critical point drying was carried out by Martin Fuller at the University of Leeds 
using a E3000 critical point dryer (Quorum Technologies Ltd, UK). This technique 
dehydrates the fibrin structure so that it can be coated with platinum in order to be 
detected under the EM. Since EM analyses the surface morphology of biological 
specimens, it is imperative that the surface of the fibrin is not disturbed in the drying 
process. This means air drying is unsuitable for this application as it can cause 
deformation and collapse of protein structures. This is because water has a high 
surface tension to air and thus the specimen is subject to considerable forces at the 
boundary between the water in the sample and the surrounding air as the liquid in the 
sample evaporates, at the so called ‘phase boundary’. In CPD, this surface tension is 
reduced by replacing the water in the sample with liquid CO2, using acetone as an 
intermediate, progressively lowering the surface tension between the sample liquid and 
surrounding air. It is then possible for the liquid CO2 to pass from liquid to gas without 
an abrupt change in state, thus avoiding damage to the surface of the sample. 
2.7.1.4 Sputter coating 
The clots were then mounted onto aluminium specimen mounts covered in a 
carbon film using tweezers. The clots were then coated in with a 7 nm thick conducting 
layer of platinum palladium applied in a 208HR high resolution sputter coater 
(Cressington, UK). Covering the sample in a thin layer of conducting metal prevents the 
sample from charging under the electron beam. 
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2.7.2 Imaging sample 
Samples were viewed and photographed using a Quanta 200F FEGESEM field-
emission scanning electron microscope (FEI, Oregon, USA) in 3 different areas of each 
clot. Images were captured using FEI's own software, designed to run with the EM. 
Fibre diameters of all clots were measured with image analysis software package 
ImageJ 1,23y.  
2.8 FXIII purification 
It was necessary to purify FXIII as the group stock ran out midway through my 
research. The commercial FXIII that is available has a large amount of albumin and 
other impurities in that can affect the clotting process. To eliminate the effect of any of 
these contaminants, pure FXIII was isolated from this product by affinity 
chromatography for use in my studies. A sepharose 6B 200 ml size exclusion column 
was attached to the BioCad ensuring that there was no air in any part of the tubing. 
The column was equilibrated for 2 hr with PB at a flow rate of 0.5 ml/min. Two vials of 
Fibrogammin P (ZLB Behring, King of Prussia, PA 19406, United States) (250 U) were 
reconstituted in 5 ml of pure water by gentle mixing. The sample was injected onto the 
BioCad and buffer flow resumed at 0.5 ml/min collecting fractions every 3 ml over 1.2 
CV (240 ml).The purified FXIIIA2B2 was eluted in the second of four peaks on the 
chromatograph. The fractions within this peak were immediately kept on ice to avoid 
protein activation or precipitation. An aliquot of each fraction was analysed on a non-
reducing SDS-PAGE gel to determine sample purity. Those fractions of sufficient purity 
were pooled and concentrated by centrifugation using vivaspin MXCO100 spin 
columns, 4,500 rpm for 5 min and final concentration determined using a Nanodrop 
ND-1000 spectrophotometer, extinction coefficient 1.31. Pure FXIIIA2B2 was aliquoted 
into appropriate volumes to avoid freeze-thawing and stored at -80 C. Activity of the 
purified protein was tested using the biotin labelled pentylamine incorporation FXIII 
activity assay as in section 4.1.9.1. 
2.9 Atomic Force Microscopy 
2.9.1.1 Sample preparation 
To visualise individual fibrinogen molecules before polymerisation a 15 µl volume 
of 0.17 mg/ml fibrinogen was diluted in 1530 µl MilliQ water. 50 µl of this mixture was 
then pippetted on to a mica and allowed to incubate for 2 min. Mica is graphite like 
material which is attached to the stage on which the sample is mounted by superglue. 
This mica material is used for its layered texture, these extremely thin layers can be 
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split and separated to reveal a new clean layer beneath, which is chemically inert and 
very smooth. Before the sample is loaded onto the mica, the top layer is cleaved by 
attaching and then removing sellotape to the surface, taking the top layer with it. Since 
the mica and fibrinogen molecule are both negatively charged, a new layer of positively 
charged material is required to help attract fibrinogen to mica. This was done by 
treating the freshly cleaved mica with 2 mM NiCl2 for 10 min. The surface was then 
washed by flooding with water and dried with pressurised nitrogen after which it was 
ready for sample loading. Once the sample had incubated for 2 min, the surface was 
rinsed with MilliQ water 10 times and dried under nitrogen. To visualise the early 
stages of fibrin polymerisation, when the protofibrils are beginning to form it was 
necessary to look at the turbidity curves produced. As the stage we are interested in 
visualising is the lag phase, an appropriate concentration of thrombin to be used had to 
be determined. This concentration would allow normal clot formation, but a long 
enough lag phase to stop the clotting reaction before gel point, when fibrin fibres begin 
to assemble (when OD begins to rise). 
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Figure 2-5. Effect of thrombin concentration on lag time of fibrin polymerisation 
A lag time of 90 sec before OD increased was obtained with a final thrombin 
concentration of 0.25 U/ml in these conditions which is appropriate for use in AFM 
sample preparation. 
 
From turbidimetirc analysis, a final thrombin concentration of 0.25 U/ml seemed 
apt for AFM analysis, as this produced a lag time of 90 sec before OD began to rise 
from baseline. From this information, to visualise fibrin fibril formation, fibrinogen (0.17 
mg/ml) was pre-mixed with 2.5 mM CaCl2 to a final volume of 10 µl in a 1.5 ml tube. 5 
µl thrombin was added (final concentration 0.25 U/ml) and the reaction allowed to 
progress for 30, 60 and 90 sec. At each time point, the reaction was stopped by dilution 
by addition of 1530 µl PB. This was applied to a mica pre-treated the NiCl2 using the 
same method as for fibrinogen monomers. 
2.9.1.2 Imaging  
The AFM is essentially a feedback system. It is composed of a sharp tip at the 
end of a cantilever, a laser, a photodiode detection system and the feedback 
mechanism. The sample surface can be scanned by the tip in various ‘modes’. The 
system relies on the forces between the tip and the sample (e.g. Van de Waals, dipole-
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dipole and electrostatic forces) affecting the deflection of the cantilever, which change 
with distance between the two. This deflection is detected by a laser which is directed 
onto the top of the tip and reflected into a photodiode. As the cantilever and tip move, 
so will the reflected laser on the photodiode as depicted in Figure 2-6. 
 
 
Figure 2-6. Diagrammatical representation of the AFM detection and feedback 
mechanism 
A laser is reflected off the top of the tip at the end of a cantilever into a photodiode. 
When the sample is scanned, vertical movements of the tip/ cantilever due to the 
topography of the sample surface are thus detected as movement of the reflected 
laser. 
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Figure 2-7. Photographs of AFM equipment  
(A) Microscope assembled on elevated platform (B) Microscope ‘reader’ with tip 
inserted; detection laser can be seen reflected off the tip and the sample surface (C) 
Nanoscope software interface. 
 
The AFM can be operated in a number of modes, divided into contact and non-
contact modes. 
A
. 
B
. 
C
. 
B. 
C. 
A. 
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2.9.1.2.1 Contact mode 
In this mode the cantilever is in constant contact with the sample surface, across 
which it is dragged. The contours of the surface are measured directly from the 
deflection of the cantilever. This mode is appropriate only for very hard sample 
surfaces, as the cantilever can damage softer samples. 
2.9.1.2.2 Non-contact mode 
In this mode, the cantilever is oscillated above the surface of the sample. 
Interactions between the tip and the sample are capable of altering the oscillation 
amplitude. These changes in oscillation are detected and analysed to produce a 
topographical image of the surface. Since the tip does not contact the surface in this 
mode, the sample is not damaged. This makes this mode ideal for soft biological 
samples. 
2.9.1.2.2.1 Tapping mode 
Samples in this study were imaged using tapping mode AFM. This mode 
bypasses the problem often encountered in non-contact mode AFM in which the tip 
‘sticks’ to the sample surface due to short range forces developed by a liquid meniscus 
forming on the sample surface in ambient conditions. Similarly to general non-contact 
mode, the cantilever is driven to oscillate up and down. However in this mode, the AFM 
adjusts the height of the cantilever in reaction to changes in forces between the tip and 
the surface when they approach each other, which would otherwise cause the 
amplitude of the oscillation to decrease. This feedback mechanism maintains set 
oscillation amplitude, producing an image by measuring the force of the intermittent 
contacts between the tip and surface. Image processing and analysis was performed 
using Nanoscope software (Veeco Instruments) 
2.10 Mass Spectrometry 
2.10.1 Principles of mass spectrometry  
A mass spectrometer consists of three components: an ion source, a mass 
analyzer, and a detector. The ion source converts the sample into gas phase ions 
which are separated according to their mass-to-charge ratio by projection through the 
mass analyzer and onto the detector which calculates the abundances of each ion 
present. The data generated are displayed as a spectrum of the relative abundance of 
ions as a function of their mass-to-charge ratio (m/z).  
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Since fibrinogen is large protein with three separate covalently, disulfide linked 
chains, it is important to reduce the protein before MS analysis as analysis of the whole 
protein would generate a single peak in a spectrum which would not give enough 
information about the individual protein chains. Following reduction, the α, β and γ 
chains were separated by SDS-PAGE and further fragmented by enzyme digestion 
with trypsin. Trypsin has a well-defined cleavage specificity, cleaving proteins on the C-
terminal side of lysine and arginine residues, except when they are immediately 
followed by proline. Consequnetly, trypsin treatment of proteins yields peptides with an 
average length of about ten to fifteen amino acid residues, ideal for MS detection.  
Having fragmented the protein into peptides, these fragments are subject to 
tandem MS analysis (MS/MS) as illustrated in Figure 2-8. Firstly, the masses of the 
sample fragments are determined in a MS survey scan. The peptide ions of interest are 
then isolated via their mass-to-charge ratio value by filtering away other ion species 
with different m/z values. The selected peptide ion species are activated by collisions 
with an inert gas such as Argon that imparts internal energy into the ions and thereby 
induces further fragmentation. The fragment ions are projected through the mass 
analyser and the m/z values determined. The presence of PTMs in proteins affects the 
molecular mass of the modified amino acids, which are detected by a mass increment 
or deficit on the MS/MS spectra.  
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Figure 2-8. Diagrammatic representation of MS/MS for mapping of PTMs 
The MS spectrum is acquired to determine the molecular mass of the peptides. 
Fragmentation of the peptide by collision induced dissociation produces a set of 
fragment ions that are then subjected to MS/MS analysis which produces a spectrum of 
relative abundance of ions as a function of their mass-to-charge ratio. The presence of 
a PTM will change the mass of the modified amino acid residue and of the peptide and 
cause a shift in the spectrum.  
 
This technique is advantageous as it is highly sensitive, effective down to the 
femtomole scale thus requiring very little sample. It is able to detect molecular mass 
shifts corresponding to modifications at both the peptide and protein level; capable of 
distinguishing between the type of PTM and its location. However, this technique has 
several limitations; digestion, ionization and MS/MS activation can lead to dissociation 
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of the PTM from the molecule if the covalent bond between the amino acid and the 
PTM adjunct is chemically unstable. While certain PTMs will remain intact during MS 
and MS/MS experiments, some may not be detected if they dissociate in the 
preparation processes inherent to this technique. There is the added complication of 
isolating the site of modification in a peptide of a size suitable for mass spectrometric 
analysis, especially as the presence of PTMs can affect the cleavage efficiency of 
trypsin, generating unexpected or large peptide products. For these reasons, it is often 
useful to consider and explore several approaches for mapping of PTMs in 
proteomics124. Consequently an electroelution technique was attempted in order to 
separate the chains without the need to excise them from a gel and digest with trypsin, 
this is advantageous because it has the potential to separate the fibrinogen chains to 
take intact mass measurement to determine modification profile.  
2.10.2 Gel processing and tryptic digestion 
A sample of each fibrinogen was run by SDS-PAGE and stained as described in 
section 2.1.3.6. Gel bands were excised and chopped into small pieces (~1 mm3), 
covered with 30% ethanol in a 1.5 ml microcentrifuge tube and heated to 70 °C for 30 
min with shaking. The supernatant was removed and replaced with fresh ethanol 
solution and the digest heated to 70 °C for 30 min. This was repeated until all 
coomassie stain was removed from the gel. The destain solution was replaced with 50 
µl 25 mM ammonium bicarbonate and was vortexed for one hr. The wash solution was 
discarded and the gel slices covered with 25 mM ammonium bicarbonate/ 50% 
acetonitrile and vortexed for ten min. The gel slices were then covered with 100% 
acetonitrile and left for five min with vortexing before the supernatant was discarded 
and replaced with a fresh aliquot of acetonitrile. Acetonitrile was removed and the gel 
pieces were completely dried under vacuum centrifugation for 30 min. Once dry, the 
gel slices were cooled on ice. The gel slices were then covered with ice cold trypsin 
solution (20 ng/µl in 25 mM ammonium bicarbonate) and left on ice for 30 min to 
rehydrate. Excess trypsin solution was removed and the gel slices were covered with a 
minimal amount of 25 mM ammonium bicarbonate. After briefly vortexing and 
centrifuging, the gel slices were incubated at 37 °C with shaking for 18 hr. The resulting 
digest was vortexed, centrifuged and 50 µl water was added. Following vortexing for 10 
min, the supernatant was recovered and added to an eppendorf containing 5 µl 
acetonitrile/ water/ formic acid (60/ 35/ 5; v/v). 50 µl acetonitrile/ water/ formic acid (60/ 
35/ 5; v/v) was added to the gel slices and vortexed for an additional 10 min. The 
supernatant was pooled with the previous wash and one additional wash of the gel 
slices was performed. The pool of three washes was dried by vacuum centrifugation. 
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The peptides were reconstituted in 20 µl acetonitrile/ water/ formic acid (2/ 97.9/ 0.1; 
v/v).   
2.10.3 Liquid chromatography-mass spectrometry 
Liquid chromatography-mass spectrometry (LC-MS/MS) analysis of the peptide 
mixtures was performed on an Ultimate 3000 nano LC system (Dionex, Amsterdam, 
Netherlands). 2 µl of each sample in water was loaded onto a C18 guard column and 
washed with 2% acetonitrile/ 0.1% formic acid for 5 min at 25 µl/min. After valve 
switching, the peptides were then separated on a PepMap C18, 100 µm i.d.x15 cm 
analytical column (Dionex, Amsterdam, NL) by gradient elution of 2-60% solvent B 
(0.05% formic acid in 20% water/ 80% acetonitrile) in solvent A (0.05% formic acid in 
98% water/ 2% acetonitrile) over 60 min at 0.3 µl/min. The column eluant was directly 
interfaced to a quadrupole-ion mobility-orthogonal time of flight mass spectrometer 
(Synapt HDMS, Waters UK, Manchester) via a Z-spray nanoflow electrospray source. 
The MS was operated in positive TOF mode using a capillary voltage of 3.2 kV, cone 
voltage of 25 V, backing pressure of 2.47 mbar and a trap bias of 4 V. The source 
temperature was 80 °C. Argon was used as the buffer gas at a pressure of 5.0×10-4 
mbar in the trap and transfer regions. Mass calibration was performed by a separate 
injection of sodium iodide at a concentration of 2 µg/µl. GluFib was infused as a lock 
mass calibrant with a one sec lock spray scan taken every 30 sec during acquisition. 
Ten scans were averaged to determine the lock mass correction factor.  Data 
acquisition was using data dependent analysis with a one sec MS over an m/z of 350-
3000 being followed by three 1 sec MS/MS taken of the three most intense ions in the 
MS spectrum. Collision energy applied was dependent upon charge state and mass of 
the ion selected. Dynamic exclusion of 60 sec was used. Data processing was 
performed using the MassLynx v4.1 suite of software supplied with the mass 
spectrometer. Peptide MS/MS data were processed with ProteinLynx Global Server 
(Waters) and searched against UniProtKB/SwissProt database (release 2011/12). 
2.10.4 Electroelution 
50 µl protein sample (0.5 µg/µl) was diluted with 30 µl 5x acetate sample buffer 
(Expedeon Ltd, Harston, UK), 8 µl 1 M DTT and 62 µl deionised water. The sample 
mixture was heated at 50 °C for 10 min. The sample was cooled to room temperature 
and applied to the loading reservoir of a 10% Tris-Acetate GELFREE cartridge. The 
collection and electrode reservoirs contained HEPES running buffer (Expedeon, 
Harston, UK). The proteins were separated on the tube gel in the cartridge and eluted 
into the collection reservoir. Following GELFREE separation, the protein resolution was 
visualised by running a 1D PAGE 10% Tris-Glycine gel. Appropriate fractions were 
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chosen for detergent removal and MS analysis of the intact chains. All mass 
spectrometry laboratory work and data analysis was performed by James Ault of the 
Faculty of Biological Sciences, University of Leeds. 
2.11 Statistical analysis 
Analysis of the data was done using SPSS program version 16 and statistical 
significance accepted at p<0.05. Between group comparisons of normally distributed 
variables were carried out using independent samples student t-test.  Unless otherwise 
specified, data is presented as mean ± standard error of the mean (SEM). Unless 
otherwise specified, a student t-test was used to assess statistical significance. The 
detonation of statistical significance is as follows: *p<0.05, **p<0.01, ***p<0.005, 
****p<0.001. More specific statistical analyses are detailed in corresponding sections. 
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Chapter 3. BβArg448Lys Variants of Fibrinogen: Effects on 
Fibrin Clot Structure & Fibrinolysis in Type 2 Diabetes 
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Introduction 
Despite advances in medical therapy, diabetes is a major health problem and 
cardiovascular complications remain the main cause of mortality in this population. The 
condition currently affects 347 million people worldwide and is projected to be the 7th 
leading cause of death by 2030 (www.who.int). The rapidly increasing global 
prevalence of diabetes is a significant cause for concern as the risk of mortality in 
diabetes subjects due to atherothrombotic complications is equal to that of nondiabetic 
individuals with a history of ischemic heart disease 120, 125, 126. In addition to increased 
risk of first atherothrombotic event, prognosis following vascular ischemia has barely 
improved, in contrast to individuals without diabetes 1, 109, 110, 120, 125-127. Current evidence 
indicates the adverse clinical outcome in diabetes following vascular ischemia is due to 
more extensive vascular pathology, increased thrombosis potential and high 
prevalence of heart failure, which is partly related to atherothrombotic complications 120, 
126. The thrombotic milieu in diabetes plays a key role in increased cardiovascular risk 
in this population. Diabetes is associated with qualitative and quantitative changes in 
procoagulant, antifibrinolytic and inflammatory proteins (e.g. platelets, tissue factor, 
thrombin, PAI-1 and fibrinogen) leading to fibrin clots with tight network structure and 
resistance to lysis, predisposing to a thrombotic environment 109, 110, 125. 
Fibrinogen BβArg448Lys is one of the most common genetic polymorphisms, 
affecting around 25% of the white population, and is associated with both increased 
vascular risk and hypofibrinolysis 1, 120, 126. When compared to Bβ448Arg, clots made 
from Bβ448Lys variant fibrinogen have a compact structure of thin fibres and small 
pores, with increased stiffness and greater resistance to lysis 99-102. It is worth bearing 
in mind that this polymorphism is associated with elevated levels of fibrinogen in 
plasma due to its strong linkage disequilibrium with two other polymorphisms 
(BßGly455Ala and BβCys148Thr), lying in areas affecting gene transcription, thereby 
determining fibrinogen levels99. The differences in fibrin structure of clots made from 
Bβ448Lys and Bβ448Arg variants of fibrinogen have been demonstrated using a 
recombinant system102, therefore directly implicating the polymorphism in the changes 
observed. This simple substitution of one polar residue for another can lead to the loss 
of multiple possible hydrogen bonds formed with the arginine residue which may play a 
role in conformation of the αC-terminal and thus affect lateral aggregation of fibrils, 
consistent with the formation of thinner fibres with Bβ448Lys variant.  
Previous work indicates that both diabetes and BβArg448Lys variants of 
fibrinogen modulate cardiovascular risk and induce thrombotic changes in fibrin 
networks. Despite the relatively high prevalence of both conditions and their role in 
atherothrombotic conditions, the effect of BβArg448Lys on clot structure in diabetes 
remains unknown. Therefore, the primary aim of this chapter was to identify any 
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additional effect of BβArg448Lys on fibrin network in a condition with complex 
pathogenesis, such as T2DM. Secondary aims of the work include analysis of the role 
of polymorphism on previous and existing vascular pathology in this population. This 
may help to discover a high risk group for thrombotic events and help encourage more 
aggressive preventative and treatment strategies in this subset of patients. 
  
83 
 
3.1 Methods 
3.1.1 Study population and examination 
The study protocol of the Edinburgh Type 2 Diabetes Study has been 
described128 and I summarise the parameters studied in relation to my work. All the 
clinical data have been collected by our collaborators, Dr. J Price and Dr. M Strachan 
in Edinburgh. A total of 1066 patients with T2DM (age, 60–75 yr) were randomly 
recruited; they are representative of those invited to participate (n=5454)129. Of these, 
822 plasma samples were available for genotyping and clot structure analysis. 
3.1.2 Diagnosis of Type 2 Diabetes 
Patients were recruited from the Lothian Diabetes Register (LDR), which includes 
those patients whose diagnosis of diabetes has been confirmed according to WHO 
criteria. Confirmation of diagnosis of type 2 diabetes was carried out by review of 
recorded data of potential participants; this was accepted as any individual treated with 
oral anti-diabetic agents and/ or insulin, or dietary modification with glycated 
haemoglobin (HbA1c) >6.5%. Patients were excluded if confirmation of a clinical 
diagnosis of type 2 diabetes was not possible by hospital or GP record review. 
3.1.3 Diagnosis of previous CVD 
Participants completed a questionnaire including questions on diabetes history 
and treatment, CVD and other co-morbidities (angina, CHD/ MI, stroke, peripheral 
arterial disease, carotid stenosis, hypertension and hypercholesterolaemia), 
medications and smoking habits. Data from hospital records and primary and 
secondary care data on the LDR were also collected to supplement self-reported 
history of CVD and diabetic complications as well as biochemical and clinical variables 
such as HbA1c, BP, serum cholesterol and glucose levels. 
3.1.4 Diagnosis of current CVD risk factors and vascular disease 
Participants also underwent physical examination for current CVD risk and 
vascular disease. 
3.1.4.1 Blood pressure 
Systolic and diastolic brachial blood pressures were measured in the right arm 
using a standard stethoscope and aneroid sphygmomanometer. 
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3.1.4.2 BMI 
Standing height was measured without shoes using a wall-mounted vertical rule, 
and weight assessed without outdoor clothing or shoes using electronic scales. These 
measures were used to calculate BMI. 
BMI = Mass (kg)/(Height (m))2 
3.1.4.3 Ankle brachial index 
To assess ankle brachial index (ABI) right and left brachial as well as posterior 
tibial and dorsalis pedic systolic pressures were recorded after 5 min rest using an 
aneroid sphygmomanometer and Doppler probe. The lowest ankle pressure was 
divided by the highest brachial pressure to calculate ABI. 
3.1.4.4 Intima media thickness 
Bilateral carotid intra mural thickness (IMT) was assessed using an ultrasound 
imaging system to measure the far wall of the artery, 1-2 cm below the carotid 
bifurcation in an area free of plaque. 
3.1.5 Collection of blood samples 
Blood samples were taken into citrated tubes without a tourniquet after a 4 hr 
fast, usually at midday. The first 5 ml were used for clinical tests (DNA extraction, 
measurement of fibrinogen, glucose, total cholesterol, low and high density lipoprotein 
cholesterol, HbA1c and total protein levels, full blood count and estimated glomerular 
filtration rate (eGFR)) and platelet poor plasma separated from subsequent samples.  
3.1.6 Genotyping for BβArg448Lys 
DNA was purified from blood samples and genotyping for BβArg448Lys variants 
of fibrinogen was performed as previously described130. Briefly, genomic DNA was 
isolated from whole blood by standard procedures and genotyping was carried out by 
KBioscience (Herts, UK) using their in-house chemistry of Competitive Allele Specific 
polymerase chain reaction (PCR). 
3.1.6.1 Assessment of fibrinogen plasma levels 
Fibrinogen levels were measured using the Clauss method90 as described in 
section 2.2. This was done in Edinburgh and I was not involved in conducting the 
laboratory analysis. 
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3.1.7 Purification of fibrinogen 
Pooled plasma samples were chosen for each variant (Arg/Arg, Arg/Lys and 
Lys/Lys; n=12 samples for each group) which were matched for sex and HbA1C levels. 
Fibrinogen was purified by affinity chromatography using a calcium dependent IF-1 
monoclonal antibody (Kamiya Biochemical, Seattle, WA, USA) and an automated 
chromatography system (Biocad sprint, Applied Biosystems, Warrington, UK), as 
described in section 2.1.3. 
3.1.8 Turbidity and Lysis 
Clot turbidity and lysis measurements were conducted for plasma samples and 
for purified fibrinogen as previously described in section 2.4. 
3.1.9 Confocal and electron microscopy  
These were conducted as previously described in section 2.6 and 2.7. 
3.1.10 Statistical analysis 
Exploratory analysis was done using SPSS program version 16 (SPSS Inc., 
Chicago, IL). Between-group comparisons of normally distributed variables were 
carried out using t-test, non-normally distributed variables were log transformed before 
a t test was carried out. The R environment for statistical computing was used to fit 
logistic regression models to identify independent associations between BβArg448Lys 
polymorphism and vascular disease. The effect of predictors in the regression model 
was characterised using 95% confidence intervals for the odds ratio coefficients. 
Statistical advice was provided by Dr. Paul Baxter.  
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3.2 Results 
3.2.1 Clinical characteristics of patients 
Clinical characteristics of patients are described in Table 3-1. Bβ448Lys variant 
was present in 31.5% of subjects with similar frequency in each gender (30.6% in male, 
32.3% in females, p=0.604). Cardiometabolic risk factors, including blood pressure, 
BMI, waist circumference, waist/hip ratio, HbA1c and lipid profile were similar in the two 
variants of fibrinogen. There was no difference in eGFR between the groups. Also, 
there was no difference in treatment comparing individuals with Bβ448Arg and 
Bβ448Lys variants of fibrinogen. 
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Table 3-1. Clinical characteristics, clot structure parameters and protein levels in 
carriers of BβArg448Lys variants of fibrinogen 
Variable Bβ448Arg Bβ448Lys P-value 
N 564 258  
Age, yr (range) 68.3 (60-75) 67.6 (60-75) 0.03 
Duration of T2DM, yr (±SEM) 8.05(±0.28) 8.19(±0.39) 0.78 
Current smokers, n (%) 71 (12.6) 36 (14.0)  
Vascular parameters    
Systolic BP, mmHg (±SEM) 133.6(±0.7) 132.1(±1.0) 0.21 
Diastolic BP, mmHg (±SEM) 69.0±(0.4) 68.5±(0.5) 0.43 
Anthropometrics    
Body mass index, kg/m2, (±SEM) 31.0±(0.2) 31.9(±0.4) 0.28 
Waist circumference, cm 
(±SEM) 
106.3(±0.6) 107.7(±0.8) 0.15 
Waist/hip ratio (±SEM) 0.96±(0.004) 0.96±(0.006) 0.77 
Metabolic and renal    
HbA1c, %/ mmol/mol, (±SEM) 
7.4(±0.05)/ 
(57±0.5) 
7.4±(0.07)/ 
57(±0.8) 
0.90 
Plasma glucose, mmol/l (±SEM) 7.48(±0.09) 7.62(±0.12) 0.34 
Total cholesterol, mmol/l (±SEM) 4.3(±0.04) 4.3(±0.05) 0.76 
HDL cholesterol, mmol/l (±SEM) 1.3(±0.01) 1.3(±0.02) 0.37 
eGFR, ml/min/m2 (±SEM) 64.4(±0.61) 63.6(±0.9) 0.44 
Treatment, n (%)    
Metformin 344 (61.0) 142 (55.0) 0.48 
Aspirin 364 (64.5) 171 (66.3) 0.82 
Insulin 57 (10.1) 33 (12.8) 0.31 
Thiazolidinediones 93 (16.5) 45 (17.4) 0.78 
ACEi & ARB 383 (67.9) 174 (67.4) 0.95 
Statins 477 (84.6) 211 (81.8) 0.76 
Sulfonylurea 180 (31.9) 69 (26.7) 0.27 
Nitrates 99 (17.6) 44 (17.1) 0.88 
Clot structure parameters    
Lag phase, sec (±SEM) 528.3(±5.3) 524.8(±7.3) 0.70 
Maximum absorbance, au 
(±SEM) 
0.35(±0.004) 0.37(±0.006) 0.02 
Lysis time, sec (±SEM) 719(±15) 761(±20) 0.003 
Plasma protein levels    
Fibrinogen, mg/ml (±SEM) 3.59(±0.03) 3.70(±0.04) 0.03 
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3.2.2 Effect of Bβ448 variant on clot characteristics of T2DM patients 
Clot MA in carriers of Bβ448Lys was 5.7% higher than Bβ448Arg, LT 5.8% longer 
and lysis area 8.2% greater. The effect of the BβArg448Lys polymorphism on LT was 
still significant after adjusting for observed differences in fibrinogen levels between the 
variants. There was no significant difference in lag time between Bβ448Arg and 
Bβ448Lys plasma. Results are summarised in Figure 3-1. 
 
 
Figure 3-1. Plasma clot parameters in T2DM patients with Bβ448Arg and 
Bβ448Lys fibrinogen as measured by turbidimetric assay 
Maximum absorance was increased with Bβ448Lys compared with Bβ448Arg 
genotype suggesting the formation of denser clots. Lysis time was longer in patients 
with Bβ448Lys variant, indicating compromised fibrinolysis. Lag time showed no 
difference comparing the two genetic variants of fibrinogen. Lysis area was larger with 
Bβ448Lys compared with Bβ448Arg variant. Lysis time and lysis area were log 
transformed before a t test was carried out. 
3.2.3 Effect of gender on clot structure of T2DM patients 
It has been previously demonstrated that clot maximum absorbance in female 
subjects with diabetes is higher than males and LT longer122. In the cohort used in this 
study, similar changes were seen; clot MA in female subjects with diabetes was 11.8% 
higher than males and LT 16.1% longer. There was no significant difference found in 
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lag time between males and females in the previous cohort or the one used in this 
study. Though not reported in the previous cohort, in this cohort lysis area was 23.6% 
greater in females than males. Consequently, the association between the 
BβArg448Lys polymorphism and clot structure in the present cohort was analysed 
separately by gender. 
 
Clot MA in carriers of Bβ448Lys was numerically higher than Bβ448Arg in both males 
(2.9%) and females (5.4%) though this failed to reach significance in both cases. LT in 
carriers of Bβ448Lys was marginally longer than Bβ448Arg in males (4.1%), with a 
bigger difference observed in females (6.6%). There was no significant difference in lag 
time in Bβ448Lys subjects when compared to Bβ448Arg in either males or females. 
Lysis area in carriers of Bβ448Lys was similar to Bβ448Arg in males, whereas a 13.1% 
increase was detected in females. When adjusted for fibrinogen levels, only the 
difference between LT in females remained significant. 
Changes in MA, LT and lysis area were significant between males and females 
when both fibrinogen BβArg448Lys variants were analysed separately. MA was 
greater, LT longer and lysis area greater in females when compared to males with both 
Bβ448Arg and Bβ448Lys. Differences in lag time were not significant between males 
and females when split by Bβ448 variant. 
Overall, females with Bβ448Lys variant of fibrinogen had the most thrombotic clot 
phenotype with an associated resistance to fibrinolysis, whereas males with Bβ448Arg 
had the most benign clot structure. Results summarised in Figure 3-2. 
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Figure 3-2. Effect of gender on plasma clot parameters in T2DM patients with 
Bβ448Arg and Bβ448Lys fibrinogen as measured by turbidimetric assay 
Maximum absorbance; no significant difference when analysed by gender. Lysis time; 
significant increase with Bβ448Lys variant in females. Lag time; no difference with 
Bβ448 variant in either males or females. Lysis area; significant increase with 
Bβ448Lys variant in females but not males. Lysis time and lysis area were log 
transformed before a t test was carried out. Values shown not adjusted for fibrinogen 
levels. 
3.2.4 Effect of Bβ448 variant on fibrinogen levels of T2DM patients 
Fibrinogen levels were 3% higher in Bβ448Lys variant when compared to 
Bβ448Arg over the whole group, however when split by gender, this difference was 
only significant in women. Across the whole group, fibrinogen levels were 7.7% higher 
in women compared with men (Figure 3-3). 
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Figure 3-3. Effect of Bβ448 fibrinogen variant on mean fibrinogen levels of T2DM 
patients 
Fibrinogen levels were significantly higher in patients with the Bβ448Lys variant. When 
split for gender, this significance was only relevant in women. 
3.2.5 Effect of Bβ448 allele clot structure of T2DM patient plasma pools 
Density of clots did not differ from plasma pools of Arg/Arg, Arg/Lys and Lys/Lys 
patients by LSCM and there was no significant difference in turbidity between each of 
the pools. Fibre thickness decreased with increasing copies of the Bβ448Lys allele 
(35.5% with Arg/Lys and 51.6% with Lys/Lys) (Figure 3-4).  
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Figure 3-4. LSCM and EM images of clots made from patient plasma pools, EM 
fibre thickness and MA 
LSCM: (A) Arg/Arg (B) Arg/Lys (C) Lys/Lys. Scale bars represent 45 µm EM: (D) 
Arg/Arg (E) Arg/Lys (F) Lys/Lys. Scale bars represent 3 µm. Clots did not differ from 
Lys/Lys to Arg/Arg in LSCM or turbidimetric analysis, but EM showed fibres to get 
thinner with increasing copies of the Bβ448Lys allele.  
  
F
ib
r
e
 t
h
ic
k
n
e
s
s
 (
n
m
)
A
rg
/A
rg
A
rg
/L
y
s
L
y
s
/L
y
s
2 0
3 0
4 0
5 0
6 0
* * * *
* * * *
M
a
x
im
u
m
 A
b
s
o
r
b
a
n
c
e
 (
a
u
)
A
rg
/A
rg
A
rg
/L
y
s
L
y
s
/L
y
s
0 .2
0 .3
0 .4 n s
n s
93 
 
Arg/Arg Arg/Lys Lys/Lys 
66 kDA 
56 kDA 
48 kDA 
α 
β 
ᵞ 
3.2.6 Effects of Bβ448 allele on fibrinogen purified from T2DM patients 
The difference in clot structure and fibrinolysis comparing the two variants of 
fibrinogen was still evident after correcting for fibrinogen levels. However, in order to 
confirm that differences in clot structure are not related to quantitative changes in 
fibrinogen or an effect of other plasma proteins, I purified fibrinogen from 3 pools of 
individuals with Arg/Arg, Arg/Lys and Lys/Lys genotype.   
3.2.6.1 Integrity of purified patient plasma fibrinogen 
All fibrinogen samples were clean and not degraded (Figure 3-5). 
 
 
 
Figure 3-5. Purified fibrinogen resolved on an 4-12% SDS PAGE gel  
The gel shows all 3 different fibrinogen chains intact confirming integrity and purity of 
the fibrinogen purified. 
3.2.6.2 Effect of Bβ448 allele on clot structure and lysis of purified patient plasma 
fibrinogen 
Fibrin network made from purified Arg/Arg fibrinogen was 79% less dense than 
that of Arg/Lys and 76% less dense than Lys/Lys as assessed by the in-house macro. 
There was no significant difference in clot density between Arg/Lys and Lys/Lys 
fibrinogen. Fibre thickness of clots made from Arg/Lys fibrinogen was 17.9% less than 
those of Arg/Arg. Lys/Lys fibrin fibres were also 34.9% thinner than Arg/Lys. Clot MA of 
Arg/Arg fibrinogen was 11.2% greater than Arg/Lys and 20.2% greater than Lys/Lys 
fibrinogen. Arg/Lys final turbidity was also 8.1% greater than that of Lys/Lys fibrinogen 
though this did not reach significance (Figure 3-7).  
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Figure 3-6. LSCM and EM images of clots made from purified patient fibrinogen 
and EM fibre thickness 
LSCM: (A) Arg/Arg (B) Arg/Lys (C) Lys/Lys. Scale bars represent 45 µm. EM: (D) 
Arg/Arg (E) Arg/Lys (F) Lys/Lys. Scale bars represent 3 µm. Clot density increased 
while fibre thickness decreased with increasing copies of the Bβ448Lys allele.  
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Figure 3-7. Maximum absorbance of clots made from purified patient fibrinogen 
Maximum absorbance decreased in a stepwise manner with increasing copies of the 
Bβ448Lys allele. 
 
Lysis time was 5.5% greater in Arg/Lys then Arg/Arg fibrinogen and 13.7% 
greater in Lys/Lys than Arg/Lys, though these differences were not significant. A 
significant difference was found between Arg/Arg and Lys/Lys fibrinogen, where 
Lys/Lys fibrinogen had a 20% greater LT than Arg/Arg (Figure 3-8), directly implicating 
the polymorphism in altered clot lysis in diabetes.  
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Figure 3-8. The effect Bβ448 fibrinogen allele on LT of clots made from purified 
patient plasma fibrinogen 
Lysis time increased with increasing copies of the Bβ448Lys allele. Data were log 
transformed before a t test was carried out 
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3.2.6.3 Differences in MA and fibre thickness  
In a plasma system, as EM fibre thickness decreases, turbidimetric MA 
concomitantly increases. However, in a purified system, as EM fibre thickness 
decreases, as does turbidimetric MA as shown in Table 3-2. 
 
Table 3-2. Changes in MA and fibre thickness in clots with the Bβ448Lys allele 
when compared with the Bβ448Arg allele 
 Plasma Plasma Pool Purified 
Fibre thickness (EM)    
MA (turbidimetric)  =  
 
3.2.7 Clinical Data 
3.2.7.1 Effect of Bβ448 variant on age of T2DM patients 
Mean age of subjects with Bβ448Lys was 1.2% lower compared with Bβ448Arg 
across the whole group. This age difference was only significant in women (1.3%) and 
not men (0.6%). Results are summarised in Figure 3-9. There was no significant 
difference in age between males and females across the whole group.  
 
 
Figure 3-9. Effect of Bβ448 fibrinogen variant on mean age of T2DM patients  
Patients with the Bβ448Lys variant were significantly younger than those with the 
Bβ448Arg variant. When split for gender, this significance was only relevant in women. 
3.2.7.2 Effect of Bβ448 variant on history of risk of cardiovascular disease 
In the whole group, the Bβ448Lys variant was associated with previous 
cerebrovascular incidents and transient ischaemic attacks [OR 1.87 (1.13, 3.11), 
p=0.015]. This value was evident even after adjusting for traditional risk factors, 
including total cholesterol (TC), high density lipoprotein cholesterol (HDL), HbA1c, 
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blood pressure and smoking [OR 1.98 (1.16, 3.37), p=0.016]. In contrast, the Bβ448Lys 
was not associated with previous history of cardiac ischaemia. 
When the group was split by gender, the predictive value of Bβ448Lys variant for 
stroke/transient ischaemic attack (TIA) was only significant in females and not males, 
whether adjusted [OR 4.18 (1.56, 11.22), p =0.003 female], [OR 1.43 (0.74, 2.76), 
p=0.27 males] or unadjusted [OR 3.69 (1.49, 9.13), p=0.0045 female] [OR 1.38 (0.73, 
2.62), p=0.32, male]. Data summarised in Figure 3-10. No association between 
BβArg448Lys polymorphism and a history of coronary artery disease or myocardial 
infarction was detected in the whole population or when men and women were 
analysed separately. 
 
Figure 3-10. Predictive value of Bβ448Lys fibrinogen variant for stroke/TIA  
Bβ448Lys fibrinogen predicted previous stroke and TIA, when split for gender this 
predictive value was only significant in women. Data displayed as odds ratio (OR), 
error bars denote ±confidence interval. Model adjusted for TC, HbA1c, sBP, dBP, 
smoking and HDL. The R environment for statistical computing was used to fit logistic 
regression models to identify independent associations between BβArg448Lys 
polymorphism and vascular disease. The effect of predictors in the regression model 
was characterised using 95% confidence intervals for the odds ratio coefficients. 
3.2.7.3 Effect of Bβ448 variant on current vascular pathology 
Carotid intima media thickness (IMT) was similar in carriers of Bβ448Arg and 
Bβ448Lys variants and no difference was detected for ankle-brachial index (ABI). 
When analysed by gender, IMT was similar in carriers of Bβ448Arg and Bβ448Lys in 
males and females. ABI was similar in carriers of Bβ448Arg and Bβ448Lys in males 
but was 6.3% higher in Bβ448Lys variant than Bβ448Arg in females.  
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3.3 Discussion 
Diabetes, a prothrombotic condition, is associated with compact fibrin networks 
and resistance to fibrinolysis, which contribute to the increased risk of vascular events 
in this population. This work is the first to investigate the functional and clinical role of 
BβArg448Lys variants of fibrinogen in individuals with diabetes and we demonstrate an 
additional effect of this polymorphism on clot structure and atherothombotic risk.  
There are a number of novel observations emerging from this work in relation to 
individuals with type 2 diabetes: i) Carriers of BβLys448 variant of fibrinogen display 
compact plasma clots and impaired fibrinolysis, changes that are independent of 
fibrinogen plasma levels, ii) BβLys448 is associated with thinner fibrin fibres, leading to 
impaired fibrinolysis, iii) maximum absorbance of plasma clots is not a simple reflection 
of fibre thickness, iv) Carriers of BβLys448 variant are younger, particularly women, 
suggesting early mortality in this group, v) BβLys448 variant may constitute a risk factor 
for cerebrovascular and peripheral vascular disease in women but not men with 
diabetes.  
When plasma samples were studied, clot density was higher, lysis time longer 
and lysis area greater in individuals with Bβ448Lys compared with Bβ448Arg variant. 
Although fibrinogen levels were higher in carriers of Bβ448Lys, correction for protein 
levels still showed a difference in clot structure parameters, suggesting a direct effect 
of the polymorphism on fibrin network structure and fibrinolysis. Confocal and electron 
microscopy data from plasma pools of Arg/Arg, Arg/Lys and Lys/Lys backed up these 
findings, showing increasing density of the clot and decreasing fibre diameter with 
increasing copies of the Bβ448Lys allele. Plasma clots from female patients also had a 
higher maximum absorbance, longer lysis time and greater lysis area than males, 
identifying them as carrier of a particularly thrombotic phenotype. When this gender 
difference was investigated further, LT and lysis area were significantly greater in 
females with the Bβ448Lys compared with the Bβ448Arg variant. This difference was 
not seen in males in either LT or lysis area, implicating gender as a predictor for the 
effect of the Bβ448 variant. Maximum absorbance was greater in carriers of the 
Bβ448Lys variant in both males and females, though in neither case did this reach 
significance though differences cannot be discounted due to the relatively small study 
size. 
As previously demonstrated, circulating plasma fibrinogen levels were 
significantly higher in patients with the Bβ448Lys variant. Interestingly, the association 
between Bβ448Lys and plasma fibrinogen levels, presumably due to LD with 
polymorphisms that determine protein levels, was only evident in women. This 
suggests that BßGly455Ala and BβCys148Thr variants of fibrinogen have little effect on 
plasma protein levels in men with diabetes and environmental factors have a more 
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important role in the population studied. It has previously been shown that female 
gender, diabetes and Bβ448Lys variant are associated with hyperfibrinogenaemia73, 125, 
131. It is interesting that our data show these conditions to have an additive effect on 
fibrinogen levels, specifically in diabetic women carriers of the Bβ448Lys variant. Since 
high concentrations of fibrinogen are associated with dense, tight clots made of thin 
fibrin fibres3 this may go some way to explaining the differences seen in clot structure 
and lysis in diabetic females with the Bβ448Lys variant.  
Although correction for fibrinogen levels did not eliminate the differences in clot 
structure/lysis comparing the two variants of fibrinogen, I have undertaken experiments 
in a purified system and conclusively demonstrated that clot maximum absorbance 
decreases with increasing number of copies of the Bβ448Lys allele. This further 
supports the role of this polymorphism in altered clot structure in individuals with 
diabetes. These turbidimetric data were reinforced by confocal and electron 
microscopy, showing increasing density of the fibrin clot and decreasing fibre thickness 
with increasing copies of the Bβ448Lys allele. Collectively, these results confirm the 
observed changes in clot structure with plasma samples are independent of fibrinogen 
levels and that the polymorphism studied has an additive effect on clot structure in 
individuals with diabetes. 
The turbidimetric and EM data (see Table 3-2) provide some interesting data 
regarding what MA in turbidimetric assays is actually a measure of, and how care 
should be taken when interpreting data using different systems. Fibre thickness 
consistently decreases in each of the preparations with increasing copies of the 
Bβ448Lys allele. However, in plasma pool data, no difference in MA could be seen, 
despite decreases in fibre thickness with the Bβ448Lys allele. In the plasma system 
MA was higher with the Bβ448Lys variant, while in the purified system MA was 
decreased, despite consistency in the decreasing fibre thickness in both preparations. 
These data suggest that plasma MA is a measure of both fibre thickness and clot 
density while in a purified system MA tends to reflect fibre thickness alone. 
Despite similarities in clot structure using purified variant fibrinogen in this study 
to that of recombinant Bβ448 variant fibrinogen, my work shows differences in clot lysis 
outside the plasma environment that are not observed in the recombinant system. In 
our previous study using recombinant protein, a difference in clot lysis between the two 
variants was only evident in plasma environment. In contrast, our current study shows 
differences in clot lysis made from the different variants of fibrinogen in the absence of 
plasma proteins. Other data (Chapter 4) using variant recombinant protein has shown 
α2-AP to prolong lysis of clots made from recombinant Bβ448Lys fibrinogen 
significantly more than those of Bβ448Arg fibrinogen, despite their equivalent lysis 
times in the absence of plasma proteins. This implicates the interaction of clot structure 
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and plasma proteins in the difference in lysis times seen in non-diabetic patients with 
the variant fibrin.  There are a number of possible explanations for the discrepancies 
between these data. The current work used purified fibrinogen, which may have been 
contaminated with small quantities of plasma proteins not detected on the SDS-PAGE 
gel. Another explanation is related to diabetes inducing post-translational modifications 
in fibrinogen that affect clot structure and fibrinolysis. A differential glycation, or other 
modification such as oxidation, may have occurred in the two variants, consequently 
resulting in altered clot lysis, particularly as lysine residues are amenable to such 
modifications. Though these suggested changes were not detected by MS of the 
recombinant BβArg448Lys variants (Chapter 4), different mechanisms could influence 
PTMs both in vivo and in diabetes. This, alongside the potential flaws of the MS 
technique used mean these modifications cannot be ruled out in this study.  
Alternatively, subtle differences in the methodology or reagents used may have 
accounted for these findings, but this was ruled out by conducting repeated studies on 
recombinant proteins, which reproduced our previous results. 
Individuals with Bβ448Lys variant were significantly younger than those with the 
Bβ448Arg variant. This indicates this fibrinogen mutation may be associated with 
premature mortality in this population, possibly related to increased thrombosis risk 
through the formation of more compact clots with compromised fibrinolysis. Such an 
observation has not been documented before and a longitudinal prospective study is 
needed to clarify whether this is indeed the case. Interestingly, this difference in age 
was only observed in women, suggesting a gender difference. The possible reduction 
in life expectancy of Bβ448Lys variant may be related to denser fibrin clots and 
impaired fibrinolysis, which we have shown in this work, predisposing to early 
cardiovascular events.  
A predictive value of Bβ448Lys for stroke and transient ischaemic attacks was 
identified in the whole group, which was still evident after adjusting for traditional risk 
factors. Again our data suggest a gender difference in the interaction between this 
polymorphism and cerebrovascular disease, a finding that has been documented in the 
non-diabetic population101, and therefore requires further investigation. However, 
Bβ448Lys showed no predictive value for cardiac ischemia or MI, in contrast to studies 
on individuals without diabetes99, 100. It is possible that the association between the 
polymorphism and coronary artery disease is weaker in individuals with diabetes due to 
the heterogeneous nature of this condition, although an effect in a subgroup of 
patients, yet to be identified, cannot be ruled out. Alternatively, the cross-sectional 
nature of the study may have failed to detect an association between this 
polymorphism and CAD and therefore future prospective studies are warranted to 
investigate this in more detail. 
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This study identifies the Bβ448Lys variant as having a functional role as a 
predictor for TIA and stroke in diabetes, independent of the traditional risk factors 
associated with these conditions. This shows diabetic women with Bβ448Lys to be a 
particularly high risk group for ischemic events. This may be explained by their 
particularly high fibrinogen levels and the Bβ448Lys variant combining to predispose to 
clots with particularly thin fibres and tight network structure which have been shown to 
increase risk of atherothombotic events. 
The data on current vascular pathology suggests that, although there was no 
difference across the whole group between BβArg448Lys variants, changes in ABI are 
associated with this polymorphism in females. ABI was lower in the presence of 
Bβ448Lys variant when compared to Bβ448Arg in females. As a low ABI is an indicator 
of peripheral vascular disease, and thus increased vascular risk, this could be another 
mechanism by which Bβ448Lys variant governs vascular risk in women with T2DM, 
though further work is needed to clarify if this is a direct effect. In contrast, 
BβArg448Lys variant had no effect on vascular pathology of men in this cohort.  
As mentioned, diabetes, female gender and the BβArg448Lys polymorphism 
predispose to hyperfibrinogenaemia. Elevated plasma fibrinogen concentration alone is 
an independent risk factor for cerebrovascular and peripheral arterial disease 
development and MI. This synergistic increase in cardiovascular risk with increasing 
fibrinogen concentration is due to a rise in fibrinogen and fibrin incorporation into 
arteriosclerotic plaques as well as increased blood viscosity and platelet aggregability 
at higher fibrinogen concentration99. This may go some way to explaining the increased 
risk of TIA and stroke in diabetic women with the Bβ448Lys variant, a patient group 
with particularly high fibrinogen levels. This, alongside the fact that even after 
adjustment for fibrinogen levels, women with the Bβ448Lys variant have an increased 
risk of stroke and TIA in this population, suggests there is a direct effect of the 
polymorphism on this risk, independent of fibrinogen levels.  
In summary, the current work demonstrates that the single gene polymorphism 
BβArg448Lys has an additive and functional effect over that of diabetes on fibrin clot 
structure, fibrinolysis, age, fibrinogen levels and predisposition to stroke and TIA. This 
indicates an important role for genetic factors in determining thrombosis risk even in a 
complex multifactorial condition such as type 2 diabetes. Furthermore, female carriers 
of Bβ448Lys variant are younger and appear to be predisposed to cerebrovascular 
disease, suggesting a direct adverse clinical effect for this polymorphism in diabetes 
that is gender specific. Given the observational nature of our study, however, we 
should be cautious in our interpretations and future long-term longitudinal studies are 
now warranted to fully establish the role of this polymorphism in predisposition to 
cardiovascular disease in individuals with diabetes. 
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Chapter 4. Molecular Mechanisms for the Differences in Clot 
Structure and Lysis in BβArg448Lys Variants of Fibrinogen 
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Introduction 
The blood clot is composed of a mesh of fibrin fibres with cellular elements 
embedded in this network. The structure of the fibrin clot can determine predisposition 
to atherothrombotic conditions, as compact clots composed of thin fibres and small 
pores are associated with premature and more severe CVD. The fibrinogen 
BβArg448Lys polymorphism occurs in 15-25% of the white population and is 
associated with changes in fibrin clot formation, structure and lysis, implicating it in 
increased risk of CAD, triple vessel pathology, venous thromboembolic disease, 
hypofibrinolysis and embolisation99-101. When compared with Bβ448Arg, clots formed 
from Bβ448Lys variant have a more compact structure composed of thin fibres and 
small pores with increased stiffness. Fibrinolysis rates are significantly slower in the 
Bβ448Lys variant when compared to Bβ448Arg in the plasma environment. However, 
in a purified system, no difference between lysis rates of clots of the two variants is 
seen102. This latter observation challenges the accepted concept that fibrin network 
structure directly determines lysis efficiency23. 
The mechanisms behind the observed changes in fibrin structure and fibrinolysis 
rates of Bβ448Arg and Bβ448Lys variants need further exploration, though many 
hypotheses for the influence of the mutation have been suggested. The proximity of the 
BβArg448Lys to 3 important sites in the β-chain that influence clot structure, formation 
and lysis (a β-chain polymerisation site, an interaction site for the C-terminal of the α-
chain and a calcium binding site on the β-chain) may implicate these areas in the 
observed changes. Impairment in lateral aggregation, altered FXIII cross-linking and 
differences in interactions with plasma fibrinolytic proteins may have a role. Loss of 
hydrogen bonds due to the polymorphism in an area of the β-chain (Bβ448-Bβ315 and 
Bβ398-Aα157) thought to be involved in lateral aggregation and stabilisation of the 
coiled-coil could also affect the conformation of the αC domain. The mutation is in 
strong LD with two other mutations, the BβGly445Ala and the BβCys148Thr which 
cause higher plasma fibrinogen levels in the Bβ448Lys variant101. Whilst this may have 
an effect in vivo, it does not explain the differences in fibrin network structure using in 
vitro studies controlling for fibrinogen levels.  
The aims of this chapter are to investigate the mechanisms for altered clot 
structure and resistance to fibrinolysis, in a plasma environment, of clots made from 
B448Lys variant of fibrinogen. Therefore, I analysed the effects of the BβArg448Lys 
variants of fibrinogen on i) FXIII activation and cross-linking to understand differences 
in clot stiffness and lysis, ii) binding and crosslinking of the main anti-fibrinolytic protein, 
α2-AP to investigate the variable lysis in plasma, iii) plasmin generation comparing the 
two variants in the presence and absence of α2-AP,  iv) early protofibril formation to 
understand the mechanisms for the differences in fibre thickness and v) potential 
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differences in post-translational protein modifications to further elucidate the reasons 
for changes in structure.  
Collectively, these studies will strengthen understanding of molecular 
mechanisms determining fibrin network structure and the effects of BβArg448Lys. 
Moreover, this work will help to elucidate the role of the αC-domain, an area of the 
fibrinogen molecule which remains fairly unexplored. This in turn will pave the way to 
develop more effective preventative and management strategies for individuals at risk 
of atherothrombotic conditions. 
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4.1 Methods 
4.1.1 Protein production 
A CHO cell line with the BβArg448Lys polymorphism was already available in the 
lab102. These were grown and protein harvested and precipitated as described in 
section 0. 
4.1.2 Protein purification 
Fibrinogen was purified by affinity chromatography using a calcium dependent IF-
1 monoclonal antibody (Kamiya Biochemical, Seattle, WA, USA) and an automated 
chromatography system (Biocad sprint, Applied Biosystems, Warrington, UK) as 
previously described in section 2.1.3. 
4.1.3 Analysis of clot formation and Lysis 
Clot turbidity and lysis measurements were conducted as previously described in 
section 2.4. 
4.1.4 Confocal microscopy  
To visualise α2-AP in the clot, it was labelled with Alexa Fluor 488 (green) 
(Invitrogen). Given the use of Alexa fibrinogen 488 by the group, initial attempts were 
made to label α2-AP using red Alexa Fluor 594 labelling kits (Invitrogen), but it was not 
possible to clearly see the protein in this preparation. Therefore, Alexa Fluor 488 was 
used instead, which is the brightest and most stable of the conjugates together with 
commercially available 594 Fibrinogen Conjugate (Invitrogen), throughout the 
experiments. Confocal clot preparation and visualisation were conducted as described 
in section 2.6. 
4.1.5 Fluorescent labelling of α2-AP 
Calbiochem α2-AP was labelled using the Alexa Fluor 488 Protein Labelling Kit 
(Invitrogen) according to kit guidelines. Briefly, 200 µg α2-AP was dissolved in 200 µl 
PB and 20 µl 1 M biocarbonate added to raise the pH of the reaction mixture to the 
optimum for tetrafluorophenyl (TFP) ester reactions. This mixture was added to a vial of 
reaction dye and stirred for 1 hr at room temperature. A provided purification column 
was assembled by addition of purification resin, which separates free dye from labelled 
proteins. The sample was then loaded onto the column and allowed to enter. Elution 
buffer was then slowly added until the protein was eluted. Progress of the protein 
through the column was checked by periodically illuminating the column with a 
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handheld UV lamp. Two coloured bands were present, the first band being the labelled 
protein and the second, slower moving band, the unincorporated dye. The first band 
was collected and stored at -20 C. 
4.1.6 Electron microscopy 
Electron microscopy was conducted as previously described in section 2.7. 
4.1.7 FXIII crosslinking gel 
For each variant, 10 l of 0.8 mg/ml fibrinogen was added to 7 tubes labelled 0, 
5, 30, 60, 120, 180 and 180(-FXIII) min and put in a 37 C DB-5A Dri-block heating 
block (Techne, Cambridge, UK). 5 l NuPAGE loading dye and 2.5 l reducing buffer 
were added to time point 0. To each tube, 10 l AM (±260 nM FXIIIA2B2, 0.25 U/ml 
thrombin, 10 mM CaCl2) was added and a timer started. Time point 0 tubes were 
immediately transferred into a 95 C heating block and incubated for 10 min. This was 
repeated for other time points as appropriate and samples kept on ice until ready to be 
run on a 4-12% NuPAGE Novex Bis-Tris gel as described in section 2.1.3.6. 
4.1.8 FXIII- α2-AP crosslinking gel and blot 
For each variant, 20 l of 0.8 mg/ml fibrinogen was added to 9 tubes labelled 0, 
5, 10, 20, 30, 45 60, 120 and 180 min and put in a 37 C heating block. 10 l of 
NuPAGE loading dye and 5 l reducing buffer were added to time point 0. 10 µl α2-AP 
(final concentration 3.3 µg/ml) was added to each time point followed by 10 l AM (260 
nM FXIIIA2B2, 0.25 U/ml thrombin, 10 mM CaCl2) and a timer started. Time point 0 
tubes were immediately transferred into a 95 C heating block and incubated for 20 
min. This was repeated for other time points as appropriate and samples kept on ice 
until ready to be run on a 4-12% NuPAGE Novex Bis-Tris gel for SDS-PAGE or 
western blot analysis. Each sample was halved and run on one of two gels, one was 
stained using coomassie blue as described in section 2.1.3.7 and one was blotted for 
α2-AP as described in section 2.5. 
4.1.9 FXIII activity assay 
4.1.9.1 Biotin incorporation 
A Nunc-Immuno MicroWell 96 well MaxiSorp flat bottom plate was coated with 
100 l 40 g/ml fibrinogen in TBS and incubated for 40 min at room temperature. The 
plate was then blocked with 300 l blocking buffer (1% bovine serum albumin (BSA)/ 
TBS) for 90 min at 37C. The plate was washed 3 times with TBS Tween buffer (0.1% 
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Tween20/ TBS) and 10 l 22 g/ml FXIIIA2B2 (or TBS for control) added to each well 
as appropriate. 90 l reaction mix (100 µM DTT (Sigma), 0.27 µM Biotin (Thermo 
Scientific), 1 U/ml thrombin, 1 mM CaCl2 in TBS) was added to each well at 10 sec 
intervals. The reaction was stopped at intended time points (0, 5, 10, 15, 20, 25 min) by 
adding 200 l of 200 mM EDTA. After the last time point, the plate was washed 3 
times. Subsequently, 100 l 1 mg/ml streptavidin alkaline phosphotase (Sigma) in 1% 
BSA/ TBS/ 0.1%Tween20 was added to each well and incubated at 37 C for 1 hr. The 
plate was washed 3 times and 100 l substrate solution (1 mg/ml p-nitrophenol 
phosphate (Sigma), 1 M Diethanolamine (Sigma), 0.1 M MgCl2) added to each well and 
the OD allowed to develop to ~0.5au. 100 µl stop solution (4 M NaOH) was added and 
the plate read at 405 nm on a MRX Microplate Reader (Dynex Technologies, Ashford, 
Middlesex, UK). 
4.1.9.2 α2-antiplasmin incorporation 
A Nunc-Immuno MicroWell 96 well MaxiSorp flat bottom plate was coated with 
100 l of 0.24 µM fibrinogen and incubated for 40 min at room temperature. The plate 
was washed 3 times with TBS pH 7.4 and blocked with 300 l blocking buffer (TBS/ 3% 
BSA) overnight at 4 C with 1 hr in the morning at 37 C. The plate was washed 3 times 
with washing buffer (TBS/ 0.05% Tween); 100 l fibrinogen AM (1 U/ml thrombin, 5 mM 
CaCl2 in TBS) was added to each well and incubated for 45 min at room temperature. 
The plate was washed 3 times with high salt washing buffer (40 mM Tris, 1 M NaCl, 
0.05% Tween20) and 3 times with washing buffer, 200 l stop solution (0.2 M EDTA) 
was then added to each well representing time point zero. 10 l 22 g/ml FXIII was 
added to each well as appropriate (TBS as a control), followed by the addition of 90 l 
FXIII reaction mix (100 µM DTT, 10 µg/ml α2-AP, 1 U/ml thrombin, 5 mM CaCl2) to 
each well at 10 sec intervals. The reaction was stopped at intended time points (0, 10, 
20, 30, 40, 50 min) by adding 200 l of 200 mM EDTA. The plate was washed 3 times 
with washing buffer, 100 l antibody solution (2 µg/ml Goat antihuman α2-AP 
peroxidase conjugate IgG (ERL) in TBS/ 0.1% Tween/ 3% BSA) was added to each 
well and incubated at room temperature for 1 hr. The plate was washed 3 times with 
washing buffer before adding 100 l OPD substrate (0.6 mg/ml OPD/ 0.41%H2O2) to 
each well at 10 sec intervals and OD allowed to develop to ~0.2 au. 100 l stop 
solution (0.5 M H2SO4) was added to each well and the plate read at 490 nm on a MRX 
Microplate Reader (Dynex Technologies, Ashford, Middlesex, UK). 
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4.1.10 S2251- plasmin generation assay 
To wells of a Grenier 96 well clear polystyrene flat bottom microplate, 100 µl 0.5 
mg/ml fibrinogen, 0.0125 mg/ml plasminogen, ±5.5 µg/ml FXIII, ±3.3 µg/ml α2-AP in 
buffer B (40 mM Tris-HCl, 0.01% Tween20, 75 mM NaCl) was added as appropriate. 
Clotting was initiated by addition of 50 µl AM containing 1.5 U/ml thrombin, 0.27 M 
CaCl2 in buffer B and clotting followed by measuring absorbance at 280 nm every 12 
sec on ELx-808 IU ultramicroplate reader (BIO-TEK Instruments INC, USA) for 15 min 
to ensure full clot formation. 50 µl LM containing 0.75 mM S2251 substrate and 0.05 
µg/ml tPA in buffer C (40 mM Tris-HCl, 0.01% Tween20, 75 mM NaCl, 1 mg/ml BSA) 
was added to the formed clot and OD monitored at 405 nm every 30 sec for 300 min at 
37 C, shaking 2 sec before every reading on ELx-808 IU ultramicroplate reader (BIO-
TEK Instruments INC, USA). 
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4.2 Results 
4.2.1  Purity, integrity and function of recombinant protein 
Both Bβ448Arg and Bβ448Lys recombinant fibrinogen were clean, pure and not 
degraded once purified, dialysed and concentrated as shown by SDS-PAGE gel 
(Figure 4-1A). Maximum turbidity of Bβ448Lys fibrinogen was 83.4% less than that of 
Bβ448Arg fibrinogen (Figure 4-1B), indicating the formation of thinner fibres with this 
variant and confirming previous data. 
 
A.                                                              B. 
 
 
 
Figure 4-1. Recombinant fibrinogen purity, integrity and function 
(A) Variant recombinant fibrinogen resolved on a 4-12% SDS PAGE gel (B) Maximum 
absorbance of clots formed from recombinant variant fibrinogen as measured by 
turbidimetric assay; significant decrease with Bβ448Lys allele pointing towards thinner 
fibres. Experiments were repeated at least on three occasions. 
 
The difference in fibrin fibres was further confirmed by EM. Fibres were 57.6% 
thinner in Bβ448Lys than Bβ448Arg as assessed by EM. Clot structure also appeared 
more compact in Bβ448Lys as assessed by both EM and LSCM (Figure 4-2). When 
confocal clot density was assessed using the in-house macro it was confirmed that 
density of fibrin fibres per unit2 was 357% higher in the Bβ448Lys variant than 
Bβ448Arg. 
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4.2.2 Effects of Bβ448 variant on clot structure 
                   Bβ448Arg                               Bβ448Lys 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-2. LSCM and EM images of clots made from Bβ448 variant recombinant 
fibrinogen and EM fibre thickness 
Clots made from Bβ448Lys fibrinogen were made of thinner fibres with denser network 
architecture. 10 fibres were measured from 3 areas of 3 different EM clots of each 
variant. Scale bars represent LSCM: 45 µm, EM; 1 µm. 
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4.2.3 Effects of Bβ448 variant on fibrin clot lysis 
Our lab has previously demonstrated that fibrinolysis rates between recombinant 
BβArg448Lys fibrinogen variants are comparable in a purified system. However, 
significant differences in lysis rates between the two variants were seen when 
recombinant protein was added to fibrinogen-depleted plasma. In this preparation, lysis 
time increased for both variants as expected, however this increase was much greater 
for the Bβ448Lys variant, confirming an independent effect of this polymorphism on 
lysis rate in the plasma environment102. Given that α2-AP is the main antifibrinolytic 
factor and the difference in plasma clot lysis comparing BβArg448Lys variants of 
fibrinogen, I tested whether α2-AP is the plasma protein responsible for this difference.  
Results presented in Figure 4-3. 
As documented previously, there was no significant difference in LT between the 
variants in the absence of plasma proteins. FXIII did not prolong LT in either variant in 
the absence of other plasma proteins. In contrast, α2-AP prolonged LT in both variants 
in the absence of FXIII. This effect was significantly greater in Bβ448Lys than in 
Bβ448Arg (50.0% in Bβ448Arg and 91.5% in Bβ448Lys). FXIII increased LT in the 
presence of α2-AP in both variants, though this increase was only marginal and non-
significant with Bβ448Arg (14.0%), whereas a more impressive increase was noted 
with Bβ448Lys variant (65.6%). Results are summarised in Figure 4-3. 
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Figure 4-3. Clot lysis parameters of clots formed from recombinant Bβ448Arg 
and Bβ448Lys fibrinogen as measured by turbidimetric assay 
Turbidity and lysis traces from (A) Bβ448Arg and (B) Bβ448Lys recombinant fibrinogen 
in clots made from recombinant fibrinogen alone, in the presence of FXIII, α2-AP or 
both FXIII and α2-AP.  (C) LT of clots ± FXIII (11 µg/ml) + α2-AP (3.3 µg/ml). A total of 
4 independent experiments were conducted in duplicate. 
  
A. B. 
C. 
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4.2.4 Effect of Bβ448 variant on fibrin FXIII crosslinking 
FXIII crosslinking activity did not differ between the variants significantly at any 
time point in the biotin assay (Figure 4-4A). FXIII crosslinking did not differ between the 
variants significantly at any time point in the α2-AP assay (Figure 4-4B).  
 
Figure 4-4. FXIII substrate crosslinking to recombinant Bβ448Arg and Bβ448Lys 
fibrin 
FXIII catalysed crosslinking of (A) biotin (B) α2-AP to recombinant BβArg448Lys 
variants. 3 independent experiments were conducted in triplicate. 
 
There was no clear difference in the FXIII crosslinking of fibrin chains between 
the variants in the absence of α2-AP (Figure 4-5A) or in its presence (Figure 4-5B) as 
assessed by FXIII crosslinking gel/ blot.  
In Figure 4-5, the species that can be identified are labelled and are as follows,in 
order of ascending molecular weight. A species of a lower molecular weight (50 kDa) 
than that expected for α2-AP. We suggest it is either a cleaved form of α2-AP or a 
contaminant of the calbiochem α2-AP used. It is unlikely this and the 67 kDa band 
represent the Met- and Asn- forms of α2-AP, as Lee and colleagues68 showed these 
two variants to run to the same molecular weight band on SDS-PAGE gels. To identify 
exactly what this band is, a sample could be sent for mass spectrometry analysis. 
However, I have run a gel of each component of the crosslinking reaction on a gel and 
blotted for α2-AP (Figure 4-6). This shows α2-AP is only picked up by the α2-AP 
antibody in the well in which it was applied with no contamination present in any other 
well. The <67 kDa molecular weight band is present in this α2-AP preparation, and thus 
we can conclude it is part of the calbiochem α2-AP and not a product of the 
crosslinking reaction. Interestingly all proteins except fibrinogen are at a concentration 
in the FXIII crosslinking reaction at which they are not picked up by coomassie staining 
on the SDS-PAGE gel, even α2-AP. γ-chain monomers can be seen at 48 kDa, these 
become less dense then disappear as time progresses and they become crosslinked, 
forming γ-dimers, as well as polymers with α-chains. These disappear first as formation 
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of γ-dimers is the first event in FXIII crosslinking. β-chain monomers can be seen at 56 
kDa, these remain the same density at each time point as they are not crosslinked by 
FXIII. α-chain monomers and be seen at 67 kDa, this band becomes less dense as 
time progresses as α-chain polymers form and α2-AP becomes crosslinked to fibrin 
chains. Free α2-AP can also be seen at 67 kDa not crosslinked to any fibrin chain. Free 
FXIII can be seen at 75 kDa and γ-γ dimers, the first product of FXIII crosslinking of 
fibrin chains, at ~100 kDa. Species of molecular weights >100 kDa are α-chain dimers 
and polymers, before α2-AP crosslinking occurs and α-chain polymers with α2-AP and 
increasingly high molecular weight polymers of α-chain with α2-AP crosslinked. These 
are presumed to fade as time increases past ~60 min not because they are no longer 
present, but as the molecular weight of the aggregates becomes so great, they can no 
longer enter the gel.  
 
There was no clear difference in FXIII crosslinking of α2-AP to the fibrinogen 
variants in gel, blot, or incorporation assays.  
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Figure 4-5. FXIII crosslinking of recombinant Bβ448Arg and Bβ448Lys fibrinogen 
(A) FXIII crosslinking of fibrin resolved on 4-12% SDS-PAGE reducing gels (B) FXIII 
crosslinking of BβArg448Lys fibrinogen resolved on 4-12% SDS-PAGE reducing gels in 
the presence of α2-AP and (C) corresponding blots for α2-AP. Numbers indicate min 
after initiation of clotting. 3 independent experiments were conducted.  
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Figure 4-6. SDS-PAGE gel and α2-AP blot of constituents of FXIII-α2-AP 
crosslinking gel 
The α2-AP antibody only picks up α2-AP in the lane in which it was run, no 
contamination present in any other well. The lower molecular weight band is present in 
this α2-AP preparation. All proteins except fibrinogen are at a concentration in the FXIII 
crosslinking reaction at which they are not picked up by coomassie staining on the gel. 
4.2.5 Confocal microscopy to visualise α2-AP incorporation  
Labelled red, α2-AP could not be detected in confocal preparations: There were 
only 1.26 moles of dye per mole protein as determined by calculations set out in the 
manual when the Dylight 584 labelling kit was used despite repeated labelling 
attempts. After labelling, the protein stock was at 80 µg/ml. The optimum number of 
moles of dye per mole protein for this labelling reaction is 4 so this may account for the 
lack of fluorescence detected. There were 4.15 moles of dye per mole of protein as 
worked out by calculations set out in the manual when the Alexa Fluor 488 labelling kit 
was used. This is within the optimum stated of 4-9 moles of dye per mole of protein. 
The stock produced was 40 µg/ml, so the yield was low, but labelling efficiency 
adequate for these preparations. Results presented in Figure 4-7. 
Labelled α2-AP could only be detected when crosslinked to the Bβ448Arg fibrin 
clot where it co-localised to fibrin. Little to no α2-AP could be detected in the equivalent 
Bβ448Lys fibrin clots (Figure 4-8). 
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When Bβ448Arg clots were lysed, there was a slight build-up of the α2-AP along 
the lysis front which was co-localised to the fibrin. When Bβ448Lys clots were lysed, 
the α2-AP seemed to ‘appear’ along the lysis front. Similarly, it was co-localised to the 
fibrin as shown by the yellow structures in the bottom panel. Results presented in 
Figure 4-9. 
 
Figure 4-7. LSCM images of fibrin, α2-AP and their co-localisation  
(A) Green fibrin, red α2-AP (B) Red fibrin, green α2-AP. α2-AP could not be detected 
when it was labelled red and was only visible when labelled green. Scale bars 
represent 45 µm. 
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Figure 4-8. LSCM images of clots made from recombinant Bβ448 variant 
fibrinogen in the presence of FXIII and α2-AP 
(A) Bβ448Arg fibrin (B) Bβ448Lys fibrin. 3 independent experiments were conducted in 
duplicate. Scale bars represent 45 µm 
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Bβ448Arg 
 
Bβ448Lys 
 
Figure 4-9. LSCM images lysis of clots made from recombinant Bβ448 variant 
fibrinogen 
Top panel; Red fibrin. Middle panel; green α2-AP. Bottom panel; overlay. 3 
independent experiments were conducted in triplicate. Min after beginning of time 
series indicated below panels. Scale bars represent 45 µm. 
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4.2.6 Effect of Bβ448 variant on plasmin generation 
S-2251 peptide cleavage assay was used to assess plasmin activity between the 
variants in the various turbidimetric conditions. This assay relies on the cleavage of the 
S-2251 substrate by plasmin as below: 
                                                      plasmin 
H-D-Val-Leu-Lys-p-Nitroanilide                   H-D-Val-Leu-Lys-OH + p-Nitroanilide  
             Colourless                        Yellow 
 
The rate of p-Nitroanilide formation is thus equivalent to the enzymatic activity of 
plasmin and can be monitored by an increase in absorbance at 405nm. This assay 
thus measures both the conversion of plasminogen to plasmin, and the consequent 
activity of the plasmin enzyme. Given that differences in lysis comparing the two 
variants are only detected in the presence α2-AP, experiments were conducted with 
and without this protein.  
Five min after initiation of lysis, plasmin generation was significantly greater in the 
presence of Bβ448Lys fibrin than Bβ448Arg, in the absence of FXIII (216.7%) as well 
as in its presence (661.5%). In the presence of α2-AP, this difference was abolished. 
Plasmin generation was not significantly different comparing Bβ448Arg and Bβ448Lys 
preparations in the presence of α2-AP alone or in the presence of α2-AP and FXIII. α2-
AP significantly reduced plasmin activity in Bβ448Lys variant both in the absence and 
presence of FXIII (72.4% and 90.9%), but made no difference to plasmin activity in 
Bβ448Arg.  
After 10 min, plasmin activity in the absence of α2-AP was still greater in 
Bβ448Lys than Bβ448Arg (116% without FXIII and 112% with FXIII), however, only a 
trend was observed. As time progressed, plasmin activity in the absence of α2-AP 
between the variants became equivalent (as shown in Figure 4-10; 20, 30 and 60 min 
panels). At 10 min, α2-AP had no effect on plasmin generation by Bβ448Arg variant in 
the absence of FXIII or in its presence. However, α2-AP significantly reduced plasmin 
activity in the Bβ448Lys preparation both in the absence of FXIII (70.0%) and in its 
presence (77.1%). There was no significant effect of FXIII on plasmin activity in the 
presence of α2-AP in either variant. 
At 15 min, α2-AP significantly reduced plasmin generation of the Bβ448Arg 
variant both in the absence (46.7%) and presence (55.0%) of FXIII. As time 
progressed, α2-AP continued to cause a significant reduction in plasmin activity with 
both fibrinogen variants in the presence of FXIII.  
At each time point, plasmin generation between the variants was equivalent in 
the presence of α2-AP alone, and in the presence of FXIII and α2-AP. FXIII had no 
significant effect on plasmin generation in the presence of α2-AP until 50 min, when it 
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increased plasmin generation in the Bβ448Lys variant (47%), but not in the Bβ448Arg 
variant. At 60 min, the addition of FXIII significantly increased plasmin activity in the 
presence of α2-AP in both Bβ448Arg (32.5%) and Bβ448Lys fibrinogen (55.0%). Data 
summarised in Figure 4-10. 
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Figure 4-10. Conversion of S2251 by plasmin in the presence of clots made of 
Bβ448Arg/Lys fibrinogen  
Conversion of S2251 substrate by plasmin as monitored by optical density in the 
presence of clots made of BβArg448Lys fibrinogen ±FXIII ±α2-AP. Panels show OD 5, 
10, 15, 20, 30 and 60 min after initiation of lysis. 
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4.2.7 Atomic Force Microscopy 
 
Figure 4-11. Individual fibrinogen molecules resolved by AFM 
An area of 5x5µm of sample was scanned (top panel), which has been zoomed in on 
x4 (middle panel) and x16 (bottom panel) to resolve individual fibrinogen molecules. 
The 3 domain structure of the fibrinogen molecule can be seen (indicated by the 3 
white arrows). Scale bars represent 0.5 µm. 
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Images of single molecules were able to be obtained as in Figure 4-11. Each of 
the 3 three domains (D-E-D) could be resolved. When clotting was attempted, no fibres 
were visualised, only large aggregates could be seen despite repeated attempts with 
various sample preparations and coating techniques (as shown in Figure 4-12C). 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 4-12. Images of fibrinogen showing various problems encountered using 
AFM 
(A) Fibrinogen on mica surface showing uneven distribution of fibrinogen molecules 
over a 2.5x2.5µm area of mica. (B) Aggregation of fibrinogen molecules on mica 
surface due to uneven drying process. (C) Typical result of initiation of clotting, large 
aggregates form ‘lumps’ on the mica surface and disrupt the rest of the image, no 
fibres are clearly seen. Scale bars represent 0.5 µm. 
A B 
C 
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4.2.8 Mass Spectrometry 
4.2.8.1 Fibrinogen α-chain 
In both BβArg448Lys variants, there was methionine oxidation at Aα254 and 259 
and proline hydroxylation at Aα566. Proline hydroxylation was evident in both variants 
at Aα 289/302 though the position remains unconfirmed. Sequence coverage was poor 
for both BβArg448Lys variants, at 20% for Bβ448Arg and 17% for Bβ448Lys. 
4.2.8.2 Fibrinogen β chain 
In both BβArg448Lys variants, there was proline hydroxylation at Bβ61 and 
methionine oxidation at Bβ148, 254, 344 and 456. There was evidence of methionine 
oxidation at Bβ477 in the Bβ448Lys variant, however we must exercise caution in this 
observation as this can also be caused as an artefact of the gel processing and 
digestion of the proteins. Sequence coverage was 55% and 50% for Bβ448Arg and 
Bβ448Lys respectively, and in both cases this covered the Bβ448 site at which no 
PTMs were detected in either variant. 
4.2.8.3 Fibrinogen γ chain 
In both BβArg448Lys variants, there was tryptophan oxidation at γ279, proline 
hydroxylation at γ102 and methionine oxidation at γ290. Twelve potential glycated 
peptides were identified as a -162 Da signal shift, characteristic of glycation, detected 
in the MS signal of each BβArg448Lys variant (Figure 4-13), but these were not 
matched to particular peptides so details of their possible localisation are not available. 
All signals observed were common to both BβArg448Lys variants. Sequence coverage 
was 45% and 53% for Bβ448Arg and Bβ448Lys respectively. 
 
Table 4-1. Summary of modifications on each fibrinogen chain as identified by 
MS analysis  
Chain Modifications 
Alpha 
Aα254 & 259 - methionine oxidation 
Aα566 & Aα289/302 – proline hydroxylation 
Beta 
Bβ61 – proline hydroxylation 
Bβ148, 254, 344 & 456 – methionine oxidation 
Bβ477 (Bβ448Lys variant only) – methionine oxidation 
Gamma 
γ279 – tryptophan oxidation 
γ201 – proline hydroxylation 
γ290 – methionine oxidation 
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Figure 4-13. Example MS spectrum  
A typical MS spectrum plotting mass/charge ratio against relative abundance. The 
characteristic 162 Da mass shift indicating glycation is shown. 
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4.3 Discussion 
Using recombinant fibrinogen, significant differences in clot structure between 
Bβ448Arg and Bβ448Lys variants were found in turbidimetric, LSCM and EM 
preparations. Bβ448Lys fibrin has nearly 6 fold lower turbidity than Bβ448Arg, 
suggesting thinner fibres, which was confirmed by EM analysis. LSCM also revealed 
the structure of clots made from Bβ448Lys fibrinogen to be more compact than those of 
Bβ448Arg. This structure has previously been linked to more thrombogenic clots91, 92 
suggesting Bβ448Lys variant may predispose to thrombotic disorders.  
The thinner fibres of clots made of Bβ448Lys fibrin suggests lateral aggregation 
is affected in this variant. Molecular modelling has shed light on some of the possible 
mechanisms behind this difference in structure. The analysis suggests the 
BβArg448Lys substitution could lead to weakening or loss of hydrogen bonds close to 
the b-site, and in the coiled-coil structure, as well as causing increased mobility of 
residues in the B-b interaction site. These changes likely affect fibrin polymerisation 
and final clot ultra structure as all are in regions proposed to be involved in lateral 
aggregation, via B-b and αC domain interactions102. 
To further investigate the mechanisms behind the thinner fibres of the Bβ448Lys 
fibrin clots, I attempted AFM analysis of early protofibril formation. The aim of this 
technique was to visualise the individual fibrinogen molecules coming together to 
assemble protofibrils, identifying differences between the BβArg448Lys variants. 
Despite success in imaging individual fibrinogen molecules using AFM, a number 
of difficulties were encountered when using this technique, rendering it inappropriate 
for use for the intended analysis. There is a great deal of sample variability across any 
given mica surface; the amount of material which adheres to the mica is uneven 
despite application of a uniform sample (as shown in Figure 4-12A). This has been 
suggested to be caused by treatment with NiCl2, which may result in a non-uniform 
charge across the mica. This in turn leads to patches that are more attractant to 
negative charge (and thus fibrinogen molecules) than others. The fibrinogen is also 
liable to aggregate on the surface which can lead to the tip becoming dirty or breaking 
with resultant drastic drop in image quality. Added to this, the way in which the mica is 
dried with nitrogen before and after sample application also affects the outcome (as 
shown in Figure 4-12B).   
When clotting was initiated, rather than being able to see fibrils forming, the 
fibrinogen molecules seemed to clump together to form large aggregates in more 
globular structures than fibre-like structures (as shown in Figure 4-12C). These 
problems may have arisen due to the materials I was using. All previous published data 
using this technique132, 133 have been obtained using commercially bought fibrinogen, 
whereas this study has used recombinant protein. This commercial material may be 
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less fragile, more robust, or contain contaminants such as FXIII which could lead to the 
difference in fibrin clot formation. Given the time constraint, I have been unable to 
develop this technique further and this approach was therefore abandoned.  
When lysis of clots formed from the BβArg448Lys variants was assessed, a 
difference in clot lysis between the two variants was only evident in the presence of 
anti-fibrinolytic proteins, with equivalent lysis times seen between the variants in their 
absence. This suggests that differences in clot structure alone do not account for 
differences in lysis between the variants. Alternatively, Arg to Lys substitution may 
result in different effects on the fibrinolytic system, accounting for similar lysis time 
despite the observed changes in clot structure. It has been suggested previously that 
this similarity in lysis in the absence of other plasma proteins could be explained by the 
increased number of thin fibres lysing at a quicker rate at the level of individual fibres, 
thus ‘evening out’ the disparity in fibre number102. 
However, our plasmin generation data suggests this phenomenon may be yet 
more complex, going further to explain the lysis rates of the BβArg448Lys variants. 
Despite the differences in clot structure, equivalent lysis rates between the variants 
may be, at least partially, explained by the initial difference in plasmin 
generation/activity identified in this assay. This suggests differences in plasmin 
generation between the variants ‘equals out’ the lysis time between the BβArg448Lys 
variants in the absence of other plasma proteins, causing them to lyse at equivalent 
rates despite their difference in structure. This implies the Bβ448Lys clot structure of 
thin fibres is more resistant to plasmin activity, but since there is more generated in the 
absence of other plasma proteins, this structure lyses at a similar rate to Bβ448Arg 
fibrin clots.  
The mechanism by which more plasmin is generated in the Bβ448Lys clot has 
not been elucidated and needs further investigation, but it may be due to the increased 
density of fibres providing more binding sites for plasminogen, where it is most rapidly 
converted to plasmin by tPA due to colocalisation on the fibrin surface. It has indeed 
been shown that binding of tPA to fibrin enhances the activation of plasminogen by 
tPA, increasing its local concentration5, 24. The increased fibrin density of the Bβ448Lys 
variant could thus work as a greater surface area to co-localise tPA and plasminogen 
on the its surface, working to enhance plasmin generation.  
The mechanism by which Bβ448Lys fibrin structure is inherently more resistant to 
plasmin is not clear and requires further investigation. It is encouraging that our work 
supports that published previously, showing dense clots made of thin fibres to be more 
resistant to lysis in the plasma environment than those made of loosely woven thick 
fibrin fibres23. However, the mechanisms behind this are not completely in line with 
those published previously. In support of our work, earlier studies suggest that at the 
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level of individual fibrin fibres, thick fibres are more resistant to lysis, but that a 
difference in distribution and movement of fibrinolytic components through the fibrin 
network results in equivalent lysis rates. They show loosely woven clots made of thick 
fibres with decreased fibrin density allow fibrinolytic components such as tPA to bind 
more broadly across the clot and move quicker through the fibrin network23. This gives 
weight to our theory that Bβ448Arg clots are less resistant to plasminogen activity: Due 
to the increased porosity of the thick fibred clot, fibrinolytic proteins move quicker 
through the structure, binding more broadly across the clot and increasing lysis rates. 
However, previous work also suggests plasminogen binding and activation may be 
inhibited in clots made of fine fibres24 an idea which contradicts the results of our study 
which suggest increased plasminogen generation in the presence of clots made of thin 
fibres. This warrants further investigation of the mechanisms behind differences in lysis 
between clots of differing structure. 
When studied in a system more akin to that in-vivo, our data show significantly 
greater prolongation of lysis in the presence of α2-AP of clots made from recombinant 
Bβ448Lys fibrinogen than those of Bβ448Arg fibrinogen, implicating the interaction of 
clot structure and plasma proteins in the difference in lysis times between the variant 
fibrins. In line with our data, it has been shown previously that when the BβArg448Lys 
recombinant variants were added to fibrinogen-depleted plasma, a comparable large 
difference in fibrinolysis rates between the variants was observed102. It was therefore 
concluded that lysis rates are not directly associated with clot structure, rather the 
interaction between structure and other plasma proteins. Differential incorporation of 
α2-AP and plasminogen into the clot and consequent conversion of plasminogen to 
plasmin could be explained by differences in crosslinking and binding, quantitatively or 
qualitatively, of plasma proteins due to the variation in clot permeability and 
compactness between BβArg448Lys fibrin variants. My data go further to identify α2-
AP as one of the main factors responsible for this prolongation in lysis, as well as the 
disparity in lysis rates between the BβArg448Lys variants in the plasma environment. 
The observation that FXIII plays a role in α2-APs inhibitory effect on fibrinolysis in our 
study indicates that cross-linking of the protein plays a key role in α2-AP induced 
changes in lysis. On the other hand, the inhibition of fibrinolysis in Bβ448Lys compared 
to the Bβ448Arg in the absence of FXIII suggests that binding also plays a role. 
Accordingly, we investigated FXIII crosslinking of BβArg448Lys fibrin as well as α2-AP 
to the fibrin variants.  
Perhaps surprisingly, given the stark differences in the clot structure between the 
variants and the role FXIII plays in formation of the clot, FXIII crosslinking of the fibrin 
chains in the absence of other factors did not differ between the variants. This suggests 
FXIII does not interact with the variant fibrinogens differently and does not play a direct 
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role in the difference in structure between Bβ448Arg and Bβ448Lys fibrinogen. 
Furthermore, our plasmin generation data suggests the difference in lysis between the 
BβArg448Lys variants is not related to differential plasmin generation. We suggest that 
in the presence of α2-AP there are equivalent amounts of plasmin between the variants 
causing the Bβ448Lys variant to lyse slower due to the fibrin structure being inherently 
more resistant to lysis, the potential mechanisms behind which are discussed above. 
Therefore, it appears that α2-AP ‘evens out’ the initial difference in plasmin generation 
between the variants in the absence of other plasma proteins, having a greater effect 
on the initially enhanced plasmin generation in the Bβ448Lys variant. This greater 
effect of α2-AP may mirror that of plasminogen and tPA discussed above; the 
increased surface area of the Bβ448Lys fibrin clot could provide more binding sites for 
α2-AP, allowing for it to exert a greater effect on both the fibrin’s resistance to lysis, and 
the conversion of plasminogen to plasmin by tPA. One difficulty in interpreting these 
results fully is the inability of this assay to distinguish between plasmin generation and 
plasmin activity so it cannot be determined definitively how the fibrin variants are 
affecting the fibrinolytic activity. Investigating plasminogen conversion to plasmin using 
immunoblotting, as recently described80, represents one technique to differentiate 
between plasminogen conversion and plasmin activity, which remains an area for 
future research. The differences in lysis between the two variants is yet more complex 
as this theory of differential plasmin generation/ activity does not account for the 
increased lysis time in the presence of FXIII when α2-AP is present, as a result this 
merits future investigation of the complex interactions between BβArg448Lys, clot 
structure, plasmin generation, FXIII cross-linking, α2-AP and lysis rates. 
Again unexpectedly, despite the differences in the effect of α2-AP between the 
variants, the rate and amount of incorporation of the protein by FXIIII into the fibrin 
network did not differ between Bβ448Arg448Lys variants in the biotin/α2-AP 
incorporation or western blot assays. This suggests the protein is incorporated to the 
same degree between the BβArg448Lys variants. Differences in lysis could thus be 
due to a different structural arrangement or interaction of the α2-AP between the two 
Bβ448 variants. This theory was further explored by LCSM analysis. 
The LCSM study of Bβ448 fibrinogen variants with fluorescently labelled α2-AP 
has produced further unexpected data and has provided further insight into the 
difference in interaction between the two proteins. It is interesting that the α2-AP can 
be seen in static clots made from Bβ448Arg only and not Bβ448Lys variant. However, 
it is clear that there is α2-AP present in the Bβ448Lys preparations as it ‘appears’, as 
green fluorescence, along the lysis front when the clot is lysed. There are two 
suggested explanations for this; the α2-AP is incorporated into the static clot through 
an unusual arrangement with the fibrin fibres that makes this undetectable until the clot 
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undergoes lysis, which exposes the protein. Alternatively, free α2-AP in the clot only 
binds to the Bβ448Lys fibrin upon initiation of clot lysis. It seems more likely, given the 
equivalent incorporation of α2-AP between the variants in other assays such as 
biotin/α2-AP crosslinking and western blot analysis, that the α2-AP is incorporated into 
the Bβ448Lys LSCM clots, but somehow differently to that in the Bβ448Arg clots, which 
could result in it not being detected in the static clot preparation. It was suggested that 
the α2-AP could be binding/crosslinking with such high affinity to the Bβ448Lys fibrin 
that the 594 Alexa signal of the fibrin was quenching the 488 Alexa α2-AP 
fluorescence. This was ruled out by preparing clots from both BβArg448Lys variants 
with only 488 Alexa α2-AP, and no labelled fibrinogen. In these preparations, the 488 
Alexa α2-AP could still only be seen in the Bβ448Arg preparations, mimicking the 
structure of the fibrin network, presumably due to it being bound to the non-fluorescent 
fibrin structure. However, 488 Alexa α2-AP fluorescence could still not be detected in 
the Bβ448Lys preparations. These findings warrant further investigation of the 
interaction between α2-AP and the BβArg448Lys variants of fibrinogen to characterise 
their binding and crosslinking activity. However we postulate that α2-AP may be 
incorporated more tightly into the fibrin fibres of the Bβ448Lys variant such that it is not 
detected in LCSM because it is embedded deeper in the fibre. Conversely the α2-AP in 
Bβ448Arg fibrin preparations may be visible due to the more loosely woven fibres 
allowing the α2-AP molecules to be seen on the outside of the fibres and thus detected 
by LCSM. Another theory suggests the different way in which α2-AP is incorporated 
into Bβ448Lys fibrin prevents excitation of the 488 flurochrome, meaning the protein 
cannot be seen in the clot but can when the clot is lysed. 
Since glycation, oxidation, phosphorylation, homocysteinylation and nitration of 
fibrinogen cause stark differences in clot structure and lead to clots which are more 
resistant to lysis (described in section 1.10.2.2.1), it was reasonable to suggest these 
changes may cause the differences seen in the recombinant BβArg448Lys variants, 
especially as lysine residues are particularly amenable to glycation and oxidation. MS 
analysis revealed evidence of glycation, oxidation, and hydroxylation across all three of 
the fibrinogen chains; though no differences in modifications between BβArg448Lys 
variant samples were observed. However, the possibility of differences in PTMs cannot 
be ruled out due to low sequence coverage, especially of the alpha chain, meaning 
some PTMs may have been missed by this analysis. Poor tandem MS fragmentation 
also meant that glycation sites could not be determined, leading to the need for further 
MS analysis. This poor coverage and fragmentation may be attributable to trypsin not 
being ideal for the digestion of fibrinogen, which has a large number of basic residues. 
The overall character of the peptides could also play a role as extreme hydrophilicity, 
poor ionisation and presence of modifications can affect the coverage of an MS 
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spectrum. These issues could be overcome by combining with alternative proteases for 
fragmentation, higher specification instrumentation and/or alternative fragmentation 
techniques. While electroelution was a promising technique for separating out the intact 
fibrinogen chains, further optimisation of sample preparation before loading onto the 
MS is needed to obtain intact mass of the individual chains. The use of electron 
transfer dissociation analysis, a method of fragmenting ions by transferring electrons to 
them, could also be valuable as it ensures sample fragmentation along the peptide 
backbone, thereby ensuring preservation of PTMs134. It should be stressed, however, 
that no difference in PTMs was seen at BβArg448Lys position comparing the two 
variants and therefore potential differences, if any, would be secondary to an indirect 
effect of the polymorphism on other sites of the fibrinogen molecule.  
It is accepted that not only rate of plasmin generation but its movement through 
the clot is rate limiting for fibrinolytic activity and that it is not fibrin fibre diameter, but 
fibrin network structure, that governs the distribution of fibrinolytic proteins23. Although 
our data lead to a similar conclusion, we suggest that fibrin network structure plays a 
much more important role than previously suggested. Clots formed from thin fibres with 
a compact structure are more resistant to lysis/ plasmin activity, most likely due to the 
decrease in porosity and permeability of these clots to fibrinolytic components. The 
observation that plasminogen activity is increased in the presence of clots made of thin 
fibres requires further investigation, especially given the discrepancy with a previous 
study which suggests plasminogen binding and activation may be inhibited in clots 
made of fine fibres, contradicting our data24.  
Together the data presenting in this chapter suggest that α2-AP is crosslinked to 
BβArg448Lys fibrin variants to a similar extent. However, the structural conformation of 
these binding and crosslinking interactions is markedly different, such that an initial 
increase in plasmin activity in the absence of α2-AP, results in similar lysis rates of the 
two variants due to the inherent increased resistance to lysis of the Bβ448Lys clot. 
However, in the presence of α2-AP, this is no longer the case and hence the 
exaggerated prolongation of clot lysis time with Bβ448Lys variant of fibrinogen. It 
follows that α2-AP has a more marked effect on plasmin generation in the Bβ448Lys 
clot, indicating an interaction between genetic variants of fibrinogen and the fibrinolytic 
system.  
In summary, we have found that differences in lysis between recombinant 
BβArg448Lys variants in the plasma environment are attributable to the interplay 
between porosity and permeability of the clot, the fibrin-α2-AP interaction and plasmin 
generation. This leads to the need for future work to clarify the mechanisms behind 
differential plasmin generation and interaction of α2-AP in fibrin clots of differing 
structure. These data indicate that the previously proposed direct association between 
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clot structure and lysis23 is perhaps a simplistic approach and in depth studies are 
needed to understand the relationship between clot structure and activation of he 
fibrinolytic system, which may have future therapeutic implications.  
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Chapter 5. Fibrinogen Birmingham II - A Novel Variant 
Associated with an Unusual Clinical Presentation and Altered 
Fibrin Network Characteristics 
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Introduction 
Dysfibrinogenemia, a group of conditions in which an abnormality in the 
fibrinogen molecule is inherited, results in defective fibrin clot formation, with a clinical 
presentation that may be life-threatening103. These conditions provide a useful tool to 
investigate the molecular mechanisms for the effect of small changes in the fibrinogen 
gene on clot structure and susceptibility to disease.  
Nonsense/missense mutations, insertions/deletions and chain truncations in the 
fibrinogen genes have all been identified as responsible for various dysfibrinogenemias 
resulting in modifications of fibrinopeptide release, fibrin polymerisation, fibrin 
crosslinking and/or fibrinolysis. The position in which the mutation lies governs whether 
the dysfibrinogenemia will present as a bleeding or prothrombotic disease. The genetic 
changes often lead to the development of hypofibrinogenemia due to their effect on 
intracellular transport mechanisms and consequent accumulation of fibrinogen in the 
endoplasmic reticulum104. In more severe cases, a complete lack of expression of the 
mutant molecules in plasma can occur due to the inability of the mutant chain to be 
assembled with the other fibrinogen chains.  The severity of the condition can depend 
on whether the variant is homo- or heterozygous. Very few homozygote 
dysfibrinogenemias have been identified, and these result in a homodimeric fibrinogen 
molecule with two mutant chains. The more common heterozygous forms can result in 
one of two homodimers (either two normal or two abnormal chains) or a heterodimer 
with one normal chain and one abnormal chain. Heterozygotes that have 50% normal 
fibrinogen molecules are usually asymptomatic as this amount of normal fibrinogen 
molecules is able to maintain normal blood coagulation. Symptoms appear when the 
dysfibrinogen interferes with functional components of the fibrinogen molecule35. 
A rare novel fibrinogen variant has been detected in a 34 year old woman, which 
is associated with hypodysfibrinogenemia108. Clinically, the individual presented with a 
bleeding tendency associated with paradoxical venous thrombotic events. A familial 
history of hypofibrinogenemia, with a bleeding tendency was recorded but there were 
no cases of thrombosis. The complex clinical picture was associated with a compound 
heterozygosity for Trp334Cys and Asn335Tyr mutations in the α-chain of fibrinogen. 
Two mutations in the polypeptide have been identified at positions 1002 and 1003 
causing a guanine and an adenine respectively to be both replaced by thiamine. The 
amino acid residues, affected by the candidate mutations, are both highly conserved 
residues in the αC domain of fibrinogen, which has a role in crosslinking reactions 
during fibrin polymerisation. 
The primary aim of this chapter was to fully characterise the effect of Fibrinogen 
Birmingham II (BII) on clot structure and lysis and elucidate whether changes in the 
fibrin network, if any, are responsible for the clinical picture. Secondary aims of the 
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work include investigating the molecular mechanisms behind the identified changes in 
the clotting of this variant using both purified and recombinant variant fibrinogen. 
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5.1 Methods 
5.1.1 Sequencing/ genotyping 
DNA was prepared using Qiagen extraction kit. Genetic analysis was carried out 
by PCR and nucleotide sequencing of the entire coding regions/splice junctions of 
FGA, FGB and FGG genes. Sequencing was carried out using BigDye terminators v1.1 
on an ABI 3130 genetic analyser. TA cloning was carried out to investigate inheritance 
pattern. This was done using a TOPO vector (Invitrogen) / TOP10 E. coli and XL1 Blue 
cells. DNA was prepared using Qiagen miniprep kit, and EcoR1 digest products 
sequenced as above. Sequencing was carried out by our collaborator, Dr. Marian Hill in 
Nottingham. 
5.1.2 SIFT analysis (Sorting Intolerant From Tolerant) 
SIFT is a program which predicts whether an amino acid substitution affects 
protein function and hence, potentially alters phenotype 
(http://www.blocks.fhcrc.org/sift/SIFT.html). Unlike Polyphen, the SIFT algorithm relies 
solely on sequence, sequence homology and the physical properties of amino acids to 
predict the effect of the amino acid substitution. To predict whether an amino acid 
substitution in a protein will affect protein function, SIFT considers the position at which 
the change occurs and the type of amino acid change. The program presumes that 
important amino acids are conserved so changes at well-conserved positions are 
predicted as deleterious. If a position in an alignment contains a hydrophobic residue 
then SIFT assumes that this position can only contain amino acids with hydrophobic 
character. At this position, changes to other hydrophobic amino acids are usually 
predicted to be tolerated but changes to other residues, such as charged or polar, will 
be predicted to affect protein function135. This analysis was performed by our 
collaborator, Dr. M Hill. 
5.1.3 Polyphen analysis (polymorphism phenotyping) 
Polymorphism Phenotyping (www.bork.embl-heidelberg.de/polyphen) is a tool 
which predicts possible impact of an amino acid substitution on the structure and 
function of a human protein. A sequence-based characterisation of the mutation site is 
performed to identify any functionally important regions (e.g. an active/ binding/ trans-
membrane region). Mutations at these sites are assessed to evaluate their effect. 
Mapping of amino acid replacement to the known 3D structure reveals whether the 
replacement is likely to destroy the hydrophobic core of a protein, electrostatic 
interactions, interactions with ligands or other important features of a protein such as 
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secondary structure, solvent accessible surface area, inter-chain contacts or contacts 
with functional sites. Accordingly, the mutation is appraised by empirically determined 
cut-offs used to predict if the substitution is ‘probably damaging’, ‘possibly damaging’ or 
‘benign’136. This analysis was performed by our collaborator, Dr. M Hill. 
5.1.4 Analysis of clot formation and Lysis 
The patient gave informed consent for her blood sample to be studied further to 
elucidate the mechanisms for the clinical presentation. Blood samples were taken into 
citrated tubes, plasma spun down within 2 hr of collection and samples were stored in -
80 °C until analysis. Clot turbidity and lysis measurements were conducted as 
previously described in section 2.4. 
5.1.5 Protein purification 
Fibrinogen was purified by affinity chromatography using a calcium dependent IF-
1 monoclonal antibody (Kamiya Biochemical, Seattle, WA, USA) and an automated 
chromatography system (Biocad sprint, Applied Biosystems, Warrington, UK) as 
previously described in section 2.1.3. 
5.1.6 Recombinant protein engineering  
5.1.6.1 Vector construction 
Vectors were constructed and recombinant protein expressed as detailed below. 
A vector including the fibrinogen Aα chain was altered using the QuickChange site-
directed mutagenesis kit (Stratagene, La Jolla, CA);  
5.1.6.1.1 Primer design 
Mutagenic primers, sourced from Invitrogen (Poole, United Kingdom) were 
designed that contained the changed bases needed to code for the new amino acid, in 
this case the two bases changed were next to each other at position 1002 and 1003 on 
the fibrinogen α-chain. These mutations present as G>T and A>T substitutions and 
cause amino acid changes Trp334Cys and Asn335Tyr respectively. The primers were 
designed using the sequence for the fibrinogen alpha-chain gene from the National 
Centre for Biotechnology Information website (http://www.ncbi.nlm.nih.gov/nucleotide/) 
and the web-based QuikChange Primer Design Program on the agilent website 
(https://www.genomics.agilent.com/CollectionSubpage.aspx). This program ensured 
the primers extended 10 to 15 bases on either side of the altered base, had an overall 
length of between 25 and 45 bases and a melting temperature of 78 °C. It was ensured 
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both of the designed mutagenic primers contained the desired mutation and annealed 
to the same sequence on opposite strands of the plasmid with a minimum GC content 
of 40% and terminated in C or G bases. The primers were PAGE purified. The primers 
generated were checked to see if they attached to any other, undesired, part of the 
plasmid using Clustal software on the European Bioinformatics Institute webpage 
(http://www.ebi.ac.uk/Tools/msa/clustalw2/). The output generated allowed 
determination of how many times the primer sequence corresponded to the plasmid 
sequence. Alignment of the primers on the sequence more than once meant they could 
not be used. The primers generated for mutation of the fibrinogen α chain (mutated 
bases in bold) were: 
Forward 5’ GAAGTGCTGGAAGCTGTTACTCTGGGAGCTCTGG 3’ and  
Reverse 5’ CTTCACGACCTTCGACAATGAGACCCTCGAGACC 3’ 
5.1.6.1.2 Genetic manipulation 
A gene is made up of many different sections, transcribed into a single RNA 
molecule and consequently translated into a specific protein. Alongside the sequence 
that is directly translated into the resulting protein, there are many regulatory 
sequences that control the translation of the protein. These are depicted in Figure 5-1. 
The promoter (P), a region that binds RNA polymerase, and the specific transcription 
starting point (Tc) lies before the transcriptional unit in an area known as the upstream 
regulatory region which may also contain enhancers and operators, which are other 
controlling elements. At the other end of the transcriptional unit lies the transcription 
stop site (tc). Between Tc and tc is the region of DNA transcribed into RNA. The coding 
sequence lies within this transcribed region and is defined by a translation start (TL) 
and stop (tL) site. This sequence is made up of translated (exons) and non-translated 
(introns) regions. The introns are removed in the nucleus before the messenger RNA is 
translated and the resulting sequence translated into amino acids to form the mature 
protein. 
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Figure 5-1. Diagrammatical representation of a gene 
Upstream regulatory region containing the promoter, coding sequence contained within 
the transcriptional unit, downstream region, transcription start and stop sites and 
translation start and stop sites are shown. 
 
To generate recombinant protein, recombinant DNA must be created, which is 
subsequently inserted into a plasmid. This can be achieved using restriction enzymes 
and DNA ligase to cut DNA, producing ‘sticky ends’ that can then be annealed together 
with other DNA fragments with complimentary cohesive ends by the same restriction 
enzymes. 
When designing a plasmid, certain considerations should be kept in mind: They 
should be fairly small DNA molecules to allow isolation and handling. They must also 
contain several regions; an origin of replication, allowing DNA copying and preservation 
of the plasmid DNA in the cell population; a selectable marker, allowing the plasmid to 
be selected for, such as an antibiotic resistance gene or fluorescence tag; and at least 
one unique restriction endonuclease recognition site to allow insertion of recombinant 
DNA. Many plasmids possess a region known as the multiple cloning site (MCS) which 
contains many unique restriction endonuclease sites in a short DNA fragment, allowing 
a choice of sites for DNA insertion. 
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Figure 5-2. Map of the plasmid containing the fibrinogen α-chain plasmid  
Alpha chain insert, major late promoter, origin of replication and ampicillin resistance 
gene are shown. 
 
We used this plasmid (Figure 5-2) and changed the bases of the inserted coding 
sequence for the fibrinogen alpha chain to our purpose with our designed primers. This 
was done with the use of The QuikChange II site-directed mutagenesis kit (Agilent, CA, 
USA) which is able to make point mutations, replace amino acids, and delete or insert 
single or multiple adjacent amino acids.  
5.1.6.1.3 Site directed mutagenesis 
The process of site directed mutagenesis works in 5 steps. Firstly mutant strand 
synthesis takes place by thermal cycling to denature the DNA template then mutagenic 
primers containing the desired mutation are annealed to the DNA and extended with 
pfuUltra DNA polymerase. The template is Dpn I digested and finally the mutated 
molecule is transformed into competent cells for nick repair. Two complimentary 
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oligonucleotides containing the desired mutation, flanked by the unmodified nucleotide 
sequence of the fibrinogen alpha chain were synthesised as above.  
A control reaction was prepared in a PCR tube containing reaction buffer, 0.2 
ng/µl pWhitescript 4.5 kb control plasmid, 2.5 ng/µl oligonucleotide control primer #1 
and #2, deoxyribonucleoside triphosphates (dNTPs) and 0.05 U/µl PfuUltra HF DNA 
polymerase. A series of 3 test reactions using various amounts of double stranded 
DNA (dsDNA) template were prepared containing reaction buffer, 5/ 20/ 50 ng dsDNA 
template, 2.5 ng/µl forward and reverse primer, dNTPs and 0.05 U/µl PfuUltra HF DNA 
polymerase. The reaction mixtures in the PCR tubes were mixed by pipetting up and 
down several times, sealed with a lid and placed in a PTC-200 Peltier Thermal Cycler 
(MJ Research, Quebec, Canada). Thermal cycling was then carried out: The reaction 
was held at 95 C for 30 sec before 18 cycles of; 30 sec at 95 C, 60 sec at 55 C and 
60 sec at 68 C. The reaction was then held at 4 C until sample collection. 
5.1.6.1.4 Digestion of non-mutated DNA 
After thermal cycling was complete, 1 μl of the Dpn I restriction enzyme (Agilent) 
(10 U/μl) was added to each amplification reaction and each reaction was then gently 
and thoroughly mixed by pipetting the solution up and down several times. The reaction 
mixtures were centrifuged for 1 min at 13000 rpm and immediately incubated at 37 °C 
for 1 hr to digest the parental (nonmutated) supercoiled dsDNA. 
5.1.6.1.5 Transformation of mutated DNA into XL-blue cells 
The nicked vector DNA containing the desired mutations was then transformed 
into XL1-Blue supercompetent cells (Agilent). XL1-Blue supercompetent cells were 
gently thawed on ice. For each control and sample reaction to be transformed, 50 μl of 
the supercompetent cells were aliquoted to a pre-chilled 15 ml Falcon tube and 1 μl of 
the Dpn I-treated DNA from each control and sample reaction transferred to separate 
aliquots of the supercompetent cells. The transformation reactions are swirled gently to 
mix and incubated on ice for 30 min. The reactions were then heat shocked for 45 sec 
at 42 °C and then placed on ice for 2 min. 0.5 ml of SOC broth (Sigma-Aldrich, MO, 
USA) preheated to 42 °C was added and the reactions incubated at 37 °C for 1 hr with 
shaking at 250 rpm. The transformation reactions were plated on agar/ampicillin plates 
(50 µg/ml ampicillin); the mix evenly distributed on the plate with the plating tool, sealed 
with film, turned upside down and incubated at 37 °C for >16 hr. For each 
transformation, 3-4 plates with different dilutions of the transformed cells were 
prepared. Volumes between 100 and 250 µl of each transformation reaction were 
used. The gene for ampicillin was introduced into the cells with the mutant vector to 
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ensure that only bacteria which were successfully transformed were able to grow in 
ampicillin-supplemented media.  
5.1.6.1.6 Colony selection 
After 16 hr, single bacterial colonies appeared on the agar/ ampicillin plates. The 
plates were removed from 37 °C and stored at 4 °C to halt colony growth. 10-15 single 
isolated colonies were picked per transformation. The colonies to be removed from the 
plate were circled on the bottom of the plate to prevent the same colony being selected 
twice if more cells had to be picked if no positive clone was found in the first batch. 
For each colony, a 15 ml falcon tube containing 5 ml LB Broth (0.17 M NaCl, 
0.063 M tryptone, yeast extract, pH 7) containing 50 µg/ml ampicillin was prepared. 
Each colony was picked with a sterile pipette tip and put in the LB broth. Tubes were 
loosely closed and incubated overnight at 37 °C with shaking (~12-16 hr). If the 
incubation period was too short, the yield of DNA was low, but if left too long, 
overgrowth killed the bacteria. The DNA from all colonies was isolated the next 
morning using a QIAprep Spin Miniprep Kit (Qiagen, CA, USA). 
5.1.6.1.7 Isolation of mutated DNA  
The QIAprep miniprep procedure is based on alkaline lysis of bacterial cells 
followed by adsorption of DNA onto silica in the presence of high salt. The procedure 
consists of three basic steps: Bacteria are lysed under alkaline conditions, and the 
lysate is subsequently neutralised and adjusted to high-salt binding conditions. DNA is 
adsorbed to the QIAprep membrane, while RNA, cellular proteins and metabolites are 
not retained on the membrane. Finally endonucleases and salts are removed by a 
wash step and high quality plasmid DNA is eluted with water. 
The bacterial cells from overnight growth were harvested by centrifugation at 
>8000 rpm (6800 g) in a MIKRO 2000 centrifuge (Hettich, Germany) for 3 min at room 
temperature. All supernatant were then removed. The pelleted bacterial cells were 
resuspended in 250 μl Buffer P1 and transferred to a microcentrifuge tube. The 
bacteria were resuspended completely by vortexing until no cell clumps remained. 250 
μl of Buffer P2 was added and mixed thoroughly until the solution became viscous and 
slightly clear. The lysis reaction was not allowed to proceed for more than 5 min before 
350 μl Buffer N3 was added and mixed until the solution became cloudy. The mix was 
centrifuged for 10 min at 13,000 rpm resulting in formation of a compact white pellet (all 
consequent centrifugation steps were carried out at 13,000 rpm). The supernatants 
were applied to the QIAprep spin column, the columns centrifuged for 60 sec and the 
flow-through discarded. The QIAprep spin columns were then washed by addition of 
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0.5 ml Buffer PB and centrifuging for 60 sec. Again, the flow-through was discarded. 
0.75 ml Buffer PE was added to the columns to wash again and the columns 
centrifuged for a further 60 sec. Having discarded the flow-through, the QIAprep 
columns were centrifuged for an additional 60 sec to remove residual wash buffer. The 
QIAprep columns were placed in clean 1.5 ml microcentrifuge tubes and DNA eluted by 
addition of 50 μl water to the centre of each QIAprep spin column, which were left to 
stand for 1 min, then centrifuged for 60 sec. Eluted DNA was stored at -20 °C. 
5.1.6.1.8 Analysis of integrity of eluted DNA 
A gel was run to check the DNA eluted from the miniprep was of sufficient quality, 
was the same length as the plasmid and had not been fragmented. For a 1.5% gel, 1.5 
g metaphor agarose powder (Lonza, Basel, Switzerland) was added to 100 ml Tris-
acetate-EDTA buffer (TAE; 40 mM Tris, 20 mM acetic acid, 1 mM EDTA, pH 8) in a 
wide necked conical flask. The flask was then weighed before microwaving with 
intermittent shaking until the mixture was dissolved.  The flask was weighed again and 
distilled water added back to the initial weight. A gel tray was set up so both ends were 
sealed and an adequate number of separators to form wells slotted in the setup.10 µl 
ethidium bromide (Sigma) was added to the gel mix which was slowly poured into the 
corner of the tray and left to set for 30 min. The ends of the tray and the separators 
were removed and the gel transferred to a chamber of TAE connected to a power 
supply. It was ensured the gel was placed in the correct orientation so the migration of 
the negative DNA towards the positive (red) electrode was in the correct direction. 
Enough TAE was added in order to cover the gel and fill the wells. For each miniprep 
elutant and the original plasmid, a 15 µl sample of 1 ng/µl DNA with 5 x DNA loading 
buffer (Bioline, MA, USA) was prepared and loaded into a well of the set gel along with 
a lane of high molecular weight bioladder (5 µl) (Bioline). The chamber was run at 100 
V for 1 hr. The gel tray was removed from the chamber and drained of excess TAE. 
The tray was placed in the MutliImageTM Light Cabinet (Alpha Innotech, CA, USA) and 
the gel viewed using Chemiimager software (Alpha Innotech).  
5.1.6.1.9  Analysis of DNA Sequence 
When confirmation that the plasmid DNA from the miniprep was not fragmented 
and of adequate quality, samples were sent off for sequencing to the University of 
Dundee (http://www.dnaseq.co.uk/products.html). Initially only the length of plasmid 
containing the desired mutation was sequenced to confirm the presence of the 
mutation. This was done with the use of pre-designed primers from the lab that attach 
throughout the length of the fibrinogen α-chain. A forward and a reverse primer that 
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read the sequence around the mutation were identified from the position they attach on 
the α-chain sequence. The sequencing results were checked for the presence of the 
mutation by searching for the wild-type sequence 10-12 base pairs around the area 
mutated (in this case TGGAACTCTGGG), since there is a repeat of this sequence 
upstream, if one of this sequence was present then the mutation was present in the 
plasmid. If two of the wild-type sequences were present, the mutation was not present. 
To further check the presence of the mutation in those plasmids with only one wild-type 
sequence, the sequence of the two amino acids in which the mutation lie were 
searched for, this time with the mutated sequence (in this case TGTTAC, rather than 
the wild-type TGGAAC). A further check was run, searching for the sequence directly 
downstream of the desired mutation (AACTCTGGG) and the two base pairs upstream 
of this checked to be ‘GA’. 
5.1.6.1.10    Further production and purification of mutant DNA 
Once the presence of the mutation in the α-chain plasmid had been confirmed by 
sequencing, a Qiagen Plasmid Maxi Prep of the mutated plasmids was performed to 
purify more DNA for the transfection into CHO cells which required more and highly 
pure DNA, requiring the removal of RNA, proteins, dyes and low-molecular weight 
impurities. 
Before starting the maxiprep, the plasmid was transformed into competent DH5α 
cells (Invitrogen). This was done in the same way as for the miniprep, but using the 
plasmid product of the miniprep, instead of PCR products, and DH5α cells, instead of 
XL-blue supercompetent cells. Cells were grown and plated in the same way. After 
overnight incubation, the maxiprep protocol began. 
Single colonies were picked from freshly streaked plates and added to 5 ml LB-
ampicillin broth and incubated for 8 hr at 37 °C with shaking at 300 rpm. 200 µl of this 
‘starter culture’ was then added to 100 ml LB-ampicillin broth and grown for 16 hr at 37 
°C with shaking at 300 rpm. The bacterial cells were harvested by centrifugation at 
6000 g for 15 min at 4 °C. The supernatant was discarded and the pellet resuspended 
completely in 10 ml of Buffer P1. 10 ml Buffer P2 was added and the solutions mixed 
before incubation at room temperature for 5 min. During this incubation period, the cap 
was screwed onto the outlet nozzle of the QIAfilter cartridge which was then placed in a 
50 ml falcon tube. 10 ml buffer P3 was added to the solution, mixed and poured into 
the barrel of the QIAfilter Cartridge and left for 10 min at room temperature. The cap of 
the QIAfilter cartridge was then removed and the plunger inserted into the top of the 
cartridge. The cell lysate was filtered into a 50 ml falcon containing 2.5 ml buffer ER. 
The tube was inverted to mix the solution and incubated on ice for 30 min. During this 
incubation, 10 ml buffer QBT was applied to a QIAGEN-tip 500 and allowed to flow 
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through the column. The incubated lysate was applied to the QIAGEN-tip and left to 
enter the column by gravity flow. The column was washed twice with 30 ml buffer QC, 
allowing movement through the column by gravity. The DNA was eluted with 15 ml 
buffer QN into a 30 ml falcon tube. DNA was precipitated by adding 10.5 ml 
isopropanol to the elutant and centrifuging at 15,000 g for 30 min at 4 °C. The 
supernatant was discarded and the DNA pellet washed with 5 ml endotoxin-free 70% 
ethanol. It was then centrifuged at 15,000 g for 10 min and the supernatant discarded. 
The pellet was air-dried for 5-10 min and the DNA redissolved in 200 µl endotoxin free 
buffer TE. The yield of DNA was determined by spectrophotometry and agarose gel 
analysis as described in section 5.1.6.1.8. The DNA was then sent to be sequenced 
again to check the mutation was still present and that no further mutations had 
occurred in the cell grow-up. This time the whole α-chain insert was sequenced using a 
whole set of forward and reverse primers for the α-chain. The DNA was frozen at -20 
°C until transfection into CHO cells. 
5.1.6.2 CHO cell engineering 
To express mutated recombinant fibrinogen, the mutated plasmid had to be 
introduced into engineered CHO cells harbouring the genes for the Bβ- and γ- chain of 
fibrinogen. Three CHO cell lines are available, each of which has 2 out of the 3 
fibrinogen genes in their genomic DNA. These cells cannot express fibrinogen because 
they lack the gene for the third chain. The CHO cells were co-transfected with 
pMSVHis, conferring resistance to L-histidine, when the third fibrinogen chain was 
transfected. During transfection, the plasmic DNAs were inserted into the genomic 
DNA, resulting in a permanent transfection. When grown in media with histadinol, 
colonies that survived had successfully taken up the selection marker and possibly the 
gene of interest. 
5.1.6.2.1 Transfection of CHO cells 
βγ CHO cells were removed from liquid nitrogen and thawed in a water bath at 37 
C. 9 ml GM was added to 1 ml of thawed cells in a 50 ml falcon and spun at 1000 rpm 
for 10 min. Media was removed from the cell pellet and the pellet resuspended in fresh 
GM and the cells transferred into a 100 mm petri dish containing 10 ml GM. After a 
growth phase, when the cells were confluent, the cells were split 1:10 with trypsin/ 
EDTA and plated; 2 experiment plates with Geneticin 418 (G418) media (GM/ 0.4 
mg/ml G418 (Invitrogen)), the remaining 8 plates with GM for freezing. The next 
morning media on experiment plates was changed to 10 ml fresh G418 media and 
incubated for 2 hr. One hr before transfection, the DNA was prepared. A total of 10-20 
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ng mutated plasmid DNA and 1 ng pMSVHis were added to 50 µl of sterile filtered 2.5 
M CaCl2 in a 15 ml tube, supplemented by water to a final volume of 500 µl. 500 µl of 
sterile filtered 2xHeBS (115 mM NaCl, 1.2 mM CaCl2, 1.2 mM MgCl2, 2.4 mM K2HPO4, 
20 mM HEPES) was put in a 50 ml falcon and this solution bubbled with a mechanical 
pippetor while the DNA/ CaCl2 solution was slowly added. The mix was then vortexed 
and rested at room temperature for 30 min. The mix of DNA/ CaCl2/ HeBS was slowly 
added to the cultured cells and carefully but thoroughly mixed with the G418 media. 
The plates were left in the incubator for 4 hr at 37 °C. Subsequently, the transfection 
process was terminated with a glycerol shock of the cells. Media were aspirated with a 
vacuum from the cells and 2 ml sterile filtered 10% glycerol solution added and left for 
3 min at room temperature. Glycerol was aspirated and the plate washed 3 times with 5 
ml sterile filtered PBS. Cells were fed 10 ml G418 media and placed in the incubator for 
2 days, followed by splitting and plating at different densities to allow the growth of 
colonies from single cells that could be picked (2x1:10, 2x1:5, 1x3:10). Plates were 
shaken softly but thoroughly to spread the cells evenly and placed in the incubator at 
37 °C. After 24 hr the G418 media was exchanged with 10 ml selection media (GM/ 0.4 
mg/ml G418/ 0.25 mM L-histidinol (Sigma)) and placed back in the incubator. To 
remove dead cells, culture media were changed to fresh selection media every 2 days. 
Cell growth was periodically checked under the microscope, to enable 
identification of single, well defined CHO cell colonies. When this was achieved, 24 
single colonies were selected under the microscope and circled on the bottom of each 
plate with permanent marker. The clones that were selected had to be well separated 
from other clones and be made of large cells that looked healthy. Wells of a 24 well 
plate were labelled with clone numbers (1-24) and to each well 0.5 ml selection media 
was added. The media on the plates with colonies was removed and autolclaved glass 
cloning cylinders placed with tweezers over the circled clones and pressed down to 
achieve good contact between the glass and the plastic plate. 50 µl trypsin/ EDTA were 
added to each cloning cylinder and the cells incubated for 5-10 min.The cells in each 
cloning cylinder were suspended by pipetting up and down with a glass pipette and 
transferred to 1 of the 24 wells containing 4 ml selection media and mixed carefully. 
The 24 well plate was placed in the incubator overnight at 37 °C. Selection media were 
replaced the next day to remove traces of trypsin/ EDTA and dead cells and to equalise 
the amount of liquid in each well. The cells were then grown without media change until 
the cells in about 60-70% of the wells reached confluence (~1 week). At this point the 
fibrinogen content in each of the 24 wells was determined by ELISA. 350 ul of media 
was removed from each well and 100 ul added in triplicate to a 96 well plate and 
fibrinogen levels were measured as described in section 2.3. From ELISA, 5-8 clones 
producing high levels of fibrinogen were selected. For each selected clone, two 60 mm 
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dishes containing 4 ml selection media were prepared. The selected clones were split 
from the 24 well plate with 0.5 ml trypsin/ EDTA and evenly distributed between the two 
60 mm dishes. Cells were left at 37 C until they reached confluence (4-5 days). 
Having reached confluence, one dish of cells was frozen (as described in section 
2.1.1.3), and the other plate washed 3x with SFM before incubation for 7 days with 4 ml 
SFM to check if cells still produced fibrinogen in this media. After this, an aliquot of 
each medium was subjected to a fibrinogen ELISA. The 2 or 3 clones producing the 
highest yield of fibrinogen were chosen for fibrinogen production in roller bottles as 
described in section 0  
5.1.7 Analysis of fibrinogen-albumin binding 
Albumin can bind fibrinogen and cause changes in clotting parameters such as 
limiting lateral fibril growth and decreasing final turbidity137. Albumin binds preferentially 
to cysteine residues due to the residues high affinity binding .Therefore, it is reasonable 
to suggest that there may be increased amounts of albumin bound to Fibrinogen 
Birmingham II when compared to control due to Trp334Cys substitution, consequently 
affecting fibrin network structure. To investigate this possibility 2 identical SDS-PAGE 
gels were run as below 
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Each gel was transferred to blotting membrane and one blotted for fibrinogen and 
the other for albumin as described in section 2.5. 
5.1.8 Confocal microscopy  
Confocal microscopy was conducted as previously described in section 2.6. 
5.1.9 Electron microscopy 
Electron microscopy was conducted as previously described in section 2.7. 
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5.2 Results 
5.2.1 Patient characteristics 
This novel fibrinogen variant was detected in a 34 year old woman and was 
associated with hypodysfibrinogenemia. Her clinical symptoms included a strong 
history of thrombosis; requiring insertion of an inferior vena cava (IVC) filter, in addition 
to a bleeding diathesis. She had suffered two deep vein thrombi ((DVT); one 6 weeks 
post-partum and one while taking the contraceptive pill), two cases of thrombophlebitis 
(vein inflammation related to a thrombus), bleeding after vein ligation and when an IVC 
filter was inserted and an IVC thrombosis. Two additional unconfirmed DVTs were 
reported and the patient is on long term anticoagulation therapy. She showed no risk 
factors for arterial thrombosis and successfully came to term on two live births with no 
history of miscarriage. 
Fibrinogen BII plasma was associated with lower fibrinogen levels (1.1 mg/ml) 
when compared with control (Normal range: 1.5-4.5 mg/ml). Prothombin time was 
increased (23 sec) compared to control (normal range 9-13 sec) and activated partial 
thromboplastin time was marginally increased (40 sec) compared to control (normal 
range 26-35 sec). Thrombin time was also prolonged (22 sec) compared to control 
(normal range 12-16 sec). Taken together, this indicates a defect of the fibrinogen, due 
to quantitative and/or qualitative change in the protein. 
5.2.2 Family history 
There was a family history of hypodysfibrinogenemia associated with a range of 
clinical symptoms, which included thrombosis and/or bleeding, and asymptomatic 
individuals. The patients’ mother bled after childbirth and post-surgery, her maternal 
grandfather had a DVT, her brother has dysfibrinogenemia but is asymptomatic and 
she has one affected and one unaffected daughter. 
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Figure 5-3. Family tree to show family history of bleeding and thrombosis in 
relatives of Fibrinogen BII patient 
Mother showed bleeding after childbirth and post-surgery, maternal grandfather had 
one DVT, brother has dysfibrinogenemia but is asymptomatic, and one of two of the 
patient’s daughters is affected. 
5.2.3 SIFT and Polyphen analysis 
SIFT analysis suggested both substitutions were deleterious (both score 0.03) 
and Polyphen analysis predicted that the Trp334Cys and Asn335Tyr changes were 
'possibly damaging' and ‘benign' (score 0.85 and 0.41 respectively).  
5.2.4 Plasma samples 
5.2.4.1 Clot formation and fibrinolysis  
Clot structure and lysis of BII plasma could not be analysed using turbidimetric 
assay as no change in absorbance could be detected when clotting was activated in BII 
plasma (Figure 5-4). Four repeats were performed in duplicate, confirming this event. 
In case the low fibrinogen levels were contributing to this, the experiment was 
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performed with 3x the amount of plasma usually added, but still no change in 
absorbance was detected. The experiment was also performed using 10x less 
thrombin than usual in case the clot was forming extremely quickly, before the plate 
reader began reading, but this proved not to be the case. In each case, BII plasma 
showed elevated baseline absorbance when compared to control, which could be 
explained by the plasma having already clotted, however clots formed from this plasma 
for LSCM and EM analysis. 
 
 
 
Figure 5-4. Analysis of clot formation and lysis of control and BII plasma by 
turbidimetric assay 
BII plasma showed an elevated baseline compared to control and no change in OD 
was detected upon activation of clot formation. 
5.2.4.2 Clot structure  
Confocal microscopy showed clots made from BII plasma to be made of a fluffy 
texture with no defined fibrin bundle structure (Figure 5-5). 
 
 
 
 
Figure 5-5. LSCM images of clots made from Fibrinogen BII and control plasma 
(A) Control and (B) BII plasma clots. Clots made from Fibrinogen BII had an atypical 
morphology with no defined fibrin bundle structure. Scale bars represent 45 µm. 
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Electron microscopy revealed clots made from Fibrinogen BII plasma to be made 
of 67.6% thinner fibres than those of control. Clots had a bizarre morphology of very 
thin and ‘fluffy’ fibrin bundles interspersed with large pores (Figure 5-6). 
 
 
 
 
Figure 5-6. EM scans of clots made from of Fibrinogen BII and control plasma 
and comparison of fibre thickness 
(A) Control and (B) BII plasma clots. Scale bars represent 3 µm. BII plasma produced a 
clot made of an atypical structure with significantly thinner fibres interspersed with large 
pores. 
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5.2.5 Purified Protein 
5.2.5.1 Integrity of purified patient plasma fibrinogen 
Purified fibrinogen showed high purity and integrity with intact chains and 
absence of significant degradation (Figure 5-7). 
 
 
 
Figure 5-7. Purified Fibrinogen BII fibrinogen resolved on an 4-12% SDS PAGE 
gel  
The gel showed all 3 different fibrinogen chains intact confirming integrity and purity of 
the fibrinogen purified. 
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5.2.5.2 Clot formation and fibrinolysis 
BII turbidity was 88% lower than that of control fibrinogen. CFT was 368.0% 
greater in BII fibrinogen than control.  Lysis time was 506.3% greater in BII than 
control.  Results summarised in Figure 5-8. 
 
 
Figure 5-8. Characteristics of clots formed from fibrinogen purified from control 
and Fibrinogen BII plasma as measured by turbidimetric assay 
(A) Maximum absorbance; significant decrease with Fibrinogen BII pointing towards 
thinner fibres. (B) Lysis time; significant increase with Fibrinogen BII pointing towards 
clots with increased resistance to lysis. (C) Clot formation time; significant increase with 
Fibrinogen BII. 
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5.2.5.3 Clot structure  
In standard LSCM preparations, Fibrinogen BII clots appeared to be made of 
shorter fibres, with more branch points and an ill defined fibre structure (Figure 5-9). 
 
 
 
 
Figure 5-9. LSCM images of clots made from control and Fibrinogen BII plasma-
purified fibrinogen 
(A) Control and (B) Fibrinogen BII plasma-purified fibrinogen clots. Clots made from 
Fibrinogen BII had an atypical morphology with no defined fibril structure. Scale bars 
represent 45 µm. 
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Fibres of clots made from fibrinogen BII purified fibrinogen were 61.0% thinner 
than those of control fibrinogen. BII fibrinogen produced a clot made of an atypical 
structure with thin fibres interspersed with large pores (Figure 5-10). 
 
 
 
 
 
 
Figure 5-10. EM of clots made from of control and Fibrinogen BII plasma-purified 
fibrinogen and comparison of fibre thickness 
(A) Control and (B) BII plasma-purified fibrinogen clots. Scale bars represent 3 µm. BII 
fibrinogen produced a clot made of an atypical structure with significantly thinner fibres 
interspersed with large pores. 
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5.2.6 Recombinant Protein 
Recombinant fibrinogen purified was clean but there was a level of alpha chain 
degradation (Figure 5-11). This may have been due to the mutations that were 
introduced which could have caused the molecule to be unstable in the culture 
conditions and thus prone to degradation. When tested for clottability 61.57±1.59% of 
the fibrinogen clotted. 
 
 
 
Figure 5-11. Recombinant BII fibrinogen resolved on a 4-12% SDS PAGE gel  
The gel shows all 3 different fibrinogen chains though there is a level of α-chain 
degradation and some high molecular weight bands. 
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5.2.6.1 Clot formation and fibrinolysis   
Final turbidity was 561.3% higher in WT than BII. Clot formation time was 55.9% 
greater with BII fibrinogen than WT. Lysis time was 67.2% greater in WT when 
compared to BII. Results are summarised in Figure 5-12. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 5-12. Characteristics of clots formed from recombinant WT and BII 
fibrinogen as measured by turbidimetric assay 
(A) Maximum absorbance; significant decrease with Fibrinogen BII pointing towards 
thinner fibres. (B) Lysis time; significant decrease with Fibrinogen BII. (C) Clot 
formation time; significant increase with Fibrinogen BII. 
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5.2.6.2 Clot structure  
BII recombinant fibrinogen formed a clot with an atypical architecture with a more 
dense structure and more curved fibrin bundles and more branch points than WT 
recombinant fibrinogen. 24 hr after clot formation, BII fibrin clot appeared to retract and 
dissolve (Figure 5-13). 
 
 
Figure 5-13. LSCM images of clots made from WT and BII recombinant fibrinogen 
WT and BII recombinant fibrinogen 4 and 24 hr after clot formation. Scale bars 
represent 45 µm. BII recombinant fibrinogen formed a clot with an atypical architecture 
with a more dense structure and more curved fibrin bundles than WT recombinant 
fibrinogen. 24 hr after clot formation, BII fibrin clot appeared to retract.  
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Clots made from BII recombinant fibrinogen were more compact and fibre 
thickness was 61.7% smaller in BII than WT fibrinogen. Results summarised in Figure 
5-14. 
 
 
Figure 5-14. EM of clots made from of Fibrinogen BII and WT recombinant 
fibrinogen and comparison of fibre thickness 
(A) WT and (B) BII recombinant fibrinogen clots. Scale bars represent 3 µm. Fibre 
thickness as determined by EM scans showed fibre thickness to significantly decrease 
with Fibrinogen BII fibrinogen.  
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5.2.7 Clot formation and fibrinolysis in the presence of plasma proteins 
The interaction of the fibrinogen variants in the presence of α2-AP was studied as 
it has been shown previously (Chapter 4) that α2-AP is one of the main plasma 
proteins implicated in causing changes in lysis of clots with differing structures. 
In a purified system, absence or presence of α2-AP had no effect on MA of 
control fibrinogen. Equally, α2-AP had no significant effect on MA of BII fibrinogen. 
Data summarised in Figure 5-15A. In a recombinant system, α2-AP had no effect on 
MA of WT fibrinogen. However, α2-AP significantly increased MA of BII fibrinogen by 
16.7%. Data summarised in Figure 5-15B. It should be noted, however, that purified 
protein had a heterozygous genotype, whereas recombinant protein is homozygous. 
α2-AP prolonged CFT by 306% and 200% in BII fibrinogen in purified and recombinant 
systems respectively, but had no effect in control/WT fibrinogen (Figure 5-16). In a 
purified system, α2-AP prolonged lysis by 286.5% in control and BII fibrinogen showed 
no sign of lysing within 2 hr in the presence of α2-AP (Figure 5-17A). In a recombinant 
system α2-AP prolonged lysis in WT by 277.5% and by 553.3% in BII fibrinogen 
(Figure 5-17B). 
 
 
 
 
 
Figure 5-15. Turbidimetric traces of Control/ WT and BII purified and recombinant 
fibrinogen in the presence of α2-AP 
(A) Purified system and (B) recombinant system. α2-AP had no effect on MA of 
control/WT fibrinogen but increased MA of BII fibrinogen.  
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Figure 5-16. Effect of α2-AP on CFT of control/ WT and BII purified and 
recombinant fibrinogen 
(A) Purified system and (B) recombinant system. α2-AP significantly prolonged CFT in 
BII fibrinogen but had no effect in control/WT fibrinogen in purified and recombinant 
systems. 
 
 
Figure 5-17. Effect of α2-AP on LT of control/ WT and BII purified and 
recombinant fibrinogen 
(A) Purified system and (B) recombinant system. α2-AP prolonged lysis in control/WT 
and BII fibrinogen. α2-AP prolonged lysis significantly longer in BII then control/WT 
fibrinogen. 
5.2.8 Albumin-Fibrinogen Binding 
Human serum albumin has a molecular weight of 67 kDa. The control albumin is 
BSA which has a molecular weight of 69,324 Da as a full length precursor; this is 
cleaved of a 2,107 Da signal peptide upon secretion and is cleaved of a further 478 
kDa propeptide, producing the mature 66,463 Da protein. The most dense bands 
picked up by the albumin antibody are between 75 and 50 kDa as predicted by these 
documented molecular weights (~67 kDa). The other bands are below 25 kDa. 
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Though albumin is present in the plasma, it does not seem to bind strongly to 
either BII or control fibrinogen as it separates on the non-reducing gel. There is a very 
low molecular weight band in the BII purified lane picked up by the albumin antibody; 
this could be a small cleavage product of albumin which has co-purified with BII 
fibrinogen, but does not remain bound in solution. 
 
 
Figure 5-18. Binding of albumin to fibrinogen in plasma, purified and 
recombinant proteins 
Individual blots of fibrinogen (left upper panel) and albumin (right upper panel) and an 
overlay of the two blots (bottom panel) are shown. Samples containing mutant and 
wild-type fibrinogen were studied. Albumin does not bind BII or control fibrinogen in 
plasma, purified or recombinant systems.  
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5.3 Discussion 
We report a novel fibrinogen variant due to co-inheritance of two missense 
mutations in αC domain (Aa p.Trp334Cys and Aa p.Asn335Tyr). This variant is 
associated with thin fibrin fibres, impaired clot formation and resistance to fibrinolysis in 
a plasma environment, and clinically both a thrombotic and bleeding tendency. 
When patient plasma was studied, EM revealed the clot to be made of fibrin 
fibres that were significantly thinner than those of control clots and made of the bizarre 
fluffy structure rather than defined fibres. Confocal microscopy also showed a lack of 
defined fibre bundles, again showing an almost fluffy texture to the fibrin network 
structure. The lack of detection of fibrinogen BII plasma clotting by turbidimetric assay 
remains unexplained. Though levels of calcium, fibrinogen and thrombin were all 
investigated, adjusting these factors had no influence on the clotting. The higher 
baseline absorbance of the BII plasma suggests it may have clotted in storage; 
however this did not seem to be the case as clots could be formed for both LSCM and 
EM preparations. It may be that the ultra structure of the clot cannot be detected at the 
wavelength used to measure the changes in absorbance, but this seems unlikely due 
to the similar structure of the clot formed from plasma purified protein (as assessed by 
LSCM and EM) being detected.  
When clots made from plasma-purified fibrinogen were studied by EM and 
LSCM, they showed a similar architecture to that in plasma, with significantly thinner 
fibres and an atypical structure of fluffy fibre bundles with increased branch points 
when compared to control plasma-purified fibrinogen clots. Similarly, BII recombinant 
fibrinogen formed a clot with an atypical architecture with a more dense structure and 
more curved fibrin bundles than WT recombinant fibrinogen in LSCM preparation. EM 
showed fibrin fibres to be thinner in the recombinant BII fibrin clot than control, in line 
with plasma and plasma-purified data.  A unique observation relating to recombinant 
BII fibrinogen is the apparent retraction of the clot in the LSCM preparation 24 hr after 
clot formation. This may have important clinical implications as retraction of a thrombus 
may mean that the patient can have a late bleeding following an injury, in line with the 
thrombotic and bleeding tendency of the BII patient. 
In both purified and recombinant preparations, CFT was significantly longer in 
fibrinogen BII, explaining the tendency for bleeding in the patient. Prolongation of CFT 
by α2-AP in BII but not control/ WT further confirms the difference in the interaction of 
plasma proteins with the fibrinogen variants. The α2-AP seems to delay lysis enough in 
the BII in order for it to reach a higher MA, which suggests the clot is not fully formed 
when it begins to lyse in the absence of α2-AP whereas control/ WT clots are already 
fully formed by the time they lyse even without the presence of lysis inhibitors. The 
mechanisms behind this need further exploration, but differential thrombin binding/ 
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activity, impaired fibrinopeptide release and delayed FXIII crosslinking of fibrils are 
likely affected by the candidate mutations as discussed. 
Lysis of clots made from purified BII fibrinogen was slower than those of control 
in a purified system, conversely, in the same system, clots formed from recombinant 
BII fibrinogen lysed significantly faster when compared to WT. Together these purified 
and recombinant data mirror those in Chapter 4, which show an increase in lysis with 
the variant plasma-purified BβArg448Lys fibrinogen in the absence of other plasma 
proteins. This suggests the structure alone does not confer resistance or susceptibility 
to lysis, but the disparity in lysis rates may be due to impurities from plasma of the 
purified protein. Alternatively, since this recombinant protein is homozygous for the 
AαTrp334Cys/Asn335Tyr, unlike the heterozygous purified protein, it forms a more 
fragile clot due to the lack of wild-type fibrinogen molecules in the milieu. 
In the presence of α2-AP, lysis time was prolonged significantly more in clots 
made from fibrinogen BII than those of control/WT fibrinogen in both plasma-purified 
and recombinant systems This suggests that the interaction between the fibrin ultra-
structure and fibrinolytic plasma proteins between the variants confers resistance to 
lysis of the BII fibrinogen in the plasma environment, and that α2-AP is one of the main 
proteins in the blood responsible for this phenomenon. 
Western blot analysis revealed that although a small amount of a low molecular 
weight product picked up by the albumin antibody co-purified out of plasma with the BII 
fibrinogen, it was not bound to fibrinogen. This mirrored the interaction of albumin and 
BII fibrinogen in plasma samples, although there was albumin present in plasma, it was 
not bound to either control or BII fibrinogen. Expectedly, there was no albumin present 
in the BII or WT recombinant fibrinogen as it was not involved at any point in the growth 
or purification or preparation of the protein. This rules-out the possibility that increased 
albumin binding to the extra cysteine residue in BII fibrinogen accounts for the 
observed changes in clot structure and lysis. 
The amino acid residues affected by the candidate mutations of fibrinogen BII are 
both highly conserved residues in the αC domain of fibrinogen, which have a role in 
crosslinking during fibrin polymerisation26. Changes in binding of fibrinolytic modulators, 
altered clot structure and increased resistance to lysis have been linked to other 
mutations in this region. Molecular modelling of the effect of these substitutions could 
not go any further than guessing at secondary structure of this region of the protein due 
to its crystal structure not yet being defined due to the intrinsic flexibility of the αC 
domain of the fibrinogen molecule. Despite difficulties with lack of certainty of the 
structural context of this area, in collaboration with Mike Harrison (University of Leeds) 
we have made some effort to predict the effects of the mutations by looking at the 
characteristics of the residues. Internalisation of the hydrophobic tryptophan could be a 
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key factor in stabilizing the fold of a globular domain, or it could contribute to a 
hydrophobic patch on the surface involved in protein-protein interactions, however it is 
hard to determine which without some basic idea of the fold. Cysteine has the potential 
for forming aberrant disulfides that could impact on function.  At the most basic level, 
the indole side chain of tryptophan is large, rigid, planar and hydrophobic, whereas the 
cysteine side chain is smaller and essentially polar, which could cause a relatively 
simple packing (steric) effect. Asparagine to tyrosine substitution could have a number 
of impacts; asparagine is a good H-bond donor on a long side chain that is 
conformationally quite flexible, this allows it to H-bond back to the peptide backbone, 
effectively capping-off the main chain -NH to =OH-bonding that maintains secondary 
structures like alpha-helices, hence it often terminates these helices. In principle, this 
could impact on β-structures too, it tends to be found at turns so removal could cause 
disruption to the overall fold, but again overall context is important here. Tyrosine is 
also a good H-bonder, but the side chain can only rotorte about its bond to the alpha 
carbon, hence only forms "outward facing" bonds. In terms of polarity, Tyr is a little 
hydrophobic, but this is moderated by its -OH group, the side chain is relatively large 
though, and its lack of rotortional movement could have an impact on packing. 
Additionally, sulphation of tyrosine is quite common, which could lead to aberrant 
modification of the side chain that could affect function. These stark differences in the 
amino acid residues at these positions may explain why they have such a significant 
effect on the clotting of this fibrinogen. This is reflected in SIFT analysis suggesting 
both substitutions to be deleterious and Polyphen identifying the Trp334Cys change as 
possibly damaging. Changes in binding of fibrinolytic modulators, altered clot structure 
and increased resistance to lysis have been linked to other mutations in this region.  
It has been shown in some dysfibrinogenemia cases that changes in clot 
structure due to mutant fibrinogens compared to healthy controls are solely due to 
changes in fibrinogen levels as in Novy Jicin103. In this fibrinogen variant, diluting 
healthy controls plasma with TRIS buffer to the patients Clauss fibrinogen levels gave 
similar clot structure to those of control subjects, revealing differences in morphology of 
the fibrin network to be concentration dependent and independent of the substitution. In 
Novy Jicin dysfibrinogenemia, the mutant molecules are not found in the clot, which is 
made up solely of the subpopulation of wildtype homodimers even though both homo 
and heterodimers were present in the circulation. Despite the hypofibrinogenemia in 
Fibrinogen BII, alterations in clot structure were not related to quantitative but to 
qualitative changes in fibrinogen, as our purified and recombinant protein data clearly 
demonstrate. It is worth bearing in mind that my recombinant protein is homogenous 
for the polymorphism as the cell line set up is inherently homozygous for a transfected 
mutation; which means all recombinant fibrinogen molecules were homodimers. This 
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confirms that the mutant fibrinogen is capable of participating in clot formation, ruling 
out the patient’s hypofibrinogenemia as the sole cause for the changes in clotting. 
Fibrinopeptide A release has repeatedly been shown to be impaired by α-chain 
mutations by as much as 75% and fibrinopeptide B by up to 25% (notably the 
Aα16Arg-Cys (Novy Jicin) mutation). This is due to the inability of thrombin to cleave 
the altered arginine 16-glycine 17 peptide bond, essential for fibrinopeptide release and 
fibrin clot formation. This impaired cleavage of fibrinopeptide A results in delayed fibrin 
clot formation and unusual fibrin clot morphology. The candidate mutations in our 
patient lead to impaired fibrinogen polymerisation with a prolonged lag phase, 
decreased final turbidity and fibre thickness: changes in fibrinopeptide release caused 
by the mutations could go some way to explaining this, though further investigation is 
needed to confirm this. Since the candidate mutations lie in the αC domain, they most 
likely influence its structure and movement, in this way they could influence fpA release 
as the αC domain may interact differently with the central E domain of the fibrinogen 
molecule to which the fibrinopeptides are anchored. It is well established that the αC 
domain of fibrinogen plays a critical role in the lateral association of fibrin fibrils, 
constituting at least part of the fibrin molecule b polymerisation site, as it has been 
shown that fibrinogen molecules missing this region form polymers that produce clots 
made of thinner fibres and reduced turbidity35. This could also go some way to 
explaining the reduced turbidity and thinner fibres in our patient. 
Koopman and colleagues35 showed prolongation of lysis of fibrinogen Dusart to 
be due to reduced binding of Lys-plasminogen and defective tPA induced plasminogen 
activation. This dysfibrinogenemia, similarly, displays thinner fibres due to impaired 
lateral association of fibrin fibrils which they conclude are responsible for the changes 
in plasminogen binding and activation as it has been shown that inhibition of fibrin 
polymerisation reduces the acceleratory effect of fibrin on tPA induced plasminogen 
activation. This mechanism could have implications for fibrinogen BII due to the similar 
morphology of thin fibrin fibres and delayed fibrin polymerisation.  
In conclusion, we report a novel fibrinogen variant due to co-inheritance of two 
missense mutations in αC domain (AαTrp334Cys and AαAsn335Tyr).  This variant is 
associated with impaired clot formation, thin fibrin fibres and resistance to fibrinolysis in 
the plasma environment.  Our data using plasma-purified and recombinant fibrinogen 
confirm the mutations are directly responsible for the changes in clot structure, 
formation and lysis. Both Albumin binding to the variant fibrinogen and overall 
quantitative changes of the protein in the blood have been ruled out as mechanisms by 
which the BII fibrinogen has altered clotting parameters.  
These findings provide mechanistic explanations for the clinical presentation of 
our patient: The excessively low clot turbidity and thin fibres are consistent with less 
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robust clots predisposing to bleeding, confounded by the greater time take for clot 
formation. On the other hand, impaired fibrinolysis of clots made from BII fibrinogen 
may explain the increased thrombotic tendency in our patient.  
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Chapter 6. Summary and Conclusions 
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Clot formation is an essential physiological process to prevent blood loss upon 
vessel injury. However changes in various parameters involved in the clotting cascade 
can lead to pathological complications with serious clinical implications. Alterations in 
clot formation, morphology and lysis can increase risk of CVD and can result in 
irreversible end organ damage. Consequently it is important to understand the 
mechanisms behind the clotting process to elucidate the impact on atherothrombosis 
and CVD in the hope of developing preventative and therapeutic targets. 
Fibrinogen is essential in the blood clotting process, which upon conversion to 
fibrin, forms the skeleton of the blood clot. A large number of factors affect clot 
structure and fibrinolysis, which modulate predisposition to vascular occlusive events, 
and studies often ignore the possible effects of genetic alterations in fibrinogen when 
investigating fibrin-related thrombosis risk in multifactorial vascular occlusive 
conditions.  
On top of a genetic effect on clot structure, environmental factors can affect clot 
formation, morphology and lysis. Diabetes is a complex multifactorial condition in which 
both genetic and environmental factors play a role. It is associated with qualitative and 
quantitative changes in procoagulant and anti-fibrinolytic proteins leading to fibrin clots 
with tight network structure and resistance to lysis, consequently predisposing to a 
thrombotic environment and premature atherosclerosis. 
While a number of studies have investigated various fibrinogen mutations, the 
role of the common BβArg448Lys variants of fibrinogen in clinical disease was only 
partially characterised. In particular, the effects of this polymorphism on fibrin clot 
structure/function and predisposition to thrombosis in high risk subjects remained 
unclear. In other words, the effect of this common polymorphism on clot structure and 
vascular events in complex multifactorial pathological conditions is unknown. Moreover, 
the mechanisms by which these genetic variants of fibrinogen cause alterations in clot 
structure were not defined. In contrast to the common BβArg448Lys substitution, a rare 
genetic mutation (AαTrp334Cys/Asn335Tyr) in the α-chain of fibrinogen has been 
found in an individual with unusual phenotype that includes both bleeding and 
thrombotic tendencies. It was unclear, however, whether this rare genetic mutation was 
directly responsible for the clinical picture in this individual.   
Therefore the three main aims of this work were to; i) identify any additional effect 
of BβArg448Lys on fibrin network in a complex multifactorial disease with increased 
vascular risk such as T2DM, ii) study the mechanisms behind the effects of the 
BβArg448Lys mutation on fibrin clot structural and functional properties and iii) 
investigate the role of fibrinogen AαTrp334Cys/Asn335Tyr on clot structure and lysis 
and its potential responsibility for abnormal patient symptoms. 
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Diabetes and BβArg448Lys polymorphism 
In the clinical part of this work, we have shown that Bβ448Lys has an effect on 
fibrin clot structure and fibrinolysis in people with type 2 diabetes. In addition we 
suggest these changes may add to an already increased level of vascular risk in 
diabetes. 
 
Figure 6-1. The effect of BβArg448Lys fibrinogen on the structure and lysis of 
fibrin clots and risk of vascular events in patients with T2DM 
When compared to Bβ448Arg, Bβ448Lys leads to formation of clots with a more dense 
structure with thinner fibres and an increased resistance to lysis independent of the 
increased fibrinogen levels in this variant. This may lead to increased vascular risk 
leading to early mortality in this patient group. Increased fibrinogen levels are not 
directly related to the polymorphism but secondary to linkage disequilibrium with 
another polymorphism in fibrinogen that controls protein levels.  
 
The observation that clots prepared from plasma of T2DM individuals with 
Bβ448Lys were more compact and more resistant to lysis indicates a more thrombotic 
environment in these individuals when compared to carriers of Bβ448Arg. A direct role 
of the polymorphism in this resistance to fibrinolysis was suggested by the fact that the 
significant difference in plasma lysis time remained after adjustment for the higher 
fibrinogen levels in these patients. Interestingly, a greater impact of environmental or 
alternative genetic factors on fibrinogen levels in men with diabetes was indicated by 
the observation that the difference in fibrinogen levels between the BβArg448Lys 
variants was only significant in women.  
To explore the role of BβArg448Lys on clot structure, and the influence of the 
disparity in fibrinogen levels between the variants, I controlled for fibrinogen levels 
using plasma-purified protein and show similar differences in clot density between the 
BβArg448Lys variants. The increasing clot density of Arg/Lys and Lys/Lys fibrin clots, 
173 
 
demonstrates that Bβ448Lys is associated with more compact clots and thinner fibrin 
fibres, confirming the direct role of the polymorphism on fibrin network structure. 
Similarly, the stepwise increase in lysis time in clots made from Arg/Arg, Arg/Lys and 
Lys/Lys fibrinogen directly implicates the polymorphism in altered clot lysis in diabetes. 
One possible explanation for these findings may be related to reduced lateral 
aggregation due to the failure of αC dissociation caused by Bβ448Lys, resulting in a 
greater density of thinner fibres, which interact with plasma proteins, prolonging lysis 
time . Alternatively we suggest a differential post-translational modification between the 
BβArg448Lys variants affecting clot structure and fibrinolysis. Most likely glycation or 
oxidation of the Bβ448Lys fibrinogen occurs resulting in altered clot morphology and 
lysis, particularly as lysine residues are amenable to such modifications. Though the 
mechanisms by which BβArg448Lys affect clot structure and lysis in T2DM are as yet 
unclear, we have identified a definitive mechanistic role of the polymorphism and 
shown that the changes in fibrinogen levels elicited by the BβArg448Lys substitution do 
not explain the difference 
Exploring the possible effects of BβArg448Lys variants on previous 
cardiovascular events, we discovered a predictive effect of BβArg448Lys on vascular 
risk, revealing Bβ448Lys variant to be associated with a history of cerebrovascular 
disease. This finding gives further weight to the suggestion that this polymorphism 
adds to the thrombotic environment already present in diabetes. Of particular interest in 
this observation is the fact that the association was only significant in women, mirroring 
a similar association between this polymorphism and cerebrovascular disease in non-
diabetic women101. Furthermore, the identification of an age difference between the 
BβArg448Lys variants, with mean age of Bβ448Lys carriers lower compared to 
Bβ448Arg (and of note, only in women), leads to speculation that mortality is increased 
in individuals with this genotype through predisposition to a thrombotic environment, an 
effect that may be gender-specific. In further support of a gender-specific association 
between this polymorphism and vascular pathology is the lower ABI in women carrying 
Bβ448Lys variant of fibrinogen.  
From this part of the work we make a number of novel observations: i) Carriers of 
Bβ448Lys variant of fibrinogen display compact plasma fibrin clots and impaired 
fibrinolysis compared with Bβ448Arg even in complex multifactorial conditions, ii) the 
polymorphism plays a direct role in the changes observed with plasma clots and iii) 
carriers of Bβ448Lys variant are younger, suggesting early mortality in this group, 
which may be gender specific and attributable to increased vascular disease.  
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BβArg448Lys and altered clot structure: potential mechanisms  
To further characterise the interaction between BβArg448Lys fibrinogen, clot 
structure and fibrinolysis, I produced recombinant protein to isolate ‘pure’ fibrinogen, 
removing the possibility of other alterations of the molecule that could affect its 
behaviour (e.g. additional genetic modification, protein level, co-purification 
contaminants). 
These data using recombinant fibrinogen showed similar differences in clot 
structure between Bβ448Arg and Bβ448Lys variants, confirming recombinant 
Bβ448Lys fibrin is made of thinner fibres and a more compact structure than 
Bβ448Arg. Analysis of the possible mechanisms behind this change in structure by 
molecular modelling found the BβArg448Lys substitution could lead to weakening or 
loss of hydrogen bonds close to the b-site, and in the coiled-coil structure, as well as 
causing increased mobility of residues in the B-b interaction site. These changes likely 
affect fibrin polymerisation and final clot ultra-structure as they are all regions proposed 
to be involved in lateral aggregation, via B-b and αC domain interactions102. 
 
The relationship between clot structure and fibrinolysis 
Previous work suggested a direct interaction between clot structure and lysis23. 
However, analysing lysis of clots formed from the BβArg448Lys variants, a difference in 
clot lysis between the two variants was only evident in the presence of anti-fibrinolytic 
proteins, with equivalent lysis times seen between the variants in their absence. We 
postulate that there is a delicate balance between the number of fibres in the clot, fibre 
thickness, porosity of the clot and plasmin generation which controls the lysis rates of 
these clots. 
In this proposed model, in the absence of other plasma proteins, the increased 
number of thin fibres of the Bβ448Lys clot lyse at a faster rate at the level of individual 
fibres than the thick fibres of Bβ448Arg. This evens out the disparity in fibre number102, 
having a neutral effect on fibrinolytic activity. In addition, an anti-fibrinolytic influence on 
the Bβ448Lys clot comes from the decreased distribution, movement and binding of 
fibrinolytic components through the fibrin network due to the decreased porosity of the 
clot. Finally, an initial increase in plasmin generation in Bβ448Lys enhances fibrinolytic 
activity, possibly attributable to the increased density of fibres in the Bβ448Lys clot 
providing more binding sites for plasminogen at the lysis front, where it is most rapidly 
converted to plasmin by tPA. In this system, the pro-fibrinolytic influence of increased 
plasmin generation is balanced by the anti-fibrinolytic influence of the decreased clot 
permeability (Figure 6-2). On the other hand, clots made from purified fibrinogen of 
diabetes patients showed longer lysis time in Lys/Lys compared with Arg/Lys variant. 
This may have been due to different post-translational modification in diabetes or 
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contamination with plasma proteins that were not visualised on SDS-PAGE gel (further 
discussed below). 
 
 
Figure 6-2. Mechanisms behind similarity in lysis times between BβArg448Lys 
fibrinogen variants in a purified system 
In the absence of fibrinolytic inhibitory proteins, the decreased movement of fibrinolytic 
proteins through the clot is balanced by in increased plasmin generation 
 
Interactions between clot structure and α2-AP: role in fibrinolytic efficiency 
When studied in a system more akin to that in-vivo, our data show significantly 
greater prolongation of lysis in the presence of α2-AP of clots made from recombinant 
Bβ448Lys than Bβ448Arg fibrinogen, implicating the interaction of clot structure and 
plasma proteins in the difference in lysis times between the variant fibrins. This may 
also explain the data with purified fibrinogen from diabetes subjects as small amounts 
of plasma proteins (e.g. α2-AP) could have co-purified with the fibrinogen.  
Our data identifies α2-AP as one of the main factors responsible for this 
prolongation in lysis, as well as the disparity in lysis rates between the BβArg448Lys 
variants in the plasma environment previously observed by our group102. This can be 
explained by the same model as above, in which the increased number of Bβ448Lys 
fibrin fibres being lysed at a faster rate at the level of individual fibres has a neutral 
effect on fibrinolytic activity. Similarly, the anti-fibrinolytic influence on the Bβ448Lys 
clot of the decreased porosity of the thin fibred clot is still at work. The difference 
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identified in this system is in the plasmin generation between the BβArg448Lys 
variants, which becomes equivalent in the presence of α2-AP. These data indicate α2-
AP has a greater effect on the initially enhanced plasmin generation in the Bβ448Lys 
variant, the mechanisms of which may mirror that of plasminogen and tPA discussed 
above; the increased surface area of the Bβ448Lys fibrin clot could provide more 
binding sites for α2-AP, allowing it to exert a greater effect on both resistance to lysis 
and conversion of plasminogen to plasmin by tPA. Consequently, in this system with 
α2-AP, the pro-fibrinolytic influence of increased plasmin generation in Bβ448Lys is 
removed and thus the anti-fibrinolytic influence of the decreased clot permeability 
prevails causing the Bβ448Lys variant to lyse slower (Figure 6-3). The effect of 
BβArg448Lys variant on plasmin generation and lysis rate are summarised in   
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Table 6-1. 
 
Figure 6-3. Mechanisms behind differences in lysis times between BβArg448Lys 
fibrinogen variants in a purified system with α2-AP 
In the presence of α2-AP, plasmin generation is equivalent between BβArg448Lys 
fibrinogen variants so the inhibitory effect of decreased porosity of the Bβ448Lys clot 
on lysis is not balanced out. 
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Table 6-1. The effect of BβArg448Lys allele on plasmin generation and lysis rate 
in the presence and absence of α2-AP 
 
 
 
 
 
 
Analysing the interaction between α2-AP and the BβArg448Lys variants revealed 
some unexpected data; despite the differences in the effect of α2-AP between the 
variants, the rate and amount of incorporation of the protein by FXIIII into the fibrin 
network did not differ between Bβ448Arg448Lys variants. Given the equivalent 
incorporation of α2-AP between the variants in crosslinking assay analysis, we suggest 
the protein is incorporated to the same degree between the BβArg448Lys variants, 
ruling out quantitative changes in α2-AP as a mechanism by which lysis is prolonged in 
Bβ448Lys variant. We suggest differences in lysis are due to a different structural 
arrangement or interaction of the α2-AP between the two Bβ448 variants whereby α2-
AP may be incorporated more tightly into the fibrin fibres of the Bβ448Lys variant, or 
embedded deeper in the fibre. This concept is supported by the confocal data that 
showed fluorescent α2-AP to only be detected in clots formed from Bβ448Arg, and not 
Bβ448Lys fibrinogen. 
These recombinant data lead to the conclusion that the fibrin network structure 
plays an important role in conferring a much greater resistance to lysis/ plasmin activity 
of clots formed from thin fibres with a compact structure, most likely due to the 
difference in porosity and permeability of the clots to fibrinolytic components. Together 
the data suggest that α2-AP is crosslinked to BβArg448Lys fibrin variants to a similar 
extent. However, the structural conformation of these binding and crosslinking 
interactions is markedly different, such that an initial increase in plasmin activity in the 
absence of α2-AP, eliciting similar lysis rates between the variants due to the inherent 
increased resistance to lysis of the Bβ448Lys clot, is normalised in the presence of α2-
AP. This results in an increased resistance to lysis of the Bβ448Lys fibrin in the 
presence of α2-AP. It follows that α2-AP has a more marked effect on plasmin 
generation in the Bβ448Lys clot, and this may be because of the mentioned difference 
in conformation of the interaction between α2-AP and the two BβArg448Lys fibrin 
variants. 
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AαTrp334Cys/Asn335Tyr and clot structure and lysis 
Plasma clots made from an individual with double mutation in the α-chain of 
fibrinogen (AαTrp334Cys/Asn335Tyr) showed impaired clot formation, with a fibrin 
network of densely packed thin fibres, increased branch points, forming a bizarre fluffy 
structure rather than defined fibre bundles. This structure may account, at least in part, 
for the clinical presentation of both a thrombotic and bleeding tendency. However, this 
did not prove that the mutation was the direct cause of change in structure and 
therefore I undertook further studies using purified and recombinant fibrinogen. The 
direct role of the amino acid substitutions in altered clot morphology were confirmed 
when clots made from plasma-purified and recombinant BII fibrinogen were studied 
showing a similar architecture to that in plasma.  
Analysis of fibrinolysis of Fibrinogen BII revealed prolonged lysis time in clots 
made from fibrinogen BII when compared to those of control/WT fibrinogen in the 
presence of α2-AP, explaining the thrombotic phenotype of the patient. This finding 
indicates the interaction between the fibrin ultra-structure and fibrinolytic plasma 
proteins between the variants confers resistance to lysis of the BII fibrinogen in the 
plasma environment, and that α2-AP is one of the main proteins in the blood 
responsible for this phenomenon. 
Furthermore, detection of retraction of the recombinant BII clot may have 
important clinical implications as retraction of a thrombus may cause the patient to 
have a late bleed following an injury, in line with the thrombotic and bleeding tendency 
of the BII patient. Moreover, the increased clot formation time of Fibrinogen BII may 
also have important implications for the tendency for bleeding.  
Despite the hypofibrinogenemia in Fibrinogen BII, alterations in clot structure 
were not related to quantitative but to qualitative changes in fibrinogen, as our purified 
and recombinant protein data clearly demonstrate. Furthermore, the homogenous 
nature of my recombinant protein confirms that the mutant fibrinogen is capable of 
participating in clot formation, ruling out the patient’s hypofibrinogenemia as the sole 
cause for the changes in clotting. 
The mechanisms by which the BII substitutions affect clot structure and lysis 
remain unclear. However, the two substitutions are both highly conserved residues in 
the αC domain of fibrinogen, an area in which other mutations have displayed changes 
in binding of fibrinolytic modulators, altered clot structure and increased resistance to 
lysis. These fibrinogen αC domain alterations have been linked to impaired 
fibrinopeptide release and disruption of the b-polymerisation site which lead to delayed 
fibrin clot formation and unusual fibrin clot morphology as well as impaired lateral 
aggregation and thus clots with thinner fibres. These mechanisms could go some way 
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to explain the prolonged lag phase and decreased final turbidity and fibre thickness in 
Fibrinogen BII.  
The mechanisms behind prolongation in lysis may mirror those of fibrinogen 
Dusart35 which was shown to support reduced plasminogen binding and activation due 
to the thinner fibres as inhibition of fibrin polymerisation reduces the acceleratory effect 
of fibrin on tPA induced plasminogen activation. Potential mechanisms for the bleeding 
and thrombotic phenotype of the Fibrinogen BII patient are described in Figure 6-4. 
 
 
Figure 6-4. Explanations for clinical presentation of bleeding and thrombosis of 
Fibrinogen Birmingham II patient 
Decreased lateral aggregation, FXIII crosslinking and FpA & B release may explain 
decreased MA, CFT and fibre thickness as well as clot retraction, leading to the 
bleeding presentation. Decreased plasminogen binding and tPA induced plasminogen 
activation may explain increased lysis time, leading to the thrombotic phenotype.  
 
To conclude this part of my work, we confirm the changes caused by the 
fibrinogen BII variant are likely to be responsible for the clinical presentation of bleeding 
and thrombosis in our patient.  Our data prove the mutations play a direct role in 
changes in clot structure, formation and lysis, providing mechanistic explanations for 
the clinical presentation of our patient: The excessively low clot turbidity and thin fibres 
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are consistent with less robust clots predisposing to bleeding, confounded by the 
greater time taken for clot formation and clot retraction, whereas impaired fibrinolysis 
may explain the increased thrombotic tendency.  
 
To summarise, studying the BβArg448Lys polymorphism in T2DM, I found 
Bβ448Lys has an additional effect on fibrin clot structure and fibrinolysis in these 
patients which may add to an already increased level of vascular risk in diabetes. 
Examining the same polymorphism in a recombinant system, I found differences in 
lysis between BβArg448Lys variants in the plasma environment are attributable to the 
interplay between permeability of the clot, the fibrin-α2-AP interaction and plasmin 
generation. Furthermore, looking at the so far unique fibrinogen BII dysfibrinogenemia, 
I established AαTrp334Cys/Asn335Tryr substitutions are directly responsible for 
changes in clot structure, formation and lysis, providing mechanistic explanations for 
the bleeding and thrombotic clinical presentation of our patient. 
 
Future work 
In relation to the work in patients with T2DM, investigation into the effect of 
BβArg448Lys on vascular risk revealed Bβ448Lys variant was associated with a history 
of cerebrovascular disease in women. A similar association between this polymorphism 
and cerebrovascular disease in non-diabetic women was documented before and 
therefore this finding merits further investigation. This can only be done using 
longitudinal prospective studies which should concentrate on the dichotomy of vascular 
risk in males and females and role of SNPs in complex clinical conditions, this could 
identify high risk patient groups and give the opportunity to provide more targeted 
therapeutic interventions.  
While important associations between clot structure and lysis have been shown 
in this work, further studies are needed to address the mechanisms behind differences 
in clot formation and consequently those by which clot structure governs lysis rates. 
The work on recombinant BβArg448Lys and AαTrp334Cys/Asn335Tryr protein has 
opened up a number of opportunities to further study the molecular mechanisms 
surrounding fibrin clot formation and lysis, including interaction with plasma proteins. 
Firstly, it is important to elucidate the mechanisms by which the fibrin fibres differ 
structurally between BβArg448Lys and AαTrp334Cys/Asn335Tryr variants which will 
clarify the effect these substitutions have on the structure and function of the fibrinogen 
molecule and consequently aid the direction of work on the disparity in lysis rates 
between the variants. AFM analysis of the protofibril formation would be valuable in this 
study, however due to the flaws of this technique, alternative approaches such as real 
time confocal and sequential EM may be of value in future work. 
A 
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While analysis of the AαTrp334Cys/Asn335Tryr substitutions in the fibrinogen BII 
patient has confirmed their responsibility for the clinical presentation of our patient, 
future work should focus on the mechanisms behind altered clot formation time, 
structure and lysis. Crystallisation of the flexible portion of the αC domain to determine 
its structure may aid these studies and production of recombinant fibrinogen with only 
one of the substitutions could identify if either one is causing the effect on fibrin 
behaviour, or if both are required for this phenotype.  
Perhaps most importantly, a large study is warranted to clarify the mechanisms 
behind resistance to lysis of clots made of thinner fibres that are more compact. The 
observation that plasminogen activity is increased in the presence of clots made of thin 
fibres requires further investigation, especially given the discrepancy with previous 
studies that contradict our data. This and the increased lysis time in the presence of 
FXIII when α2-AP is present merit future investigation of the complex interactions 
between BβArg448Lys, clot structure, plasmin generation, FXIII cross-linking, α2-AP 
and lysis rates. Further characterisation of the binding and crosslinking of α2-AP to 
fibres of differing diameters and/ or BβArg448Lys variants in a full clot based system, 
alongside investigation of the structural conformation of the α2-AP-fibrin interaction, 
would help to ascertain the effect α2-AP has in these preparations. 
Lastly, in both BβArg448Lys and AαTrp334Cys/Asn335Tyr variants, lysis of clots 
made from variant plasma-purified fibrinogen was slower than those of control in a 
purified system in the absence of other anti-fibrinolytic plasma proteins. Conversely, in 
the same system, clots formed from recombinant fibrinogen lysed at equivalent rates 
(Bβ448Lys) or faster (Aα334Cys/335Tyr) when compared to WT. This disparity in lysis 
rates warrants further investigation to investigate the possibility of impurities from 
plasma of the purified protein and/ or posttranslational modifications. 
Though this study has provided valuable insight into clot formation and lysis, 
improvement and development of new techniques could greatly enhance the clinical 
applicability of the knowledge gained. Whilst turbidimetric techniques used in this work 
have the advantage of studying clot formation and lysis as a dynamic process, this 
system does not take into account other factors that affect coagulation such as 
platelets and blood flow. Techniques to visualise the clot (EM and LSCM), whilst 
providing both high resolution and hydrated conditions respectively, also fail to 
represent these in-vivo conditions. Development of a flow model to study all these 
components together would thus be greatly beneficial to this field of research. 
The lack of a reliable technique to assess binding/crosslinking of α2-AP to fibrin 
was a severe drawback to this work. Whilst the plate based FXIII crosslinking assays 
hold merit in their reproducibility, they have the limitation that although fibrin is formed 
(arguably more relevant than un-polymerised fibrinogen) it is formed on a surface, 
183 
 
which does not represent the in-vivo environment fully. Whilst this problem is overcome 
in FXIII crosslinking gels, these have the drawback of poor reproducibility and an 
element of subjectivity. Though attempts were made to produce a method by which α2-
AP incorporation could be assessed in a full clot, these were unsuccessful. LSCM 
analysis, whilst promising, proved complicated due to the lack of α2-AP signal detected 
in the Bβ448Lys preparations. Furthermore an ELISA to measure α2-AP incorporation 
by assessing α2-AP concentration in the clotting reaction and subsequent clot 
supernatant was complicated by the fragility of the recombinant and plasma-purified 
fibrin clot. It would thus be beneficial to develop a technique by which this could be 
assessed, perhaps by ELISA of a formed clot, or radioactive assay with labelled α2-AP. 
 
 
  
184 
 
 
References 
 
(1)  Ajjan R, Grant PJ. Coagulation and atherothrombotic disease. Atherosclerosis 
2006 June;186(2):240-59. 
(2)  Knighton DR, Ciresi KF, Fiegel VD, Austin LL, Butler EL. Classification and 
treatment of chronic nonhealing wounds. Successful treatment with autologous 
platelet-derived wound healing factors (PDWHF). Ann Surg 1986 
September;204(3):322-30. 
(3)  Wolberg AS. Thrombin generation and fibrin clot structure. Blood Rev 2007 
May;21(3):131-42. 
(4)  Ajjan RA, Standeven KF, Khanbhai M, Phoenix F, Gersh KC, Weisel JW, 
Kearney MT, Ariens RA, Grant PJ. Effects of aspirin on clot structure and fibrinolysis 
using a novel in vitro cellular system. Arterioscler Thromb Vasc Biol 2009 
May;29(5):712-7. 
(5)  Schaller J, Gerber SS. The plasmin-antiplasmin system: structural and 
functional aspects. Cell Mol Life Sci 2011 March;68(5):785-801. 
(6)  Huntington JA, Read RJ, Carrell RW. Structure of a serpin-protease complex 
shows inhibition by deformation. Nature 2000 October 19;407(6806):923-6. 
(7)  Wang H, Pap S, Wiman B. Inactivation of antiplasmin at low pH: evidence for 
the formation of latent molecules. Thromb Res 2004;114(4):301-6. 
(8)  Fuss C, Palmaz JC, Sprague EA. Fibrinogen: structure, function, and surface 
interactions. J Vasc Interv Radiol 2001 June;12(6):677-82. 
(9)  Mosesson MW, Finlayson JS, Galanakis DK. The essential covalent structure of 
human fibrinogen evinced by analysis of derivatives formed during plasmic hydrolysis. 
J Biol Chem 1973 November 25;248(22):7913-29. 
(10)  Zhang JZ, Redman C. Fibrinogen assembly and secretion. Role of intrachain 
disulfide loops. J Biol Chem 1996 November 22;271(47):30083-8. 
(11)  Henschen A, Lottspeich F, Kehl M, Southan C. Covalent structure of fibrinogen. 
Ann N Y Acad Sci 1983 June 27;408:28-43. 
(12)  Acuna AU, Gonzalez-Rodriguez J, Lillo MP, Naqvi KR. Protein structure probed 
by polarization spectroscopy. II. A time-resolved fluorescence study of human 
fibrinogen. Biophys Chem 1987 April;26(1):63-70. 
(13)  Wolfenstein-Todel C, Mosesson MW. Human plasma fibrinogen heterogeneity: 
evidence for an extended carboxyl-terminal sequence in a normal gamma chain variant 
(gamma'). Proc Natl Acad Sci U S A 1980 September;77(9):5069-73. 
(14)  Huang S, Mulvihill ER, Farrell DH, Chung DW, Davie EW. Biosynthesis of 
human fibrinogen. Subunit interactions and potential intermediates in the assembly. J 
185 
 
Biol Chem 1993 April 25;268(12):8919-26. 
(15)  Scheraga HA. The thrombin-fibrinogen interaction. Biophys Chem 2004 
December 20;112(2-3):117-30. 
(16)  Doolittle RF. Structural basis of the fibrinogen-fibrin transformation: 
contributions from X-ray crystallography. Blood Rev 2003 March;17(1):33-41. 
(17)  Carr ME, Jr., Qureshi GD. The impact of delayed fibrinopeptide-A release on 
fibrin structure. Studies of an abnormal fibrinogen. J Biol Chem 1987 November 
15;262(32):15568-74. 
(18)  Medved' LV, Gorkun OV, Manyakov VF, Belitser VA. The role of fibrinogen 
alpha C-domains in the fibrin assembly process. FEBS Lett 1985 February 
11;181(1):109-12. 
(19)  Collet JP, Moen JL, Veklich YI, Gorkun OV, Lord ST, Montalescot G, Weisel 
JW. The alphaC domains of fibrinogen affect the structure of the fibrin clot, its physical 
properties, and its susceptibility to fibrinolysis. Blood 2005 December 1;106(12):3824-
30. 
(20)  Rixon MW, Chan WY, Davie EW, Chung DW. Characterization of a 
complementary deoxyribonucleic acid coding for the alpha chain of human fibrinogen. 
Biochemistry 1983 June 21;22(13):3237-44. 
(21)  Chung DW, Que BG, Rixon MW, Mace M, Jr., Davie EW. Characterization of 
complementary deoxyribonucleic acid and genomic deoxyribonucleic acid for the beta 
chain of human fibrinogen. Biochemistry 1983 June 21;22(13):3244-50. 
(22)  Chung DW, Chan WY, Davie EW. Characterization of a complementary 
deoxyribonucleic acid coding for the gamma chain of human fibrinogen. Biochemistry 
1983 June 21;22(13):3250-6. 
(23)  Collet JP, Park D, Lesty C, Soria J, Soria C, Montalescot G, Weisel JW. 
Influence of fibrin network conformation and fibrin fiber diameter on fibrinolysis speed: 
dynamic and structural approaches by confocal microscopy. Arterioscler Thromb Vasc 
Biol 2000 May;20(5):1354-61. 
(24)  Longstaff C, Thelwell C, Williams SC, Silva MM, Szabo L, Kolev K. The 
interplay between tissue plasminogen activator domains and fibrin structures in the 
regulation of fibrinolysis: kinetic and microscopic studies. Blood 2011 January 
13;117(2):661-8. 
(25)  Kroll MH, Hellums JD, McIntire LV, Schafer AI, Moake JL. Platelets and shear 
stress. Blood 1996 September 1;88(5):1525-41. 
(26)  Siebenlist KR, Mosesson MW. Factors affecting gamma-chain multimer 
formation in cross-linked fibrin. Biochemistry 1992 January 28;31(3):936-41. 
(27)  Muszbek L, Yee VC, Hevessy Z. Blood coagulation factor XIII: structure and 
function. Thromb Res 1999 June 1;94(5):271-305. 
186 
 
(28)  Tsurupa G, Yakovlev S, McKee P, Medved L. Noncovalent interaction of 
alpha(2)-antiplasmin with fibrin(ogen): localization of alpha(2)-antiplasmin-binding sites. 
Biochemistry 2010 September 7;49(35):7643-51. 
(29)  Muszbek L, Bereczky Z, Bagoly Z, Komaromi I, Katona E. Factor XIII: a 
coagulation factor with multiple plasmatic and cellular functions. Physiol Rev 2011 
July;91(3):931-72. 
(30)  Collet JP, Shuman H, Ledger RE, Lee S, Weisel JW. The elasticity of an 
individual fibrin fiber in a clot. Proc Natl Acad Sci U S A 2005 June 28;102(26):9133-7. 
(31)  Weisel JW. The mechanical properties of fibrin for basic scientists and 
clinicians. Biophys Chem 2004 December 20;112(2-3):267-76. 
(32)  Brown AE, Litvinov RI, Discher DE, Purohit PK, Weisel JW. Multiscale 
mechanics of fibrin polymer: gel stretching with protein unfolding and loss of water. 
Science 2009 August 7;325(5941):741-4. 
(33)  Averett LE, Schoenfisch MH, Akhremitchev BB, Gorkun OV. Kinetics of the 
multistep rupture of fibrin 'A-a' polymerization interactions measured using atomic force 
microscopy. Biophys J 2009 November 18;97(10):2820-8. 
(34)  Falvo MR, Millard D, O'Brien ET, III, Superfine R, Lord ST. Length of tandem 
repeats in fibrin's alphaC region correlates with fiber extensibility. J Thromb Haemost 
2008 November;6(11):1991-3. 
(35)  Koopman J, Haverkate F, Grimbergen J, Lord ST, Mosesson MW, DiOrio JP, 
Siebenlist KS, Legrand C, Soria J, Soria C, . Molecular basis for fibrinogen Dusart (A 
alpha 554 Arg-->Cys) and its association with abnormal fibrin polymerization and 
thrombophilia. J Clin Invest 1993 April;91(4):1637-43. 
(36)  Ariens RA, Philippou H, Nagaswami C, Weisel JW, Lane DA, Grant PJ. The 
factor XIII V34L polymorphism accelerates thrombin activation of factor XIII and affects 
cross-linked fibrin structure. Blood 2000 August 1;96(3):988-95. 
(37)  Takagi T, Doolittle RF. Amino acid sequence studies on factor XIII and the 
peptide released during its activation by thrombin. Biochemistry 1974 February 
12;13(4):750-6. 
(38)  Robinson BR, Houng AK, Reed GL. Catalytic life of activated factor XIII in 
thrombi. Implications for fibrinolytic resistance and thrombus aging. Circulation 2000 
September 5;102(10):1151-7. 
(39)  Valnickova Z, Enghild JJ. Human procarboxypeptidase U, or thrombin-activable 
fibrinolysis inhibitor, is a substrate for transglutaminases. Evidence for 
transglutaminase-catalyzed cross-linking to fibrin. J Biol Chem 1998 October 
16;273(42):27220-4. 
(40)  Ritchie H, Robbie LA, Kinghorn S, Exley R, Booth NA. Monocyte plasminogen 
activator inhibitor 2 (PAI-2) inhibits u-PA-mediated fibrin clot lysis and is cross-linked to 
187 
 
fibrin. Thromb Haemost 1999 January;81(1):96-103. 
(41)  Bale MD, Westrick LG, Mosher DF. Incorporation of thrombospondin into fibrin 
clots. J Biol Chem 1985 June 25;260(12):7502-8. 
(42)  Sane DC, Moser TL, Pippen AM, Parker CJ, Achyuthan KE, Greenberg CS. 
Vitronectin is a substrate for transglutaminases. Biochem Biophys Res Commun 1988 
November 30;157(1):115-20. 
(43)  Bendixen E, Borth W, Harpel PC. Transglutaminases catalyze cross-linking of 
plasminogen to fibronectin and human endothelial cells. J Biol Chem 1993 October 
15;268(29):21962-7. 
(44)  Mosher DF. Cross-linking of cold-insoluble globulin by fibrin-stabilizing factor. J 
Biol Chem 1975 August 25;250(16):6614-21. 
(45)  Mosher DF, Schad PE. Cross-linking of fibronectin to collagen by blood 
coagulation Factor XIIIa. J Clin Invest 1979 September;64(3):781-7. 
(46)  Barry EL, Mosher DF. Factor XIII cross-linking of fibronectin at cellular matrix 
assembly sites. J Biol Chem 1988 July 25;263(21):10464-9. 
(47)  Prince CW, Dickie D, Krumdieck CL. Osteopontin, a substrate for 
transglutaminase and factor XIII activity. Biochem Biophys Res Commun 1991 June 
28;177(3):1205-10. 
(48)  Bockenstedt P, McDonagh J, Handin RI. Binding and covalent cross-linking of 
purified von Willebrand factor to native monomeric collagen. J Clin Invest 1986 
August;78(2):551-6. 
(49)  Hada M, Kaminski M, Bockenstedt P, McDonagh J. Covalent crosslinking of 
von Willebrand factor to fibrin. Blood 1986 July;68(1):95-101. 
(50)  Cohen I, Young-Bandala L, Blankenberg TA, Siefring GE, Jr., Bruner-Lorand J. 
Fibrinoligase-catalyzed cross-linking of myosin from platelet and skeletal muscle. Arch 
Biochem Biophys 1979 January;192(1):100-11. 
(51)  Inbal A, Lubetsky A, Krapp T, Castel D, Shaish A, Dickneitte G, Modis L, 
Muszbek L, Inbal A. Impaired wound healing in factor XIII deficient mice. Thromb 
Haemost 2005 August;94(2):432-7. 
(52)  Brown LF, Lanir N, McDonagh J, Tognazzi K, Dvorak AM, Dvorak HF. 
Fibroblast migration in fibrin gel matrices. Am J Pathol 1993 January;142(1):273-83. 
(53)  Grinnell F, Feld M, Minter D. Fibroblast adhesion to fibrinogen and fibrin 
substrata: requirement for cold-insoluble globulin (plasma fibronectin). Cell 1980 
February;19(2):517-25. 
(54)  Dardik R, Krapp T, Rosenthal E, Loscalzo J, Inbal A. Effect of FXIII on 
monocyte and fibroblast function. Cell Physiol Biochem 2007;19(1-4):113-20. 
(55)  Sarvary A, Szucs S, Balogh I, Becsky A, Bardos H, Kavai M, Seligsohn U, 
Egbring R, Lopaciuk S, Muszbek L, Adany R. Possible role of factor XIII subunit A in 
188 
 
Fcgamma and complement receptor-mediated phagocytosis. Cell Immunol 2004 
April;228(2):81-90. 
(56)  Dardik R, Solomon A, Loscalzo J, Eskaraev R, Bialik A, Goldberg I, Schiby G, 
Inbal A. Novel proangiogenic effect of factor XIII associated with suppression of 
thrombospondin 1 expression. Arterioscler Thromb Vasc Biol 2003 August 
1;23(8):1472-7. 
(57)  Asahina T, Kobayashi T, Takeuchi K, Kanayama N. Congenital blood 
coagulation factor XIII deficiency and successful deliveries: a review of the literature. 
Obstet Gynecol Surv 2007 April;62(4):255-60. 
(58)  Kobayashi T, Terao T, Kojima T, Takamatsu J, Kamiya T, Saito H. Congenital 
factor XIII deficiency with treatment of factor XIII concentrate and normal vaginal 
delivery. Gynecol Obstet Invest 1990;29(3):235-8. 
(59)  Asahina T, Kobayashi T, Okada Y, Goto J, Terao T. Maternal blood coagulation 
factor XIII is associated with the development of cytotrophoblastic shell. Placenta 2000 
May;21(4):388-93. 
(60)  Nahrendorf M, Hu K, Frantz S, Jaffer FA, Tung CH, Hiller KH, Voll S, Nordbeck 
P, Sosnovik D, Gattenlohner S, Novikov M, Dickneite G, Reed GL, Jakob P, 
Rosenzweig A, Bauer WR, Weissleder R, Ertl G. Factor XIII deficiency causes cardiac 
rupture, impairs wound healing, and aggravates cardiac remodeling in mice with 
myocardial infarction. Circulation 2006 March 7;113(9):1196-202. 
(61)  AbdAlla S, Lother H, Langer A, el FY, Quitterer U. Factor XIIIA 
transglutaminase crosslinks AT1 receptor dimers of monocytes at the onset of 
atherosclerosis. Cell 2004 October 29;119(3):343-54. 
(62)  Lucas MA, Fretto LJ, McKee PA. The binding of human plasminogen to fibrin 
and fibrinogen. J Biol Chem 1983 April 10;258(7):4249-56. 
(63)  Christensen U, Bangert K, Thorsen S. Reaction of human alpha2-antiplasmin 
and plasmin stopped-flow fluorescence kinetics. FEBS Lett 1996 May 27;387(1):58-62. 
(64)  Rijken DC, Sakharov DV. Basic principles in thrombolysis: regulatory role of 
plasminogen. Thromb Res 2001 September 30;103 Suppl 1:S41-S49. 
(65)  Wolberg AS, Campbell RA. Thrombin generation, fibrin clot formation and 
hemostasis. Transfus Apher Sci 2008 February;38(1):15-23. 
(66)  Lee KN, Jackson KW, Christiansen VJ, Chung KH, McKee PA. A novel plasma 
proteinase potentiates alpha2-antiplasmin inhibition of fibrin digestion. Blood 2004 May 
15;103(10):3783-8. 
(67)  Lijnen HR, Van Hoef B, Collen D. Inactivation of the serpin alpha(2)-antiplasmin 
by stromelysin-1. Biochim Biophys Acta 2001 June 11;1547(2):206-13. 
(68)  Lee KN, Jackson KW, Christiansen VJ, Lee CS, Chun JG, McKee PA. Why 
alpha-antiplasmin must be converted to a derivative form for optimal function. J Thromb 
189 
 
Haemost 2007 October;5(10):2095-104. 
(69)  Lee KN, Lee CS, Tae WC, Jackson KW, Christiansen VJ, McKee PA. Cross-
linking of wild-type and mutant alpha 2-antiplasmins to fibrin by activated factor XIII and 
by a tissue transglutaminase. J Biol Chem 2000 December 1;275(48):37382-9. 
(70)  Law RH, Sofian T, Kan WT, Horvath AJ, Hitchen CR, Langendorf CG, Buckle 
AM, Whisstock JC, Coughlin PB. X-ray crystal structure of the fibrinolysis inhibitor 
alpha2-antiplasmin. Blood 2008 February 15;111(4):2049-52. 
(71)  Lu BG, Sofian T, Law RH, Coughlin PB, Horvath AJ. Contribution of conserved 
lysine residues in the alpha2-antiplasmin C terminus to plasmin binding and inhibition. 
J Biol Chem 2011 July 15;286(28):24544-52. 
(72)  Heinrich J, Funke H, Rust S, Schulte H, Schonfeld R, Kohler E, Assmann G. 
Impact of polymorphisms in the alpha- and beta-fibrinogen gene on plasma fibrinogen 
concentrations of coronary heart disease patients. Thromb Res 1995 February 
1;77(3):209-15. 
(73)  Jacquemin B, Antoniades C, Nyberg F, Plana E, Muller M, Greven S, Salomaa 
V, Sunyer J, Bellander T, Chalamandaris AG, Pistelli R, Koenig W, Peters A. Common 
genetic polymorphisms and haplotypes of fibrinogen alpha, beta, and gamma chains 
affect fibrinogen levels and the response to proinflammatory stimulation in myocardial 
infarction survivors: the AIRGENE study. J Am Coll Cardiol 2008 September 
9;52(11):941-52. 
(74)  Standeven KF, Grant PJ, Carter AM, Scheiner T, Weisel JW, Ariens RA. 
Functional analysis of the fibrinogen Aalpha Thr312Ala polymorphism: effects on fibrin 
structure and function. Circulation 2003 May 13;107(18):2326-30. 
(75)  Rasmussen-Torvik LJ, Cushman M, Tsai MY, Zhang Y, Heckbert SR, 
Rosamond WD, Folsom AR. The association of alpha-fibrinogen Thr312Ala 
polymorphism and venous thromboembolism in the LITE study. Thromb Res 
2007;121(1):1-7. 
(76)  Kapczynska K, Stefanowicz P, Jaremko L, Jaremko M, Kluczyk A, Szewczuk Z. 
The efficient synthesis of isotopically labeled peptide-derived Amadori products and 
their characterization. Amino Acids 2011 March;40(3):923-32. 
(77)  Kijewska M, Stefanowicz P, Kluczyk A, Szewczuk Z. The isotopic exchange of 
oxygen as a tool for detection of the glycation sites in proteins. Anal Biochem 2011 
December 15;419(2):81-7. 
(78)  Thornalley PJ, Battah S, Ahmed N, Karachalias N, Agalou S, Babaei-Jadidi R, 
Dawnay A. Quantitative screening of advanced glycation endproducts in cellular and 
extracellular proteins by tandem mass spectrometry. Biochem J 2003 November 
1;375(Pt 3):581-92. 
(79)  Andrades ME, Lorenzi R, Berger M, Guimaraes JA, Moreira JC, Dal-Pizzol F. 
190 
 
Glycolaldehyde induces fibrinogen post-translational modification, delay in clotting and 
resistance to enzymatic digestion. Chem Biol Interact 2009 August 14;180(3):478-84. 
(80)  Ajjan RA, Gamlen T, Standeven KF, Mughal S, Hess K, Smith KA, Dunn EJ, 
Anwar MM, Rabbani N, Thornalley PJ, Philippou H, Grant PJ. Diabetes is associated 
with posttranslational modifications in plasminogen resulting in reduced plasmin 
generation and enzyme-specific activity. Blood 2013 July 4;122(1):134-42. 
(81)  Henschen-Edman AH. Fibrinogen non-inherited heterogeneity and its 
relationship to function in health and disease. Ann N Y Acad Sci 2001;936:580-93. 
(82)  Upchurch Jr GR, Ramdev N, Walsh MT, Loscalzo J. Prothrombotic 
Consequences of the Oxidation of Fibrinogen and their Inhibition by Aspirin. J Thromb 
Thrombolysis 1998;5(1):9-14. 
(83)  Azizova OA, Aseichev AV, Piryazev AP, Roitman EV, Shcheglovitova ON. 
Effects of oxidized fibrinogen on the functions of blood cells, blood clotting, and 
rheology. Bull Exp Biol Med 2007 September;144(3):397-407. 
(84)  Ajjan RA, Ariens RA. Cardiovascular disease and heritability of the 
prothrombotic state. Blood Rev 2009 March;23(2):67-78. 
(85)  Svensson J, Bergman AC, Adamson U, Blomback M, Wallen H, Jorneskog G. 
Acetylation and glycation of fibrinogen in vitro occur at specific lysine residues in a 
concentration dependent manner: a mass spectrometric and isotope labeling study. 
Biochem Biophys Res Commun 2012 May 4;421(2):335-42. 
(86)  Haglund AC, Ronquist G, Frithz G, Ek P. Alteration of the fibrinogen molecule 
and its phosphorylation state in myocardial infarction patients undergoing thrombolytic 
treatment. Thromb Res 2000 April 15;98(2):147-56. 
(87)  Sauls DL, Warren M, Hoffman M. Homocysteinylated fibrinogen forms disulfide-
linked complexes with albumin. Thromb Res 2011 June;127(6):576-81. 
(88)  Parastatidis I, Thomson L, Burke A, Chernysh I, Nagaswami C, Visser J, 
Stamer S, Liebler DC, Koliakos G, Heijnen HF, Fitzgerald GA, Weisel JW, 
Ischiropoulos H. Fibrinogen beta-chain tyrosine nitration is a prothrombotic risk factor. J 
Biol Chem 2008 December 5;283(49):33846-53. 
(89)  Veldman FJ, Nair CH, Vorster HH, Vermaak WJ, Jerling JC, Oosthuizen W, 
Venter CS. Dietary pectin influences fibrin network structure in hypercholesterolaemic 
subjects. Thromb Res 1997 May 1;86(3):183-96. 
(90)  Hess K, Alzahrani SH, Mathai M, Schroeder V, Carter AM, Howell G, Koko T, 
Strachan MW, Price JF, Smith KA, Grant PJ, Ajjan RA. A novel mechanism for 
hypofibrinolysis in diabetes: the role of complement C3. Diabetologia 2012 
April;55(4):1103-13. 
(91)  Jorneskog G, Egberg N, Fagrell B, Fatah K, Hessel B, Johnsson H, Brismar K, 
Blomback M. Altered properties of the fibrin gel structure in patients with IDDM. 
191 
 
Diabetologia 1996 December;39(12):1519-23. 
(92)  Collet JP, Allali Y, Lesty C, Tanguy ML, Silvain J, Ankri A, Blanchet B, Dumaine 
R, Gianetti J, Payot L, Weisel JW, Montalescot G. Altered fibrin architecture is 
associated with hypofibrinolysis and premature coronary atherothrombosis. Arterioscler 
Thromb Vasc Biol 2006 November;26(11):2567-73. 
(93)  Stone MC, Thorp JM. Plasma fibrinogen--a major coronary risk factor. J R Coll 
Gen Pract 1985 December;35(281):565-9. 
(94)  Smith FB, Lee AJ, Fowkes FG, Price JF, Rumley A, Lowe GD. Hemostatic 
factors as predictors of ischemic heart disease and stroke in the Edinburgh Artery 
Study. Arterioscler Thromb Vasc Biol 1997 November;17(11):3321-5. 
(95)  Carter AM, Catto AJ, Grant PJ. Association of the alpha-fibrinogen Thr312Ala 
polymorphism with poststroke mortality in subjects with atrial fibrillation. Circulation 
1999 May 11;99(18):2423-6. 
(96)  Carter AM, Catto AJ, Kohler HP, Ariens RA, Stickland MH, Grant PJ. alpha-
fibrinogen Thr312Ala polymorphism and venous thromboembolism. Blood 2000 August 
1;96(3):1177-9. 
(97)  Yarnell JW, Baker IA, Sweetnam PM, Bainton D, O'Brien JR, Whitehead PJ, 
Elwood PC. Fibrinogen, viscosity, and white blood cell count are major risk factors for 
ischemic heart disease. The Caerphilly and Speedwell collaborative heart disease 
studies. Circulation 1991 March;83(3):836-44. 
(98)  Vadseth C, Souza JM, Thomson L, Seagraves A, Nagaswami C, Scheiner T, 
Torbet J, Vilaire G, Bennett JS, Murciano JC, Muzykantov V, Penn MS, Hazen SL, 
Weisel JW, Ischiropoulos H. Pro-thrombotic state induced by post-translational 
modification of fibrinogen by reactive nitrogen species. J Biol Chem 2004 March 
5;279(10):8820-6. 
(99)  Behague I, Poirier O, Nicaud V, Evans A, Arveiler D, Luc G, Cambou JP, 
Scarabin PY, Bara L, Green F, Cambien F. Beta fibrinogen gene polymorphisms are 
associated with plasma fibrinogen and coronary artery disease in patients with 
myocardial infarction. The ECTIM Study. Etude Cas-Temoins sur l'Infarctus du 
Myocarde. Circulation 1996 February 1;93(3):440-9. 
(100)  French JK, Van de Water NS, Sutton TM, Lund M, Gao W, McDowell J, Liu-
Stratton Y, Pohorence J, Szymanski D, Goldschmidt-Clermont P, White HD, Browett 
PJ, Cooke G. Potential thrombophilic mutations/polymorphisms in patients with no flow-
limiting stenosis after myocardial infarction. Am Heart J 2003 January;145(1):118-24. 
(101)  Carter AM, Catto AJ, Bamford JM, Grant PJ. Gender-specific associations of 
the fibrinogen B beta 448 polymorphism, fibrinogen levels, and acute cerebrovascular 
disease. Arterioscler Thromb Vasc Biol 1997 March;17(3):589-94. 
(102)  Ajjan R, Lim BC, Standeven KF, Harrand R, Dolling S, Phoenix F, Greaves R, 
192 
 
Abou-Saleh RH, Connell S, Smith DA, Weisel JW, Grant PJ, Ariens RA. Common 
variation in the C-terminal region of the fibrinogen beta-chain: effects on fibrin structure, 
fibrinolysis and clot rigidity. Blood 2008 January 15;111(2):643-50. 
(103)  Kotlin R, Chytilova M, Suttnar J, Riedel T, Salaj P, Blatny J, Santrucek J, Klener 
P, Dyr JE. Fibrinogen Novy Jicin and Praha II: cases of hereditary Aalpha 16 Arg--
>Cys and Aalpha 16 Arg-->His dysfibrinogenemia. Thromb Res 2007;121(1):75-84. 
(104)  Mimuro J, Hamano A, Tanaka T, Madoiwa KS, Sugo T, Matsuda M, Sakata Y. 
Hypofibrinogenemia caused by a nonsense mutation in the fibrinogen Bbeta chain 
gene. J Thromb Haemost 2003 November;1(11):2356-9. 
(105)  Lee MH, Kaczmarek E, Chin DT, Oda A, McIntosh S, Bauer KA, Clyne LP, 
McDonagh J. Fibrinogen Ledyard (A alpha Arg16----Cys): biochemical and physiologic 
characterization. Blood 1991 October 1;78(7):1744-52. 
(106)  Bogli C, Hofer A, Baudo F, Redaelli R, Furlan M. Fibrinogen Milano IV, another 
case of congenital dysfibrinogenemia with an abnormal fibrinopeptide A release (A 
alpha 16 Arg----His). Haemostasis 1992;22(1):7-11. 
(107)  Furlan M, Leupin L, Biasiutti FD, Lammle B. [Fibrinogen Bern III: a further case 
of hereditary fibrinogen variants with substitution A alpha 16 Arg----Cys]. Schweiz Med 
Wochenschr 1991 July 20;121(29):1068-71. 
(108)  Hill M, Thompson N, Gordon B, Ajjan R, Ariens RAS, Williams M, Dolan G. 
Fibrinogen Birmingham II - A novel variant associated with hypodyfibrinogenemia, due 
to compound heterzygosity for TRP334CYS and ASN335TYR in the fibrinogen A alpha 
chain. 2009. 
(109)  Kannel WB, D'Agostino RB, Wilson PW, Belanger AJ, Gagnon DR. Diabetes, 
fibrinogen, and risk of cardiovascular disease: the Framingham experience. Am Heart J 
1990 September;120(3):672-6. 
(110)  Pieters M, van Zyl DG, Rheeder P, Jerling JC, Loots dT, van der Westhuizen 
FH, Gottsche LT, Weisel JW. Glycation of fibrinogen in uncontrolled diabetic patients 
and the effects of glycaemic control on fibrinogen glycation. Thromb Res 
2007;120(3):439-46. 
(111)  Dunn EJ, Ariens RA, Grant PJ. The influence of type 2 diabetes on fibrin 
structure and function. Diabetologia 2005 June;48(6):1198-206. 
(112)  Raynaud E, Perez-Martin A, Brun J, Aissa-Benhaddad A, Fedou C, Mercier J. 
Relationships between fibrinogen and insulin resistance. Atherosclerosis 2000 
June;150(2):365-70. 
(113)  Diamant M, Nieuwland R, Pablo RF, Sturk A, Smit JW, Radder JK. Elevated 
numbers of tissue-factor exposing microparticles correlate with components of the 
metabolic syndrome in uncomplicated type 2 diabetes mellitus. Circulation 2002 
November 5;106(19):2442-7. 
193 
 
(114)  Vaidyula VR, Rao AK, Mozzoli M, Homko C, Cheung P, Boden G. Effects of 
hyperglycemia and hyperinsulinemia on circulating tissue factor procoagulant activity 
and platelet CD40 ligand. Diabetes 2006 January;55(1):202-8. 
(115)  Mansfield MW, Heywood DM, Grant PJ. Circulating levels of factor VII, 
fibrinogen, and von Willebrand factor and features of insulin resistance in first-degree 
relatives of patients with NIDDM. Circulation 1996 November 1;94(9):2171-6. 
(116)  Ceriello A, Esposito K, Ihnat M, Zhang J, Giugliano D. Simultaneous control of 
hyperglycemia and oxidative stress normalizes enhanced thrombin generation in type 1 
diabetes. J Thromb Haemost 2009 July;7(7):1228-30. 
(117)  Dunn EJ, Philippou H, Ariens RA, Grant PJ. Molecular mechanisms involved in 
the resistance of fibrin to clot lysis by plasmin in subjects with type 2 diabetes mellitus. 
Diabetologia 2006 May;49(5):1071-80. 
(118)  Watala C, Pluta J, Golanski J, Rozalski M, Czyz M, Trojanowski Z, Drzewoski J. 
Increased protein glycation in diabetes mellitus is associated with decreased aspirin-
mediated protein acetylation and reduced sensitivity of blood platelets to aspirin. J Mol 
Med (Berl) 2005 February;83(2):148-58. 
(119)  Carter AM, Cymbalista CM, Spector TD, Grant PJ. Heritability of clot formation, 
morphology, and lysis: the EuroCLOT study. Arterioscler Thromb Vasc Biol 2007 
December;27(12):2783-9. 
(120)  Alzahrani SH, Ajjan RA. Coagulation and fibrinolysis in diabetes. Diab Vasc Dis 
Res 2010 October;7(4):260-73. 
(121)  Undas A, Kolarz M, Kopec G, Tracz W. Altered fibrin clot properties in patients 
on long-term haemodialysis: relation to cardiovascular mortality. Nephrol Dial 
Transplant 2008 June;23(6):2010-5. 
(122)  Alzahrani SH, Hess K, Price JF, Strachan M, Baxter PD, Cubbon R, Phoenix F, 
Gamlen T, Ariens RA, Grant PJ, Ajjan RA. Gender-specific alterations in fibrin structure 
function in type 2 diabetes: associations with cardiometabolic and vascular markers. J 
Clin Endocrinol Metab 2012 December;97(12):E2282-E2287. 
(123)  Undas A, Szuldrzynski K, Stepien E, Zalewski J, Godlewski J, Tracz W, 
Pasowicz M, Zmudka K. Reduced clot permeability and susceptibility to lysis in patients 
with acute coronary syndrome: effects of inflammation and oxidative stress. 
Atherosclerosis 2008 February;196(2):551-7. 
(124)  Larsen MR, Trelle MB, Thingholm TE, Jensen ON. Analysis of posttranslational 
modifications of proteins by tandem mass spectrometry. Biotechniques 2006 
June;40(6):790-8. 
(125)  Puri R, Kataoka Y, Uno K, Nicholls SJ. The distinctive nature of atherosclerotic 
vascular disease in diabetes: pathophysiological and morphological insights. Curr Diab 
Rep 2012 June;12(3):280-5. 
194 
 
(126)  Ferreiro JL, Gomez-Hospital JA, Angiolillo DJ. Platelet abnormalities in diabetes 
mellitus. Diab Vasc Dis Res 2010 October;7(4):251-9. 
(127)  Mercer BN, Morais S, Cubbon RM, Kearney MT. Diabetes mellitus and the 
heart. Int J Clin Pract 2012 July;66(7):640-7. 
(128)  Price JF, Reynolds RM, Mitchell RJ, Williamson RM, Fowkes FG, Deary IJ, Lee 
AJ, Frier BM, Hayes PC, Strachan MW. The Edinburgh Type 2 Diabetes Study: study 
protocol. BMC Endocr Disord 2008;8:18. 
(129)  Marioni RE, Strachan MW, Reynolds RM, Lowe GD, Mitchell RJ, Fowkes FG, 
Frier BM, Lee AJ, Butcher I, Rumley A, Murray GD, Deary IJ, Price JF. Association 
between raised inflammatory markers and cognitive decline in elderly people with type 
2 diabetes: the Edinburgh Type 2 Diabetes Study. Diabetes 2010 March;59(3):710-3. 
(130)  Marioni RE, Deary IJ, Murray GD, Lowe GD, Strachan MW, Luciano M, 
Houlihan LM, Gow AJ, Harris SE, Rumley A, Stewart MC, Fowkes FG, Price JF. 
Genetic associations between fibrinogen and cognitive performance in three Scottish 
cohorts. Behav Genet 2011 September;41(5):691-9. 
(131)  Meade TW, Chakrabarti R, Haines AP, North WR, Stirling Y. Characteristics 
affecting fibrinolytic activity and plasma fibrinogen concentrations. Br Med J 1979 
January 20;1(6157):153-6. 
(132)  Allan P, Uitte de WS, Abou-Saleh RH, Connell SD, Ariens RA. Evidence that 
fibrinogen gamma' directly interferes with protofibril growth: implications for fibrin 
structure and clot stiffness. J Thromb Haemost 2012 June;10(6):1072-80. 
(133)  Abou-Saleh RH, Connell SD, Harrand R, Ajjan RA, Mosesson MW, Smith DA, 
Grant PJ, Ariens RA. Nanoscale probing reveals that reduced stiffness of clots from 
fibrinogen lacking 42 N-terminal Bbeta-chain residues is due to the formation of 
abnormal oligomers. Biophys J 2009 March 18;96(6):2415-27. 
(134)  Syka JE, Coon JJ, Schroeder MJ, Shabanowitz J, Hunt DF. Peptide and protein 
sequence analysis by electron transfer dissociation mass spectrometry. Proc Natl Acad 
Sci U S A 2004 June 29;101(26):9528-33. 
(135)  Ng PC, Henikoff S. SIFT: Predicting amino acid changes that affect protein 
function. Nucleic Acids Res 2003 July 1;31(13):3812-4. 
(136)  Ramensky V, Bork P, Sunyaev S. Human non-synonymous SNPs: server and 
survey. Nucleic Acids Res 2002 September 1;30(17):3894-900. 
(137)  Galanakis DK, Lane BP, Simon SR. Albumin modulates lateral assembly of 
fibrin polymers: evidence of enhanced fine fibril formation and of unique synergism with 
fibrinogen. Biochemistry 1987 April 21;26(8):2389-400. 
 
 
